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Abstract
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List of Recommendations
1. Screening and cardiovascular disease risk
assessment
Measurement of lipids
1.1

In adults with endocrine disorders, we recommend
a lipid panel for the assessment of triglyceride
levels and for calculating low-density lipoprotein
cholesterol. (1⊕⊕⊕O)

Technical Remarks:
• Non-fasting lipid panels are acceptable for initial
screening.
• If triglyceride levels are elevated or if genetic dyslipidemia
is suspected, repeat a fasting lipid panel.
• If lipoprotein(a) levels are measured, fasting or
nonfasting samples can be obtained.
Cardiovascular risk assessment
1.2

In adults with endocrine disorders, we recommend
conducting a cardiovascular risk assessment
by evaluating traditional risk factors, including
the calculation of 10-year atherosclerotic
cardiovascular disease risk using a tool such as the
Pooled Cohort Equations. (1⊕⊕⊕O)

1.3

In adults with endocrine disorders at borderline
or intermediate risk (10-year atherosclerotic

cardiovascular disease risk 5%–19.9%), particularly
those with additional risk-enhancing factors, in
whom the decision about statin treatment and/
or other preventive interventions is uncertain, we
suggest measuring coronary artery calcium to
inform shared decision making. (2⊕⊕⊕O)
Technical Remarks:
• Borderline and intermediate cardiovascular risk are
defined as 5%–7.4% and 7.5%–19.9% 10-year
atherosclerotic cardiovascular disease risk using the
Pooled Cohort Equations.
• Risk-enhancing factors are additional features, including
diseases, that enhance the risk of atherosclerotic
cardiovascular disease beyond the risk associated with
major risk factors and/or the calculated 10-year risk of
atherosclerotic cardiovascular disease.
• In patients with additional risk-enhancing factors,
including elevated lipoprotein(a), as described below,
risk assessment should consider traditional 10-year
atherosclerotic cardiovascular disease risk assessment
and the presence of risk-enhancing factors. The coronary
artery calcium score should be considered when risk
assessment and treatment decisions remain uncertain.
• At present, we suggest measuring coronary artery
calcium as the preferred tool for assessment of
subclinical atherosclerosis. Other techniques to assess
atherosclerotic burden are being developed.
• Coronary artery calcium = 0 marks very low risk of
atherosclerotic cardiovascular disease. In patients with
baseline coronary artery calcium = 0, evidence suggests
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Objective: This guideline will provide the practicing endocrinologist with an approach to
the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the
objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis.
The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease
(ASCVD) risk in patients with endocrine disorders and discusses the evidence for the
correction of dyslipidemia by treatment of the endocrine disease. The guideline also
addresses whether treatment of the endocrine disease reduces ASCVD risk.
Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with
endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine
disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the
available evidence, recommendations are made for the assessment and management of
dyslipidemia in patients with endocrine diseases.
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1.4

In adult patients with a family history of premature
atherosclerotic cardiovascular disease, or a
personal history of atherosclerotic cardiovascular
disease or a family history of high lipoprotein(a),
we suggest measuring lipoprotein(a) to inform
decision-making about short-term and lifetime
atherosclerotic cardiovascular disease risk and
the need to intensify low-density lipoprotein
cholesterol–lowering therapy. (2⊕⊕OO)

Technical Remarks:
• Lipoprotein(a) ≥50 mg/dL (125 nmol/L) enhances the
risk of atherosclerotic cardiovascular disease.
• Lipoprotein(a) testing does not need to be repeated if it
has previously been measured (ie, in childhood or early
adulthood).
• It is not yet known whether reducing lipoprotein(a)
reduces atherosclerotic cardiovascular disease risk.

2. Hypertriglyceridemia

as a first-line therapy to reduce triglyceride levels.
(2⊕OOO)
Technical Remark:
• Plasmapheresis may be useful in those who do
not respond to conventional methods of lowering
triglycerides, such as individuals who have
extraordinarily elevated triglyceride levels (eg, over
10 000 mg/dL [112.9 mmol/L]) or in extremely highrisk situations, such as pregnancy.
2.3

Technical Remark:
• When uncontrolled diabetes is present, insulin therapy
should be used to normalize glucose levels.
2.4

In adults with fasting triglyceride levels over
500 mg/dL (5.6 mmol/L), we recommend
pharmacologic treatment as adjunct to diet and
exercise to prevent pancreatitis. (1⊕OOO)

Technical Remark:
• Patients with triglyceride levels over 1000 mg/dL
(11.3 mmol/L) often do not get an adequate response
to medications and, therefore, control of diabetes,
modification of diet, and weight loss are essential.
2.2

In patients with triglyceride-induced pancreatitis,
we suggest against the use of acute plasmapheresis

In adults who are on statins and still have
moderately
elevated
triglyceride
levels
>150 mg/dL (1.7 mmol/L), and who have
either atherosclerotic cardiovascular disease
or diabetes plus 2 additional risk factors, we
suggest adding eicosapentaenoic acid ethyl ester
to reduce the risk of cardiovascular disease.
(2⊕⊕⊕O)

Technical Remarks:
• Risk factors include traditional risk factors and riskenhancing factors.
• The dose of eicosapentaenoic acid ethyl ester is 4 g/
day.
• If eicosapentaenoic acid ethyl ester is not available or
accessible, then it is reasonable to consider a fibrate.
2.5

2.1

In patients without diabetes and who have
triglyceride-induced pancreatitis, we suggest
against the routine use of insulin infusion.
(2⊕OOO)

In patients with elevated triglycerides (>150 mg/
dL to 499 mg/dL [1.7 mmol/L to 5.6 mmol/L]),
we suggest checking triglycerides before and after
starting a bile acid sequestrant. (2⊕OOO)

Technical Remark:
• Bile acid sequestrants are contraindicated when
triglycerides are above 500 mg/dL (5.6 mmol/L).

3. Type 2 diabetes mellitus
3.1

In adults with type 2 diabetes and other
cardiovascular risk factors, we recommend

Downloaded from https://academic.oup.com/jcem/article/105/12/3613/5909161 by guest on 04 August 2022

that it is reasonable to repeat a coronary artery calcium
scan after 5 to7 years in low-risk patients, 3 to 5 years in
borderline-to-intermediate risk patients, and in 3 years
for high-risk patients or those with diabetes.
• In patients without diabetes or atherosclerotic
cardiovascular disease and with low-density lipoprotein
>70 mg/dL (1.8 mmol/L), and 10-year atherosclerotic
cardiovascular disease risk >7.5%, or 10-year
atherosclerotic cardiovascular disease risk of 5% to
7.4% plus 1 or more risk-enhancing factors, or coronary
artery calcium score over the 75th percentile for age, sex,
and race, or coronary artery calcium score >100, the
initiation of a statin, as adjunct to diet and exercise, is
advised after a discussion of the risks/benefits with the
patient.
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statin therapy in addition to lifestyle
modification in order to reduce cardiovascular
risk. (1⊕⊕⊕⊕)

3.2

In adults with type 2 diabetes and other
cardiovascular risk factors, we suggest lowering
low-density lipoprotein cholesterol to achieve
a goal of low-density lipoprotein cholesterol
<70 mg/dL (1.8 mmol/L) in order to reduce
cardiovascular risk. (2⊕OOO)

Technical Remarks:
• A statin should be added to lifestyle modifications
if low-density lipoprotein cholesterol is >70 mg/dL
(1.8 mmol/L).
• Low-density lipoprotein cholesterol should be
<55 mg/dL (1.4 mmol/L) in patients with established
cardiovascular disease or multiple risk factors.
• Additional low-density lipoprotein-lowering therapy
(ezetimibe, proprotein convertase subtilisin/kexin type 9
inhibitor) may be needed if the low-density lipoprotein
cholesterol goal is not reached with statins.
• Risk factors include traditional risk factors and riskenhancing factors.
3.3

In adults with type 2 diabetes on a statin at
low-density lipoprotein goal with residual
triglycerides over 150 mg/dL (1.7 mmol/L) and
with two additional traditional risk factors
or risk-enhancing factors, we suggest adding
eicosapentaenoic acid ethyl ester to reduce
cardiovascular risk. (2⊕⊕⊕O)

Technical Remarks:
• Consider 4 g/day of eicosapentaenoic acid ethyl ester.
• If eicosapentaenoic acid ethyl ester is not available or
accessible, then it is reasonable to consider a fibrate such
as fenofibrate.

In adults with type 2 diabetes with chronic kidney
disease stages 1–4 and postrenal transplant,
we suggest statin therapy, irrespective of the
cardiovascular risk score, to reduce cardiovascular
risk. (2⊕OOO)

Technical Remarks:
• When selecting the statin, consider the renal clearance
of the statin. Pitavastatin, pravastatin, and rosuvastin
all have at least partial clearance through the kidney,
whereas atorvastatin, fluvastatin, lovastatin, and
simvastatin are cleared via the liver.
• All statins require dose adjustments in chronic kidney
disease, except for atorvastatin and fluvastatin.
3.5

In adults with type 2 diabetes and diabetic
retinopathy, we suggest fibrates in addition
to statins to reduce retinopathy progression.
(2⊕OOO)

Technical Remarks:
• This recommendation applies regardless of triglyceride
levels.
• The preferred fibrate is fenofibrate.

4. Type 1 diabetes mellitus
4.1

In adults with type 1 diabetes, age 40 years
and older and/or with duration of diabetes
>20 years, and/or microvascular complications,
we suggest statin therapy, irrespective of
the cardiovascular risk score, to reduce
cardiovascular risk. (2⊕OOO)

Technical Remarks:
• Low-density lipoprotein should be the primary target
for lipid-lowering therapy.
• Consider therapy if low-density lipoprotein is over
70 mg/dl (1.8 mmol/L).
• Statins should not be used in women who are pregnant
or trying to become pregnant.
4.2

In adults with type 1 diabetes with chronic kidney
disease in stages 1–4, we suggest statin therapy,
irrespective of the cardiovascular risk score, to
reduce cardiovascular risk. (2⊕OOO)

Technical Remarks:
• Low-density lipoprotein should be the primary target
for lipid-lowering therapy.
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Technical Remarks:
• High-intensity statins should be chosen in patients with
atherosclerotic cardiovascular disease, or those with
risk factors for atherosclerotic cardiovascular disease or
risk-enhancing factors.
• Statins should not be used in women who are pregnant
or trying to become pregnant.
• In patients over the age of 75, continuation of statin
treatment or initiation of statin treatment depends upon
atherosclerotic cardiovascular disease risk, prognosis,
potential interacting medications, polypharmacy, mental
health, and the wishes of the patient.
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4.3

In adults with type 1 diabetes with obesity, or
with high triglycerides and low high-density
lipoprotein cholesterol, we suggest statin therapy,
irrespective of the cardiovascular risk score, to
reduce cardiovascular risk. (2⊕OOO)

Technical Remarks:
• Low-density lipoprotein should be the primary target
for lipid-lowering therapy.
• Consider therapy if low-density lipoprotein cholesterol
is over 70 mg/dL (1.8 mmol/L).
4.4

In adults with type 1 diabetes and diabetic
retinopathy, we suggest statin therapy, irrespective
of the cardiovascular risk score, to reduce
cardiovascular risk. (2⊕OOO)

• Systolic blood pressure ≥130 mm Hg or diastolic
blood pressure ≥85 mm Hg or on blood pressure
medication.
• Elevated waist circumference (men ≥ 40 in [102 cm]
and women ≥ 35 in [88 cm]), except for East and South
Asian men (≥ 35 in [90 cm]) and women (≥ 31.5 in
[80 cm]).
• Hyperglycemia (but not yet with type 2 diabetes) is
defined by cutoffs for prediabetes according to fasting
blood glucose, oral glucose tolerance, and/or hemoglobin
A1c.
• Body fat distribution can be assessed in clinical practice
by measuring the waist size or the waist/hip ratio.
• Waist size measurement in people with a body mass
index greater than 35 kg/m2 has potential limitations.
5.2

Technical Remarks:
• Reductions in low-density lipoprotein cholesterol and
increases in high-density lipoprotein cholesterol are
modest compared to the decrease in triglycerides with
lifestyle measures that produce weight loss.
• Lifestyle therapy–induced changes in the lipid profile in
obesity have not been shown to reduce cardiovascular
disease events.
5.3

Technical Remarks:
• Low-density lipoprotein should be the primary target.
• Consider therapy if low-density lipoprotein cholesterol
is over 70 mg/dL (1.8 mmol/L).

5. Obesity
5.1

In individuals who have obesity, we advise
assessment of components of the metabolic
syndrome and body fat distribution to accurately
determine the level of cardiovascular disease risk.
(Ungraded Good Practice Statement)

Technical Remarks:
• Diagnosis of MetS requires the presence of three of the
following criteria:
• Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) or on
triglyceride-lowering medication.
• Reduced high-density lipoprotein cholesterol <50 mg/dL
(1.3 mmol/L) in women and <40 mg/dL (1.0 mmol/L)
in men.

In individuals who have obesity, we suggest lifestyle
measures as the first-line treatment to reduce
plasma triglycerides to lower cardiovascular and
pancreatitis risk. (2⊕OOO)

In individuals who have obesity, we recommend
the assessment of 10-year risk for atherosclerotic
cardiovascular disease to guide the use of lipidlowering therapy. (1⊕⊕⊕O)

Technical Remarks:
• Calculation of 10-year risk for atherosclerotic
cardiovascular disease may be done using Pooled Cohort
Equations.
• Elevated low-density lipoprotein cholesterol is predictive
of cardiovascular risk.
5.4

In individuals who have obesity and are on
pharmacological therapy for weight reduction,
we suggest the reassessment of the lipid profile
to evaluate the risk of cardiovascular disease and
pancreatitis. (2⊕OOO)

Technical Remark:
• As there are no data on the timing of lipid measurements
after weight loss, we suggest the reassessment of lipids
after 5% weight loss and periodically thereafter and
when the weight is stable.
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• Consider therapy if low-density lipoprotein is over
70 mg/dL (1.8 mmol/L).
• When selecting the statin, consider the renal clearance
of the statin: pitavastatin, pravastatin, and rosuvastatin
all have at least partial clearance through the kidney,
whereas atorvastatin, fluvastatin, lovastatin, and
simvastatin are cleared via the liver.
• All statins require dose adjustments in chronic kidney
disease except for atorvastatin and fluvastatin.
• Ezetimibe can be added to the statin if required to lower
low-density lipoprotein cholesterol further. No dose
adjustments of ezetimibe are needed in chronic kidney
disease.
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In individuals with obesity, (body mass index >40
or >35 kg/m2 with comorbidities) who undergo
bariatric surgery, we suggest the measurement of
the lipid profile after bariatric surgery to assess
cardiovascular risk. (2⊕OOO)

6. Thyroid disease
6.1

In patients with hyperlipidemia, we recommend
ruling out hypothyroidism as the cause of the
hyperlipidemia before treatment with lipidlowering medications. (1⊕⊕⊕⊕)

Technical Remark:
• Hypothyroidism can elevate both cholesterol and
triglyceride levels, which improve with treatment.

6.2

In patients with hyperthyroidism, we recommend
re-evaluating the lipid panel after the patient
becomes euthyroid. (1⊕⊕⊕⊕)

Technical Remark:
• Changes in low-density lipoprotein cholesterol have
been observed as early as 3 months after the patient is
euthyroid.

7. Excess glucocorticoids
7.1

Technical Remark:
• Monitor lipid profile at the time of diagnosis and
periodically afterwards at the discretion of the treating
physician.
Lipid-lowering therapy in Cushing syndrome
7.2

6.4

In patients with overt hypothyroidism, we suggest
against treating hyperlipidemia until the patient
becomes euthyroid in order to more accurately
assess the lipid profile. (2⊕OOO)
In patients with subclinical hypothyroidism
(thyroid-stimulating hormone <10 mIU/L) with
associated hyperlipidemia, we suggest considering
thyroxine treatment as a means of reducing lowdensity lipoprotein levels. (2⊕OOO)

In adults with persistent endogenous Cushing
syndrome, we suggest statin therapy, as adjunct
to lifestyle modification, to reduce cardiovascular
risk, irrespective of the cardiovascular risk score.
(2⊕OOO)

Technical Remarks:
• Low-density lipoprotein cholesterol should be the
primary target, and therapy should be considered if
low-density lipoprotein cholesterol is over 70 mg/dL
(1.8 mmol/L).
• Patients receiving mitotane therapy for Cushing
syndrome commonly develop secondary dyslipidemia
from therapy.
• Lipid-lowering therapy may not be appropriate for
patients with limited life expectancy, such as those with
an underlying malignancy.
7.3

6.3

In adult patients with Cushing syndrome, we
recommend monitoring the lipid profile in order
to identify cases of dyslipidemia. (1⊕⊕OO)

In adults with cured Cushing syndrome, we advise
the approach to cardiovascular risk assessment
and treatment be the same as in the general
population. (Ungraded Good Practice Statement)

Lipid management in chronic glucocorticoid therapy
7.4

In adults receiving chronic glucocorticoid therapy
above replacement levels, we suggest assessment
and treatment of lipids and other cardiovascular
risk factors because of the increased risk of
cardiovascular disease. (2⊕OOO)
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Technical Remarks:
• Malabsorptive bariatric surgery procedures (eg, Rouxen-Y gastric bypass) are more effective than restrictive
procedures (eg, banding, sleeve gastrectomy) in
decreasing low-density lipoprotein cholesterol levels.
• Both restrictive and malabsorptive procedures decrease
triglycerides.
• Reassess the lipid profile 1 to 3 months after bariatric
surgery and periodically thereafter and when the weight
is stable.

Technical Remark:
• Take into consideration the patient’s age and general
health, the possibility of suppression of thyroidstimulating hormone, and whether the patient has
cardiovascular disease.
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Technical Remark:
• Effects of glucocorticoid therapy on lipids and
cardiovascular risk will vary based on the dose of
glucocorticoid, duration of treatment, and underlying
disease/indication.

Cardiovascular risk: effect of treatment of polycystic ovary
syndrome on lipids
9.2

In women with polycystic ovary syndrome, we
suggest against using lipid-lowering therapies to
treat hyperandrogenism or infertility. (2⊕OOO)

8. Disorders of growth hormone secretion
Adult growth hormone deficiency

10. Menopause and hormonal replacement

In adults with growth hormone deficiency, we
recommend obtaining a lipid profile at diagnosis
to assess for dyslipidemia. (1⊕⊕⊕O)

10.1

8.2

In adults with growth hormone deficiency
associated with hypopituitarism, we suggest
assessment and treatment of lipids and other
cardiovascular risk factors. (2⊕OOO)

Technical Remarks:
• Hormone therapy increases the risk of cardiovascular
disease, specifically venous thromboembolism and
stroke. However, the absolute risk of cardiovascular
disease is lower in younger compared to older
postmenopausal women.
• Hormone therapy is described as estrogen ±
progesterone/a progestin.

Technical Remarks:
• Low-density lipoprotein cholesterol should be the
primary target.
• Consider therapy if low-density lipoprotein cholesterol
is over 70 mg/dL (1.8 mmol/L).
8.3

In adult patients with growth hormone deficiency,
we recommend against using growth hormone
replacement solely to lower low-density lipoprotein
cholesterol to reduce cardiovascular risk. (1⊕⊕⊕O)

Growth hormone excess (acromegaly)
8.4

In adults with acromegaly, we suggest measurement
of the usual lipid profile before and after treatment
of growth hormone excess. (2⊕OOO)

9. Polycystic ovary syndrome
Lipid abnormalities
9.1

In women with polycystic ovary syndrome, we
recommend obtaining a fasting screening lipid
panel at diagnosis to assess cardiovascular risk.
(1⊕⊕⊕O)

Technical Remarks:
• Polycystic ovary syndrome is associated with
cardiovascular risk factors.
• Conduct lipid screening both before and intermittently
during hormonal therapy.
• In polycystic ovary syndrome, hypertriglyceridemia is
the most common lipid abnormality.

10.2

In postmenopausal women on hormone therapy
and with other risk factors for cardiovascular
disease, we recommend statin therapy to reduce
cardiovascular risk. (1⊕⊕⊕⊕)

Technical Remarks:
• Hormone therapy increases the risk of cardiovascular
disease, specifically venous thromboembolism and
stroke. However, the absolute risk of cardiovascular
disease is lower in younger compared to older
postmenopausal women.
• Hormone therapy is described as estrogen ±
progesterone/a progestin.
• Menopause may be associated with an increase in lowdensity lipoprotein cholesterol and a decrease in highdensity lipoprotein cholesterol.
• Risk factors may be traditional risk factors or riskenhancing factors.
10.3

In women who enter menopause early (<40 to
45 years old), we recommend assessment and
treatment of lipids and other cardiovascular risk
factors. (1⊕⊕⊕O)

Technical Remarks:
• Early menopause enhances cardiovascular disease
risk.
• Atherosclerotic cardiovascular disease risk should be
calculated and followed after menopause.
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In postmenopausal women, we recommend
treating dyslipidemia with statin therapy, rather
than hormone therapy. (1⊕⊕OO)

8.1
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11. Hypogonadism and testosterone replacement
and abuse
11.1

11.2

In patients with low testosterone levels, we suggest
testosterone therapy as symptomatically indicated,
and not as an approach to improve dyslipidemia
or cardiovascular disease risk. (2⊕⊕OO)

Technical Remark:
• Supraphysiological doses of androgens will reduce highdensity lipoprotein cholesterol levels.

12. Gender-affirming hormone therapy
12.1

In transwomen and transmen who have taken or
are taking gender-affirming hormone therapy, we
advise assessing cardiovascular risk by guidelines
for nontransgender adults. (Ungraded Good
Practice Statement)

Technical Remark:
• There are no data to guide the selection of a gender
marker in risk calculators for individuals on genderaffirming hormone therapy.

Introduction
Hormones modulate every pathway involved in lipoprotein metabolism. This includes expression of lipoprotein
receptors, production of apolipoproteins (apos), the activity of plasma lipoprotein–modifying enzymes, and the
circulating levels of substrates such as fatty acids and glucose used for triglyceride (TG) synthesis. Therefore, it is
anticipated that endocrine diseases might alter the lipid
profile and enhance atherosclerotic cardiovascular disease (ASCVD) risk. However, with the exception of type
2 diabetes (T2D), many endocrine diseases are not mentioned, or not described in detail, in cholesterol management guidelines. The present guideline addresses this gap
in information. The primary objectives are as follows:
• Describe lipid abnormalities and cardiovascular disease
(CVD) risk in endocrine diseases.
• Assess whether treatment of the underlying endocrine
disorder improves the lipid profile and/or lowers
ASCVD risk.

Based upon the available evidence, recommendations are
made for direct lipid treatment and endocrine disease
treatment to manage dyslipidemia in endocrine diseases.
The first part of the guideline addresses lipid measurement and ASCVD risk assessment. The second section
addresses hypertriglyceridemia, dyslipidemia in type 1
diabetes (T1D) and T2D, obesity, thyroid disease, excess
glucocorticoids, growth hormone deficiency (GHD) and
excess, polycystic ovary syndrome (PCOS), menopause
and hormonal replacement of menopause, testosterone
replacement in hypogonadism, testosterone abuse, and
gender-affirming hormone therapy. The last section of
the guideline discusses implementation, including lifestyle therapy, and the efficacy and safety of lipid-lowering
medications. In addition, this section provides a patient
perspective on statin use. A summary of lipid metabolism
and a discussion of other cholesterol management guidelines are provided in 2 appendices (see Appendix B and
Appendix C, respectively).

Commissioned Systematic Review
The Endocrine Society Writing Committee commissioned
2 systematic reviews, which were conducted by the Mayo
Clinic Evidence-based Practice Center to support recommendations on the management of hyperlipidemia in patients with endocrine disorders.
The Writing Committee requested a first systematic
review to investigate the impact of therapy for overt
and subclinical hypo- and hyperthyroidism on serum
lipids. The review summarized evidence from heterogeneous studies and suggested that treatment of overt but
not subclinical hyperthyroidism was associated with
worsening of lipid profile. Levothyroxine (LT4) therapy
in both overt and subclinical hypothyroidism (SCH) led
to improvement in the lipid profile, including lipoproteins, with the magnitude of improvement being larger
for overt hypothyroidism (1).
The second systematic review requested by the Writing
Committee was to estimate the magnitude of change in
lipid parameters associated with weight loss in adults.
This review summarized data from multiple randomized
trials and presented the change of lipid parameters associated either with losing 1 kg or 1 unit of body mass index
(BMI) by means of lifestyle interventions, pharmacologic
interventions, and bariatric surgery, at 6 and 12 months.
Another finding from the systematic review was that
low-carbohydrate diets resulted in reductions in TG and
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In patients with low high-density lipoprotein
(<30 mg/dL [0.8 mmol/L]), especially in the
absence of hypertriglyceridemia, we advise clinical
or biochemical investigation of anabolic steroid
abuse. (Ungraded Good Practice Statement)

• Assess the evidence for using lipid-lowering medications,
as adjunct to diet and physical activity, in patients with
these endocrine diseases.
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increases in high-density lipoprotein cholesterol (HDL-C),
whereas low-fat diets resulted in reductions across the lipid
panel, including high-density lipoprotein (HDL). Results
for surgery were consistent across malabsorptive and restrictive surgery (2).
The Writing Committee suggested that data
from these 2 systematic reviews can support shared
decision-making and help with recommending treatment
for hyperlipidemia.

Measurement of lipids
1.1

In adults with endocrine disorders, we recommend
a lipid panel for the assessment of TG levels and
for calculating low-density lipoprotein cholesterol
(LDL-C). (1⊕⊕⊕O)

Technical Remarks:
• Nonfasting lipid panels are acceptable for initial
screening.
• If TG levels are elevated or if genetic dyslipidemia is
suspected, repeat a fasting lipid panel.
• If lipoprotein(a) [Lp(a)] levels are measured, fasting or
nonfasting samples can be obtained.
Evidence and discussion
In adults, the long-standing standard clinical approach
for lipid assessment uses blood obtained after an 8to 10-hour fast overnight, allowing only water and
noncaffeinated beverages. The lipid panel consists of
plasma or serum concentrations of total cholesterol, TG,
HDL-C, and a calculated value of LDL-C. Table 1 shows
typical changes in lipid and lipoprotein levels, including
Lp(a) in the endocrine and metabolic disorders discussed
in this guideline. HDL-C, and TG have normal ranges
based upon population distribution. LDL-C does not
have a normal range because “optimal” LDL-C concentrations vary according to the degree of ASCVD risk of
the individual.
The initial classification of hyperlipidemia proposed by
Fredrickson in 1967 introduced a system for identifying
lipoprotein disorders and arbitrarily required 12 to 16
hours of fasting (3, 4). The Friedewald formula, subsequently introduced in the 1970s, has been widely used to
estimate LDL-C by subtracting the sum of HDL-C and very
low-density lipoprotein (VLDL) cholesterol (estimated by
TG/5) from total cholesterol, and used fasting data (5).
This equation uses a fixed ratio of 5:1 between TG and

VLDL cholesterol. With the development of standardized, automated, high throughput enzymatic analyses in
the 1980s, rapid measurement of serum cholesterol and
TG has been possible. The Friedewald formula is generally
considered accurate within serum TG levels under 150 mg/
dL (1.7 mmol/L) and LDL-C levels of at least 70 mg/dL
(1.8 mmol/L) (6). In people with high TG, estimated low
LDL-C, diabetes, or obesity, apolipoprotein B (apoB) or
non-HDL-C may be useful for assessment of ASCVD risk.
Since it has become evident that the Friedewald formula
underestimates LDL-C as serum TG levels increase above
150 mg/dL (1.7 mmol/L) or with LDL-C levels under 70 mg/
dL (1.8 mmol/L), new and more accurate approaches to estimate LDL-C have been developed. The Martin-Hopkins
formula is gaining wider use for calculation of LDL-C and
uses an adjustable correction factor based on TG and nonHDL-C levels. It appears to have greater accuracy in both
fasting and nonfasting samples as well as in settings of low
LDL-C and high TG (7, 8). The Martin-Hopkins equation reduces the need for routine, direct measurement of
LDL-C and is gaining wider use. Recently, in 2020, a new
equation developed from the NIH proposes LDL-C estimation that can be used in patients with TG up to 800 mg/dL
(9.0 mmol/L) (9).
Fasting versus nonfasting lipid testing
In the past decade, there has been a push toward nonfasting
measurements of lipids because of convenience and practicality. Nonfasting blood samples simplify the process for
patients, laboratories, and clinicians and are likely to improve patient follow-through with lipid testing. There is
some evidence that nonfasting lipid panels may improve
cardiovascular (CV) risk prediction (10–12). A metaanalysis of 68 prospective studies in over 300 000 individuals, from the Emerging Risk Factors Consortium (13)
suggests that lipid assessment in vascular disease can be
simplified by measurement of either total cholesterol,
HDL-C, or apos from nonfasting samples without regard
to TG. In the 20 studies that used nonfasting blood samples, the strength of the association between plasma lipid
concentrations and incident CV events was preserved.
Nonfasting non-HDL-C and nonfasting calculated LDL-C
were superior to fasting measurements for predicting CV
risk (n = 103 354; number of events 3829). A nonfasting
TG level of 175mg/dL (2.0 mmol/L) has been suggested
as a cutoff point to identify CV risk (14). However, a
pooled study of 2 large cohorts showed an increase in CV
risk even in the 89–176 mg/dL (1.0–2.0 mmol/L) range
for nonfasting TG (15). Further, almost all clinical trials
with lipid-lowering drugs have used fasting lipid samples.
Limited data suggests that for the same individual, fasting
and nonfasting lipid levels are similarly associated with CV
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1. Screening and cardiovascular disease risk
assessment
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Table 1. Lipids and lipoproteins in select endocrine disorders
LDL-C

HDL-C

TG

Lp(a)

Type 2 diabetes
Type 1 diabetes
Obesity
Hypothyroidism
Subclinical hypothyroidism
Hyperthyroidism
Cushing’s syndrome/disease
Chronic glucocorticoid therapy
Adult growth hormone deficiency
Acromegaly
Polycystic ovary syndrome
Menopause vs premenopause
Oral HRT for menopause
Male hypogonadism
Testosterone replacement for male hypogonadism
Anabolic steroid abuse
Gender affirming hormone therapy: transmen
Gender affirming hormone therapy: transwomen

No change or ↑
No change or ↑
No change or ↑
No change or ↑
No change or ↑
↓
No change or ↑
No change or ↑
↑
No change or ↑
No change or ↑
↑
↓
↑
No change or ↓
↑
↑
–

Normal or ↓
Normal or ↓
↓
Normal or ↑
Normal or ↓
Normal or ↓
Normal or ↓
Normal or ↑
Normal or ↓
Normal or ↓
↓
Normal or ↓
↑
Normal or ↓
Normal or ↓
↓
↓
–

↑
↑
↑
Normal or ↑
Normal
Normal or ↑
↑
Normal or ↑
Normal or ↑
↑
↑
Normal
↑
↑
Normal or ↓
Normal or ↑
↑
↑

–
–
–
Normal or ↑
Normal
↓
Normal or ↑
–
Normal
↑
↑
Normal or ↑
↓
Normal or ↑
↓
↓
–
–

Abbreviations: CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HRT, hormone replacement therapy; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein(a), TG, triglycerides.
The normal range for HDL-C is ≥40 mg/dL (1.0 mmol/L) in men and ≥50 mg/dL (1.3 mmol/L) in women. The normal range for TG is 0–150 mg/dL (0–1.7 mmol/L).
Lp(a) ≥50 mg/dL (125 mmol/L) is considered a CVD risk-enhancing factor. Evidence is limited on the effects of transgender hormone therapy on lipids.
↓, decreased; ↑, increased; Normal, indicates within the normal range; –, data insufficient.

events (16); however, no randomized outcomes trials have
been conducted using nonfasting TG as a key biomarker.
•
Cardiovascular risk assessment
1.2

1.3

In adults with endocrine disorders, we recommend
conducting CV risk assessment by evaluating
traditional risk factors, including calculation
of 10-year ASCVD risk using a tool such as the
Pooled Cohort Equations. (1⊕⊕⊕O)
In adults with endocrine disorders at borderline or
intermediate risk (10-year ASCVD risk 5–19.9%),
particularly those with additional risk-enhancing
factors, in whom the decision about statin
treatment and/or other preventive interventions is
uncertain, we suggest measuring coronary artery
calcium (CAC) to inform shared decision-making.
(2⊕⊕⊕O)

Technical Remarks:
• Borderline and intermediate CV risk are defined as 5%
to 7.4% and 7.5% to 19.9% 10-year ASCVD risk using
the Pooled Cohort Equations.
• Risk-enhancing factors are additional features, including
diseases, that enhance the risk of ASCVD beyond the risk

•

•

•

associated with major risk factors and/or the calculated
10-year risk of ASCVD.
In patients with additional risk-enhancing factors,
including elevated Lp(a), as described below, risk
assessment should consider traditional 10-year ASCVD
risk assessment and the presence of risk-enhancing
factors. The CAC score should be considered when risk
assessment and treatment decisions remain uncertain.
At present, we suggest measuring CAC as the preferred
tool for assessment of subclinical atherosclerosis. Other
techniques to assess atherosclerotic burden are being
developed.
CAC = 0 marks very low risk of ASCVD. In patients with
baseline CAC = 0, evidence suggests that it is reasonable
to repeat a CAC scan after 5 to 7 years in low-risk
patients, 3 to 5 years in borderline-to-intermediate risk
patients, and in 3 years for high-risk patients or those
with diabetes.
In patients without diabetes or ASCVD and with
LDL-C >70 mg/dL (1.8 mmol/L) and 10-year ASCVD
risk >7.5%, or 10 year ASCVD risk 5% to 7.4% plus
1 or more risk-enhancing factors, or CAC score over
the 75th percentile for age, sex, and race, or CAC score
>100, the initiation of a statin, as adjunct to diet and
exercise, is advised after a discussion of the risks/
benefits with the patient.
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1.4

In adult patients with a family history of premature
ASCVD, or a personal history of ASCVD or family
history of high Lp(a), we suggest measuring Lp(a)
to inform decision-making about short-term and
lifetime ASCVD risk and the need to intensify
LDL-C–lowering therapy. (2⊕⊕OO)

Evidence and discussion
Clinical risk assessment is critical for matching the intensity of treatment to the degree of absolute CV risk.
There is a rich amount of literature on advanced risk
assessment in CV medicine (17). Previously, studies assessed whether a single new marker might “add” to traditional risk factors for risk stratification; new studies
increasingly compare multiple markers to each other and
assess advanced metrics such as area under the receiver
operating curve and net reclassification index (NRI) (18).
Through this process, a hierarchy has emerged of tests
that add the most to global risk discrimination and those
that add the least. Current expert consensus in the field
is summarized below.
The first step in risk prediction is the calculation of
10-year risk using a clinical risk tool, which in the United
States should be the American College of Cardiology
(ACC)/American Heart Association (AHA) Pooled Cohort
Equations
(http://static.heart.org/riskcalc/app/index.
html#!/baseline-risk), derived from the following cohorts:
Framingham Heart and Framingham Offspring, Coronary

Artery Risk Development in Young Adults (CARDIA),
Atherosclerosis Risk in Community (ARIC), and the
Cardiovascular Health Study (CHS) (19, 20). This risk algorithm uses traditional risk factors, including age, sex,
race, systolic blood pressure, treatment for hypertension,
total cholesterol, HDL-C, smoking, and diabetes, for the
calculation of 10-year risk of myocardial infarction (MI),
stroke, and CV death. Additional risk-enhancing factors
include family history of premature coronary artery disease (CAD), metabolic syndrome (MetS), chronic kidney
disease (CKD), chronic inflammatory conditions such
as rheumatoid arthritis, history of early menopause, or
preeclampsia, and high-risk race/ethnicities, including
South Asian ancestry. Risk assessment is described in
Table 2.
Novel risk assessment tools that can be added to traditional risk assessment and risk-enhancing factors are generally grouped into 4 categories: genetic, lipid, other serum
biomarkers, and imaging.
Genetic tests for risk stratification, such as polygenic
risk scores (21), may modestly improve risk prediction.
However, these are not currently available in clinical
practice.
Advanced lipid testing can include direct serum measurement of apoB, fractionation of conventional lipid subclasses
(eg, differentiation of small, dense LDL-C from larger, more
buoyant particles), direct measurement of lipoprotein particle number, and measurement of Lp(a) (22, 23). Current
evidence suggests that some of these tests may be helpful in
further characterizing lipid abnormalities, including diagnosis of underlying genetic dyslipidemias. However, multiple expert panels and guidelines have concluded that these
tests add little to risk prediction beyond the standard lipid
profile (19, 23). In particular, non-HDL-C (total cholesterol – HDL-C), which can be calculated from a standard
fasting or nonfasting lipid panel, predicts risk similarly

Table 2. Assessment of ASCVD risk in patients with endocrine diseases
Suggested Steps in Risk Assessment
•
•
•
•
•
•

Determine if the patient has established ASCVD or long-standing diabetes. If not, proceed with risk assessment.
Calculate the 10-year risk using the Pooled Cohort Equations (http://static.heart.org/riskcalc/app/index.html#!/baselinerisk)
Assess for presence of additional risk-enhancing factors.
The Endocrine Society considers persistent Cushing syndrome and Cushing disease, high-dose chronic glucocorticoid
therapy, and possibly adult GHD, acromegaly, and hypothyroidism as risk-enhancing factors.
In borderline-to-intermediate risk patients (10-year ASCVD risk of 5% to 19.9%), consider a coronary artery calcium
score, particularly when risk enhancing factors are present.
Conduct a clinician–patient risk discussion, including discussion of lifetime risk and lifetime lipid-lowering treatment benefit, along with patient preferences.

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; GHD, growth hormone deficiency.
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Technical Remarks:
• Lp(a) ≥50 mg/dL (125 nmol/L) enhances risk of ASCVD.
• Lp(a) testing does not need to be repeated if it has
previously been measured (ie, in childhood or early
adulthood).
• It is not yet known whether reducing Lp(a) reduces
ASCVD.
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to apoB testing or other advanced lipid testing (23, 24).
ApoB ≥130 mg/dL (1.3 g/L) or non-HDL >190 mg/dL
(4.9 mmol/L) should be considered risk-enhancing factors.

Measurement of coronary artery calcium
Common imaging tests for advanced risk assessment are
aimed at directly assessing the burden of subclinical atherosclerosis. Most notable among these are carotid ultrasound tests for carotid intima-media thickness (cIMT) and
carotid plaque, and cardiac-gated computed tomography
(CT) scans for the assessment of CAC. These tests have the
advantage of directly assessing end-organ damage, thus
integrating a variety of risk exposures and personalizing
this assessment to the individual patient in a particular
vascular bed of interest, such as the coronary arteries (36).
A drawback of these tests can be the subsequent management of incidental findings, for example of small nodules
identified in the lung fields.
Many studies directly compare the performance of
multiple advanced risk assessment strategies (37, 38). The
most promising tests have been hsCRP, to test for subclinical inflammation and CAC, and carotid ultrasound
to test for subclinical atherosclerosis. In comparative effectiveness analysis, there is consensus that the single best
test for improving risk assessment is the CAC score (39).
The CAC score leads to the largest improvements in area
under the receiver operating curve over traditional risk factors (C-statistic change ~0.05) and the largest NRI values
(~0.60 in intermediate risk patients). Furthermore, the
CAC score outperforms carotid ultrasound in head-to-head
comparative effectiveness analysis (40).
CAC can be performed on any modern multidetector CT
scanner in about 10 to 15 minutes with about 1 mSv of radiation (approximately similar to a bilateral mammogram).
When the CAC score is zero (CAC = 0), patients are low risk
and can be reclassified into lower-risk groups with less aggressive lipid therapies (41). When the CAC score is elevated
(CAC >100 or >75th percentile for age, sex, and race), patients
can be moved into higher-risk categories and treated more aggressively, using statins with or without nonstatin therapies to
achieve lower LDL-C levels (42). There is good evidence that
CAC can identify select patients with severe lipid disorders
but who have no detectable (calcified) coronary atherosclerosis and who are, therefore, at relatively low risk (43) (Fig. 1).
The 2017 guidelines from the Society of Cardiovascular
Computed Tomography (SCCT) defined 2 broad groups that
might benefit from CAC testing for advanced risk assessment: (1) those with a 10-year ASCVD risk of 5% to 20%,
and (2) those with a 10-year risk <5%, with a family history
of premature CAD or with another risk condition (44). The
2018 AHA/ACC Cholesterol Guidelines also endorse CAC,
with an IIA recommendation in patients at borderline-tointermediate risk (10-year ASCVD risk 5–19.9%) and in
highly selected lower-risk patients with risk-enhancing
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Measurement of lipoprotein(a)
Lp(a) is a modified low-density lipoprotein (LDL)-like
particle in which apolipoprotein a (apo[a]), a large protein
with structural similarity to plasminogen, is covalently
bound to apoB. Circulating Lp(a) levels are primarily
determined by the apo(a) genotype, without significant
dietary or environmental influences (25). Epidemiological
studies, Mendelian randomization studies, and genomewide association studies all show increased CVD risk
in individuals with elevated Lp(a) (25–28), but clinical
trial data showing CV benefit of lowering Lp(a) are
lacking. Inhibitors of Lp(a) production (ie, apo[a] antisense oligonucleotides and siRNA) are currently in development (29). Standardized immunoassays for Lp(a) are
now widely available (30). Values are reported as nmol/L
or mg/dL; the nmol/L level being roughly 2 to 3 times
greater than the mg/dL level. Lp(a) appears to be unaffected by fasting status and can be measured in fasting
or nonfasting states.
Lp(a) levels can be very helpful for assessment of familial
risk. In cases of early advanced atherosclerosis, Lp(a) testing
may also be useful to explain less-than-expected LDL-C reduction with statins, since statins do not lower Lp(a) levels,
but when these are elevated, the cholesterol content of Lp(a)
contributes significantly to calculated and directly measured LDL-C. However, this test adds little in terms of global
risk assessment across the general population and thus does
not have characteristics of a good screening test (19, 23).
However, some experts believe that every patient should
have Lp(a) measured once, perhaps in childhood or early
adulthood during routine lipid screening (31). In appropriately selected patients with familial risk, elevated Lp(a)
≥50 mg/dL or ≥125 nmol/L should be considered a riskenhancing factor that may drive more aggressive treatment
or the need for advanced risk assessment. Evidence from the
Women’s Health Study and the Women’s Health Initiative
suggest that elevated Lp(a) only predicts ASCVD in women
with total cholesterol above 220 mg/dL (5.7 mmol/L) (32).
Multiple serum biomarkers have been proposed for advanced risk assessment that test for inflammation, oxidative stress, endothelial dysfunction, thrombosis, and other
important pathways (19). In general, although widely
available, serum markers suffer from higher intertest variability. At this time, even multiple biomarker panels have
been shown to add little to global risk assessment (33, 34).
Only elevated high-sensitivity C-reactive protein (hsCRP)
≥2.0 mg/L (19.0 nmol/L), a serum biomarker of inflammation supported by robust risk-prediction literature, should
be used as a risk-enhancing factor that may drive more

aggressive treatment or the need for advanced risk assessment (35).
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factors (35). According to the AHA/ACC guidelines, riskenhancing factors that can be used to justify CAC scanning
include MetS, inflammatory disorders (eg, rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis),
HIV, hypertriglyceridemia, South Asian ancestry, history of
premature menopause (before age 40 years), and pregnancyrelated complications such as preeclampsia. The present
Endocrine Society guideline identifies additional disorders
that enhance ASCVD risk: Cushing syndrome, Cushing disease, high-dose chronic glucocorticoid therapy, and possibly
adult GHD, acromegaly, and hypothyroidism.
Table 3 shows a general approach to using CAC to inform
initial lipid-lowering therapy. In patients with an initial CAC
of zero, a repeat CAC test should be considered to re-assess
the CAC score and therefore possible risk (and treatment)
reclassification; recent data from an analysis of CAC scores
and coronary events in Multi-Ethnic Study of Atherosclerosis
supports the following schedule: low-risk patient (10-year
ASCVD risk <5%, 5 to 7 years), borderline-to-intermediate
risk patient (10-year ASCVD risk 5% to 19.9%, 3 to 5 years),
high-risk patient (10-year ASCVD risk ≥20%, 3 years) or patient with diabetes (3 years) (45, 46). Coronary artery calcium should generally not be repeated in already aggressively
treated patients, as it is not designed to be a measure of lipidlowering treatment efficacy.
Caution must be taken when applying CAC scoring to
patients with high risk, such as genetically proven familial
hypercholesterolemia (FH). As CAC identifies only the calcified component of coronary plaque (as seen first in a
type 4 atheroma), early noncalcified plaque can be missed.
In young patients with high risk, genetically proven FH or

Values and preferences
This guideline places a high value on the shared
decision-making process (the clinician–patient risk discussion). Additional risk information is considered highly important in carrying out an effective clinician–patient risk
discussion regarding individualization of preventive therapies. For example, a general discussion of lifetime ASCVD
risk, and accordingly, lifetime treatment benefit, may be an
important part of the clinician–patient risk discussion in
younger adults. When a patient is unwilling or unable to take
medication or prefers taking preventive medication at any
level of risk, there is little value in advanced risk stratification
beyond the standard traditional risk factor assessment.

2. Hypertriglyceridemia
2.1

In adults with fasting TG levels over 500 mg/
dL (5.6 mmol/L), we recommend pharmacologic
treatment as adjunct to diet and exercise to
prevent pancreatitis. (1⊕OOO)

Technical Remark:
• Patients with TG levels over 1000 mg/dL (11.3 mmol/L)
often do not get an adequate response to medications;
therefore, control of diabetes, modification of diet, and
weight loss are essential.
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Figure 1. CVD events per 1000 person-years by strata of CAC and LDLC. CAC predicts ASCVD risk independent of LDL-C. Patients with lower
LDL-C but higher CAC remain high risk, while patients with higher LDL-C
but CAC = 0 remain low risk. Abbreviations: CAC, coronary artery calcium; CVD, cardiovascular disease; LDL, low-density lipoprotein; LDL-C,
low-density lipoprotein cholesterol. Reproduced with permission from
Martin SS, Blaha M, Blankenstein R, et al. “Dyslipidemia, coronary
artery calcium, and incident atherosclerotic cardiovascular disease:
implications for statin therapy from the multi-ethnic study of atherosclerosis.” Circulation, 2014;129(1):77–86. (43)

other atherogenic endocrine conditions that might have been
present from a young age (eg, severe obesity, diabetes), such
early plaque is indicative of the need for continued aggressive lipid lowering, and CAC should not be used as the only
deciding factor about the intensity of lipid-lowering therapy.
In limited scenarios, CT angiography can be used to detect
early noncalcified plaque, although such testing is generally
reserved for symptomatic patients. Caution also is advised in
interpreting CAC as zero in active smokers, who have additional thrombotic risk beyond their burden of atherosclerosis.
There is now excellent evidence that CAC reclassifies risk
in patients with MetS and T2D. For example, Malik et al
studied 1738 participants with MetS and 881 participants
with T2D from the National Institutes of Health/National
Heart, Lung, and Blood Institute-funded Multi-Ethnic Study
of Atherosclerosis (48). After a mean 11.1 years of follow-up,
the NRI for CAC in MetS was 0.22, and the NRI for CAC
in diabetes was 0.23, indicating good risk reclassification of
these groups. Participants with MetS and T2D with CAC of
zero had low event rates, and CAC ≥400 was associated with
a 3.2- and 3.5-fold increased risk of ASCVD, respectively. The
CAC score predicted risk even after controlling for diabetes
duration of 10 years or longer at baseline, insulin use, and
glycemic control. CAC scoring also predicts risk in T1D (49).
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Table 3. Proposed decision-making approach to selective use of coronary artery calcium measurement for risk prediction
Using 10-year ASCVD Risk Estimate plus CAC Score to Guide Statin Therapy
Patient’s 10-year ASCVD risk estimate

<5%

5–7.4%

7.5–19.9%

≥20%

Consulting ASCVD risk estimate alone

Statin not
recommended
Statin not
recommended
Statin may be
considered
X
CAC less effective for
this population

Consider statin

Recommend statin

Recommend statin

Statin generally not
recommended
Recommend statin

Statin generally not
recommended
Recommend statin

Recommend statin

✓
CAC can reclassify
risk up or down

✓
CAC can reclassify
risk up or down

Consulting ASCVD risk
estimate + CAC

If CAC score = 0
If CAC score >0

Does CAC score modify treatment plan?

Recommend statin

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium.
CAC = 0 should not be used as sole justification for use of lifestyle alone, to the exclusion of pharmacotherapy in familial hypercholesterolemia, advanced diabetes,
and/or active smoking.
From Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. “Coronary Calcium Score and Cardiovascular Risk.” J Am Coll Cardiol. 2018; 72(4): 434–447.
(47)

Evidence and discussion
Although the relationship between severe hyper
triglyceridemia and incident acute pancreatitis is well established, the lack of randomized-controlled trials (RCTs)
testing whether TG reduction does prevent pancreatitis
has led some to question whether the relationship is causal
(50). In patients with marked hypertriglyceridemia, it is
important to assess medications, and if possible, discontinue those such as estrogen and bile acid sequestrants
that contribute to TG elevations. A more extensive list
is in the section on “Considerations for Implementation
of the Guidelines.” Medications such as statins, fibrates,
and omega-3 fatty acids, as adjunct to lifestyle modification, can adequately reduce TG in patients with TG
500 to 1000 mg/dL (5.6 to 11.3 mmol/L), and thereby
reduce the risk of pancreatitis. However, in patients with
severely elevated TG above 1000 mg/dL (11.3 mmol/L),
these medications may not adequately lower TG and,
therefore, a very low fat diet, weight loss, avoidance of
alcohol, and glycemic control in people with diabetes
may be needed to prevent pancreatitis. Recently, however,
volanesorsen, an investigational antisense oligonucleotide to apoC3, has been reported to dramatically reduce
TG levels in patients with severe TG elevation (fasting
chylomicronemia syndrome) due to homozygous lipoprotein lipase (LPL) deficiency (51, 52). However, safety
considerations include thromobocytopenia, which can be
severe and is unpredictable. The New Drug Application
for volanesorsen was not approved by the US Food and
Drug Administration (FDA); however, volanesorsen has
been approved for use in the European Union.

2.2

In patients with TG-induced pancreatitis, we
suggest against the use of acute plasmapheresis as
first-line therapy to reduce TG levels. (2⊕OOO)

Technical Remark:
• Plasmapheresis may be useful in those who do
not respond to conventional methods of lowering
TG, such as individuals who have extraordinarily
elevated TG levels (eg, over 10 000 mg/dL
[112.9 mmol/L]) or in extremely high-risk situations
such as pregnancy.
Evidence and discussion
Plasmapheresis has been suggested to be useful for the
acute management of TG-induced pancreatitis (53–58).
However, for most cases of TG-induced pancreatitis, there
is no evidence to support its superiority over cessation
of oral fat intake, after which TG levels fall rapidly if no
additional chylomicrons enter the circulation. Moreover,
plasmapheresis only improves TG levels temporarily
without addressing the underlying cause (59). In 1 single
site study, outcomes from TG-induced pancreatitis were
not improved when a plasmapheresis protocol was introduced (60). Use of plasmapheresis should be considered
an option only in patients who do not respond to conventional methods or who have extraordinarily elevated TG
levels (eg, over 10 000 mg/dL [112.9 mmol/L]). In addition,
plasma exchange to supply apolipoprotein CII is beneficial in the extremely rare patients with apolipoprotein CII
deficiency.
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X
CAC not effective
for this population
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2.3

In patients without diabetes who have TG-induced
pancreatitis, we suggest against the routine use of
insulin infusion. (2⊕OOO)

Technical Remark:
• When uncontrolled diabetes is present, insulin therapy
should be used to normalize glucose levels.

2.4

In adults who are on statins and still have
moderately elevated TG levels >150 mg/dL
(1.7 mmol/L), and who have either ASCVD or
diabetes plus 2 additional risk factors, we suggest
adding eicosapentaenoic acid (EPA) ethyl ester to
reduce the risk of CVD. (2⊕⊕⊕O)

Technical Remarks:
• Risk factors include traditional risk factors and riskenhancing factors.
• The dose of EPA ethyl ester is 4 g/day.
• If EPA ethyl ester is not available or accessible, then it is
reasonable to consider a fibrate.

Evidence and discussion
The relationship between hypertriglyceridemia and increased CV risk has been known for nearly 50 years. This
association was found in several epidemiology studies and
was stronger in women (67). Within the last decade, a
number of genetic analyses implicated genes that modulate
TG levels to be causal in the pathophysiology of atherosclerosis and CVD (68–70), and they have confirmed that
heterozygous deletion and other types of mutations of LPL
increase CVD risk (71).
The VA-HIT trial in men with coronary disease,
low HDL-C, mild elevation in TG (mean TG 160 mg/d
[1.8 mmol/L]) and mean LDL-C 112 mg/dL (2.9 mmol/L)
found a significant reduction in the composite primary
endpoint of nonfatal MI or coronary death in subjects randomized to gemfibrozil versus placebo (72). This trial was
conducted before the widespread use of statins in people
with ASCVD. Subsequently, studies of fibrates have been
interpreted as showing reduced CV events in post hoc analyses in patients with increased TG levels and low HDL
levels; however, the overall benefit of these drugs in statintreated patients has not been shown. Although a series of
fenofibrate studies, including ACCORD, which was confined to subjects with T2D, have shown no overall CV
benefit in statin-treated patients, subgroup analyses of
those patients with TG levels over 200 mg/dL (2.3 mmol/L)
and low levels of HDL (<40 mg/dL [1.0 mmol/L]) showed
benefit (73). These subgroup analyses were not prespecified,
with the exception of the ACCORD trial. These results are
statistically imperfect, as they involved subgroups merged
for a meta-analysis. An ongoing CV outcome study of a
PPAR alpha agonist, PROMINENT, is confined to individuals with hypertriglyceridemia (TG 200–499 mg/dL [2.3–
5.6 mmol/L]) and low HDL-C (<40 mg/dL [1.0 mmol/L] in
men and women) and will, for the first time, provide a valid
test of the important question of CVD effects of a fibrate
added to a statin in the setting of high TG.
Multiple trials have failed to show any CVD benefit
of 1 g/d of mixed EPA + dososahexanoic acid (DHA),
generally as omega-3 acid ethyl esters (O3AEE) (74, 75).
In contrast, in a double blind RCT, REDUCE-IT, in a
high-risk statin treated population with LDL-C below
100 mg/dL (2.6 mmol/L) and elevated fasting TG up to
500 mg/dL (5.6 mmol/L), EPA ethyl ester 4 g daily reduced CVD events (relative risk reduction [RRR] 25%)
(76). The study population consisted of patients with
either ASCVD, or T2D and 2 additional risk factors.
Although the inclusion criteria specified that patients
with diabetes have at least 1 additional risk factor, analysis of the actual trial population revealed that most
patients with diabetes had at least 2 other risk factors
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Evidence and discussion
There is little data to support the use of insulin infusion in TG-induced pancreatitis. In nonhyperglycemic
patients, low-dose insulin (1 to 2 units per hour) is usually sufficient to block adipose tissue lipolysis, reduce
circulating free fatty acid (FFA) levels, and theoretically reduce TG production by the liver. Insulin also can
increase LPL activity, which may accelerate the clearance of TG from plasma. Although a reduction in TG
after insulin infusion in individuals without diabetes
who have TG-induced pancreatitis has been reported
in several case studies (61–65), whether similar changes
would have occurred simply by restricting oral intake
without the use of insulin is unclear (66). A single study
of chylomicronemia associated with uncontrolled diabetes demonstrated that fasting plus insulin infusion led
to more rapid TG lowering than insulin alone (66). This
is likely due to a reduction in adipose tissue lipolysis
leading to reduced hepatic TG synthesis; plasma FFAs
are normally reduced with very low doses of insulin.
Given there is no clear evidence and only small studies
in which possible efficacy cannot be ruled out, judicious
use of low-dose insulin could be considered.
The use of high doses of insulin, such as the amounts
routinely used for diabetic ketoacidosis (>0.1 units/kg),
increases the risk of acute hypoglycemia. When used with
concomitant glucose infusion to prevent hypoglycemia, it is
likely to lead to carbohydrate-induced increase in TG production, which would be counterproductive.
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2.5

In patients with elevated TG (>150 mg/dL to
499 mg/dL [1.7 mmol/L to 5.6 mmol/L]), we
suggest checking TG before and after starting a
bile acid sequestrant. (2⊕OOO)

Technical Remark:
• Bile acid sequestrants are contraindicated when TG are
> 500 mg/dL (5.6 mmol/L).
Evidence
Although bile acid sequestrants are seldom used today
for the treatment of hypercholesterolemia, they are used
on occasion in people with diabetes because they also
lower hemoglobin A1c (HbA1c) (79). Use of bile acid
sequestrants can lead to an increase in plasma TG due
to an increase in VLDL production rates, although this
effect is variable (80). Individuals with high baseline levels
of TG (>500 mg/dL [5.6 mmol/L]) can reach very high
levels after treatment with bile acid sequestrants (81). As
a result, it has been suggested that hypertriglyceridemia
is a relative contraindication to the use of this class of
drugs (81). In a meta-analysis, TG were also shown to

increase significantly after the use of a newer bile acid
sequestrant, colesevelam (82). Due to the variability of
the response, we suggest checking plasma TG before
starting and again several weeks after initiating a bile
acid sequestrant.

3. Type 2 diabetes mellitus
3.1

In adults with T2D and other CV risk factors, we
recommend statin therapy in addition to lifestyle
modification in order to reduce CV risk. (1⊕⊕⊕⊕)

Technical Remarks:
• High-intensity statins should be chosen in patients with
ASCVD, or those with risk factors for ASCVD, or risk
enhancing factors.
• Statins should not be used in women who are pregnant
or trying to become pregnant.
• In patients over the age of 75, continuation of statin
treatment or initiation of statin treatment depends
upon ASCVD risk, prognosis, potential interacting
medications, polypharmacy, mental health, and the
wishes of the patient.
Evidence and discussion
Dyslipidemia in T2D is characterized by hyper
triglyceridemia, low levels of HDL-C, and average or
borderline elevations of LDL-C (83). LDL particles are typically small and dense (83). Total apoB levels are elevated
(84), reflecting an increase in the number of TG-rich lipoprotein and small, dense LDL particles. Similar lipid abnormalities are often observed in MetS in the absence of overt
diabetes (85).
There is consensus that ASCVD risk is increased 2- to
4-fold in T2D (86, 87), the magnitude of the increased
risk varying between studies. Some have considered
T2D to be a “CVD risk equivalent” (88) (ie, as strong a
risk factor as established CVD). Others suggest that the
risk is less strong than established CVD (89), but there
is no disagreement that CVD risk is indeed increased
in T2D. A population-based retrospective cohort study
showed the transition to a high-risk category for CVD
at a younger age for people with diabetes than for those
without (mean difference 14.6 years). Men and women
with diabetes entered the high-risk category for acute
MI, stroke, or death from any cause at ages 47.9 and
54.3 years, respectively (90). This study also found that
the protective effect of female sex on CVD was attenuated by diabetes. The age-adjusted hazards ratio (HR)
for acute MI in people without diabetes was 2.56 (95%

Downloaded from https://academic.oup.com/jcem/article/105/12/3613/5909161 by guest on 04 August 2022

(77). The latter were either traditional risk factors or
factors that would be considered risk-enhancing factors:
hsCRP > 3 mg/L; creatinine clearance >30 and <60 mL/
min; and retinopathy, microalbuminuria, and ankle brachial index <0.9 (78). The reduction in ASCVD events
did not appear to be related either to the degree of baseline TG elevation or to the on-treatment TG levels <150
vs >150 mg/dL (<1.7 vs >1.7 mmol/L) (76). Further, a
prespecified subgroup analysis of those patients with or
without T2D showed similar benefits.
REDUCE-IT was not the first randomized CVD outcomes trial to show benefit with pure EPA. CVD benefit
was reported in a randomized but open-label trial of
pure EPA, using 1.8 g/d of an ethyl-ester preparation
essentially identical to EPA ethyl ester, in a population of Japanese patients, but this trial was open label,
which could introduce bias. The CVD benefit seen in
REDUCE-IT does not apply to other omega-3 fatty
acids, particularly those with a mix of EPA and DHA.
STRENGTH was the first trial of a mix of EPA plus
DHA at full dose (4 g/d) in patients recruited for elevated
TG (200–499 mg/dL [2.3–5.6 mmol/L], along with low
HDL-C (<40 mg/dL [1.0 mmol/L] in men and <45 mg/
dL [1.2 mmol/L] in women). Participants did not have a
history of CVD events but were at high risk of CVD. The
trial was discontinued by the data monitoring board due
to its low likelihood of success. No data are yet available
to support the use of supplements containing both EPA
and DHA to reduce ASCVD risk.
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study, intensive glucose control in patients with poorly controlled T2D had no significant effect on the rates of major
CV events or death after a follow-up period of 5.6 years
(106). Pioglitazone in Pro-Active (107); the GLP-1 receptor
agonists liraglutide in the LEADER trial (108), dulaglutide
in REWIND (109), and albiglutide in HARMONY
OUTCOMES (110); the SGLTL2 inhibitors empagliflozin
in EMPA REG OUTCOMES (111); canagliflozin in the
CANVAS trial (112); and dapagliflozin in DECLARE-TIMI
58 (113) have all been reported to reduce CVD outcomes,
although the role of glucose lowering per se is unclear.
Of the various therapies to prevent or treat CVD in
T2D, the most successful to date has been statins, which act
mainly by inhibiting HMG-CoA reductase, the rate-limiting
enzyme in cholesterol synthesis, thereby upregulating
LDL receptors and lowering plasma LDL-C levels. Even
though LDL-C levels are not usually elevated in diabetes,
the benefit of statins was first demonstrated in the Heart
Protection Study, an RCT comparing 40 mg simvastatin
daily to placebo (114). In a prespecified secondary analysis
of participants with diabetes randomized to simvastatin
40 mg, the rate of first major vascular events (eg, major
coronary events, strokes, revascularizations) was reduced
by 22% (95% CI: 13–30) over 5 years (115). Subsequent
events were also reduced (115). In those with diabetes who
did not have a history of vascular events at entry into the
study, there was a significant 33% (95% CI: 17–46) reduction in the rate of vascular events.
In CARDS, 10 mg atorvastatin daily, in comparison to
placebo, over 3.9 years, reduced the risk of first CV events,
including stroke, by 37% (95% CI: -52 to -17, P = 0.001)
in patients with T2D, without high LDL-C levels and with
no history of CVD (116). However, these findings were
not confirmed in the ASPEN trial, albeit this trial had several design problems (117). Nonetheless, meta-analyses
that include more than 100 000 subjects (118) strongly
support the beneficial effect of statins in CVD prevention
in T2D. Statins have purported pleotropic effects other
than lipid lowering effects, so it is conceivable that some
of these pleotropic effects might have contributed to the
prevention of CVD events. However, the meta-analyses (of
statin RCTs) indicate that CVD events decrease by about
20% and mortality by about 10% for every 40-mg/dL
(1.0 mmol/L) reduction in LDL-C in people with diabetes
(118, 119), suggesting that lipid lowering plays a much
greater role in CVD prevention than possible pleotropic
effects. In the Cholesterol Treatment Trialists (CTT) metaanalysis of people with diabetes in 14 randomized trials
of statins, with a mean treatment duration of 4.3 years,
similar reductions in MI or coronary death (0.78, 0.69–
0.87; P <0.0001), coronary revascularization (0.75, 0.64–
0.88; P <0.0001), and stroke (0.79, 0.67–0.93; P = 0.0002)
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confidence interval [CI]: 2.53–2.60) in men compared
with women, and in people with diabetes 1.40 (CI: 1.36–
1.43) in men compared with women, and lower when adjusted for sociodemographic factors, comorbidities, and
use of health care services. Individuals with diabetes (and
MetS) often have several CVD risk factors, including
hyperglycemia, hypertension, nephropathy, and cigarette
use, in addition to dyslipidemia. It is difficult to apportion the extent that each risk factor contributes to overall
CVD risk. However, in an analysis of risk factors in the
UK Prospective Diabetes Study (UKPDS), LDL-C was the
strongest predictor of CVD events (91). This observation
is supported by strong evidence that CVD risk is reduced
to a greater extent by lowering LDL-C levels than by
treatment of other risk factors.
Dyslipidemia often improves following the initiation of
all modalities of glucose-lowering therapy. In particular,
the initiation of insulin often leads to TG reduction.
Metformin, which often is the first drug used for treatment
of T2D, can lower TG and lead to small improvements in
HDL-C (92, 93). How much of these changes is due to
glucose lowering versus weight reduction is unclear. Other
glucose-lowering drugs associated with beneficial changes
in the lipid profile include glucagon-like peptide (GLP-1)
receptor agonists (94, 95) and thiazolidinediones (93, 95).
Sodium-glucose co-transporter 2 (SGLT2) inhibitors (96,
97) can modestly increase LDL-C levels (98, 99). The relative contribution of glucose control, specific actions of the
drug, and weight loss is difficult to assess. Sulfonylureas,
dipeptidyl peptidase-4 inhibitors, meglitinides, and
α-glucosidase inhibitors are generally considered to be
lipid neutral (93, 95, 100).
UKPDS found that intensive diabetes treatment resulted in a 16% nonsignificant risk reduction for MI (101).
However, significant risk reductions for MI and death from
any cause were observed during the 10 years of post-trial
follow-up (102). In UKPDS 34, which analyzed diabetes
endpoints and CVD outcomes in 342 overweight patients
allocated intensive treatment with metformin or conventional therapy, the metformin group had a significantly
lower risk of mortality and of MI compared with subjects
in the conventional therapy group (103). Tight glycemic
control failed to improve CV outcomes in 3 large studies
of intensive insulinization (104–106). In ACCORD, intensive insulin treatment for 3.5 years resulted in the expected target reduction in HbA1c, yet mortality increased
and major CV events were not significantly reduced (104).
In ADVANCE, in which various strategies to lower blood
glucose achieved a target HbA1c of 6.5%, the intensity of glucose control did not significantly change major
macrovascular events, death from CV causes, or death from
any cause after 5 years of follow-up (105). In the VADT
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were observed in people with and without diabetes (118).
Moreover, in clinical trials in subjects without diabetes, the
strong relationship between in-trial LDL-C levels and CVD
events independent of the modality of cholesterol lowering
(120–122) suggests that LDL-C reduction is a major mechanism of lowering ASCVD risk.
3.2

In adults with T2D and other CV risk factors,
we suggest lowering LDL-C to achieve a goal
of LDL-C <70 mg/dL (1.8 mmol/L) in order to
reduce CV risk. (2⊕OOO)

Evidence and discussion
Considerable evidence from RCTs of statins, and trials of
statins in combination with ezetimibe or monoclonal antibodies to PCSK9, conducted in patients with and without
ASCVD and in subgroups including patients with diabetes,
demonstrates that the greater the reduction in LDL-C
levels, the greater the reduction in the risk of CV events
(123, 124). This benefit depends upon the absolute reduction in LDL-C and the baseline risk of ASCVD (125). The
CTT individual participant data meta-analysis of 26 statin
trials found that for every 1 mmol/L (39 mg/dL) reduction
in LDL-C, there was a 22% RRR in major ASCVD events
(HR 0.78; 95% CI: 0.76–0.80; P < 0.0001).
In the PROVE-IT TIMI 22 trial, conducted in very
high-risk patients with acute coronary syndrome, there was
a progressive reduction in risk (death, MI, stroke, recurrent
ischemia, revascularization), as LDL-C levels fell from 80
to 100 mg/dL (2.1 to 2.6 mmol/L) through 60 to 80 mg/
dL (1.6 to 2.1 mmol/L), through 40 to 60 mg/dL (1.0 to
1.6 mmol/L), and <40 mg/dL (1.0 mmol/L) (126). In the
TNT trial in patients with stable coronary heart disease
(CHD), reduction in LDL-C to 77 mg/dL (2.0 mmol/L)
provided greater ASCVD benefit (CHD death, nonfatal
MI, fatal or nonfatal stroke, resuscitation after cardiac arrest) compared with the reduction in LDL-C to 101 mg/
dL (2.6 mmol/L) (127). Further, in the CTT meta-analysis
of individual participant data from 5 statin trials comparing more intensive to less intensive statin treatment,
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Technical Remarks:
• A statin should be added to lifestyle modifications if
LDL-C is >70 mg/dL (1.8 mmol/L).
• LDL-C should be <55 mg/dL (1.4 mmol/L) in patients
with established CVD or multiple risk factors.
• Additional LDL-lowering therapy (ezetimibe, proprotein
convertase subtilisin/kexin type 9 inhibitor) may be
needed if the LDL-C goal is not reached with statins.
• Risk factors include traditional risk factors and riskenhancing factors.

more intensive treatment led to a significant 15% (95%
CI: 11–18, P < 0.001) additional reduction in major vascular events, with separately significant reductions in coronary death or nonfatal MI of 13%, in ischemic stroke
of 16%, and in coronary revascularization of 19% (123).
Today, very low LDL-C levels can be achieved with either a
combination of statins plus ezetimibe, or PCSK9 inhibitors
with or without statins and/or ezetimibe. The addition of
ezetimibe to statin therapy after acute coronary syndromes
resulted in the incremental lowering of LDL-C and improved CV outcomes (120), including in the 27% of the
study population with diabetes. The mean LDL-C in the
ezetimibe plus statin group was 53 mg/dL (1.4 mmol/L),
which is below previous LDL-C target levels.
Injectable PCSK9 antibodies have been available since
2015. They trap PCSK9 in plasma, thereby preventing
PCSK9 from binding to LDL receptors at the hepatocyte
surface. As a result, LDL receptors are targeted for recycling to the cell surface rather than for lysosomal degradation. Because of the resulting increase of LDL receptors at
the cell surface, PCSK9 antibodies lower LDL-C levels beyond those usually achievable with statins with or without
ezetimibe (128, 129). Two secondary prevention trials
of PCSK9 antibodies on a background of statin therapy,
FOURIER (129) and in patients with ASCVD ODYSSEY
OUTCOMES (130) in patients with ACS, both achieved
very low in-trial LDL-C levels (30 mg/dL [0.8 mmol/L] and
53 mg/dL [1.4 mmol/L] on treatment, respectively), which
were lower than previous guidelines. Both studies showed
a CVD benefit from this additional LDL lowering and in
prespecified analyses, similar RRR in the primary composite
CV endpoint in patients with diabetes compared with those
without diabetes. In FOURIER, 11 031 of 27 564 patients
(40%) had T2D. Evolocumab significantly reduced the
relative risk (RR) of the primary composite endpoint (CVD
death, MI, stroke, coronary revascularization, or hospital admission for unstable angina) in patients with diabetes by 17% (HR 0.83 (95% CI: 0.75–0.93; P = 0.0008)
over 3 years (131). In ODYSSEY OUTCOMES, 5444 of
18 924 patients (28.8%) had diabetes, 8246 (43.6%) had
prediabetes, and 5234 (27.7%) were normoglycemic (132).
Alirocumab significantly reduced the RR of the primary
composite endpoint in patients with diabetes by 16% (HR
0.84, 95% CI: 0.74–0.97) over 2.8 years, and the RRR
was similar among patients with diabetes, prediabetes, or
normoglycemia. In view of the very high risk of CVD in
people with T2D, we suggest targeting the lower LDL-C
levels achieved in these newer trials, with a practical
goal of <70 mg/dL (1.8 mmol/L). Because the data from
these clinical trials demonstrate additional benefit at even
lower levels of LDL-C, we suggest that those patients with
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diabetes who are at the highest risk (ie, those with established CVD or multiple risk factors) achieve LDL-C levels
even lower than 70 mg/dL (1.8 mmol/L).

hemorrhagic stroke (140). A prospective cohort study of
27 937 women who were enrolled in the Women’s Health
Study (WHS) showed 0.8% of women with LDL-C levels
of 70 mg/dL (1.8 mmol/L) or lower had suffered a hemorrhagic stroke, double the rate of women with LDL-C
levels between 100 mg/dL (2.6 mmol/L) and 130 mg/dL
(3.4 mmol/L), although this study did not provide any
data regarding the effect of lipid-lowering therapy on
stroke (141).
In several clinical trials and meta-analyses, statins
produced a small increase in HbA1c of the magnitude
of 0.1%, which seems unlikely to significantly change
CVD risk (142). Statins, however, increase the risk of
developing diabetes (143), with an absolute increase of
0.2% per year in major statin RCTs (142), but the benefit/
risk ratio is favorable because of the significant reduction in the high risk of MI and stroke in diabetes (144,
145). The risk of newly diagnosed diabetes is especially
increased in those taking high doses of potent statins and
individuals predisposed to diabetes, such as those with
MetS (146). These findings are consistent with Mendelian
Randomization studies that show an association between
low LDL-C and diabetes risk (147–149). However, the
PCSK9 antibody evolocumab, in the FOURIER trial
(131), and alirocumab in ODYSSEY OUTCOMES (132)
did not increase the risk of new-onset diabetes or worsen
glycemia in patients with diabetes, although these studies
were relatively short term and, therefore, cannot be considered definitive.
3.3

In adults with T2D on a statin at LDL goal with
residual TG over 150 mg/dL (1.7 mmol/L) and
with 2 additional traditional risk factors or riskenhancing factors, we suggest adding EPA ethyl
ester to reduce CV risk. (2⊕⊕⊕O)

Technical Remarks:
• Consider 4g/day of EPA ethyl ester.
• If EPA ethyl ester is not available or accessible, then it is
reasonable to consider a fibrate, such as fenofibrate.
Evidence and discussion
Omega-3 fatty acids are effective at lowering elevated TG
levels (150). Some data suggests that EPA ethyl ester, a
highly purified EPA ethyl ester, reduces selected inflammatory markers in patients with elevated TG (151) and may
have other biological effects that could play a role in reducing atherosclerosis (152). In the placebo-controlled trial
REDUCE-IT, in 8179 subjects, a high dose (4 g/day) of EPA
ethyl ester, lowered major adverse cardiac events (MACE)
by an additional 25% in statin-treated subjects, with residual fasting hypertriglyceridemia (median at baseline in
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Benefits and risks/harms
The benefits of achieving very low cholesterol levels are
a reduction in CVD events (fatal and nonfatal MI, ischemic stroke, coronary revascularization procedures)
and mortality. Whether low LDL-C levels confer a risk
to the patient has been addressed by data from numerous
RCTs of statins, meta-analyses of the RCTs, and, more recently, RCTs of PCSK9 inhibitors. These trials have found
that low LDL-C levels, including LDL-C as low as 10 to
20 mg/dL (0.3 to 0.5 mmol/L) in patients taking PCSK9
inhibitors, are not associated with an increase in serious
adverse events. Observational studies in 1989 and 1994
reported an association of high cholesterol with thromboembolic or nonhemorrhagic stroke but, in contrast, an inverse relationship between cholesterol and intracerebral
hemorrhage (133–135). However, subsequent large outcome trials of statins did not confirm this. Individual
trials and meta-analyses of these RCTs, which included
about 170 000 subjects followed for a mean of 4 years,
found that, in people without a history of stroke, LDL-C
reduction reduced ischemic stroke and did not increase
hemorrhagic stroke (118). However, 1 RCT, SPARCL,
in a secondary stroke/transient ischemic attack population that was not included in the CTT meta-analyses,
showed a small increase in hemorrhagic stroke events (55
vs 33) in participants randomized to atorvastatin 80 mg
daily compared with placebo but, importantly, a significant reduction in total stroke and ischemic stroke (136,
137). Additional analyses showed that the risk of hemorrhage was higher in those with a hemorrhagic stroke
as an entry event but was not associated with baseline or
treated LDL-C (138). A subsequent RCT compared the
effect of LDL-C reduction, using statins and (as needed)
ezetimibe, to a goal below 70 mg/dL (1.8 mmol/L) and
a goal of 90 to 110 mg/dL (2.3 to 2.8 mmol/L) in individuals with a history of ischemic stroke or TIA (139).
Cardiovascular events, including ischemic stroke, were
significantly reduced in the group randomized to the
lower LDL-C goal, but intracerebral hemorrhage was numerically increased (18 vs 13 events), although not statistically significant. The implications of these data are not
clear because the trial ended early due to a loss of funding,
and therefore, the prespecified number of patients to
be enrolled was not achieved. Also, without a placebo
group, causality could not be determined. Analysis of
stroke in ODYSSEY OUTCOMES, a trial of alirocumab,
targeting LDL-C levels of 25 to 50 mg/dL, found a significant decrease in ischemic stroke, without an increase in
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3.4

In adults with T2D with CKD stages 1–4 and
postrenal transplant, we suggest statin therapy,
irrespective of the CV risk score, to reduce CV
risk. (2⊕OOO)

Technical Remarks:
• When selecting the statin, consider the renal clearance
of the statin. Pitavastatin, pravastatin, and rosuvastatin
all have at least partial clearance through the kidney,
whereas atorvastatin, fluvastatin, lovastatin, and
simvastatin are cleared via the liver.
• All statins require dose adjustments in CKD except for
atorvastatin and fluvastatin.
Evidence and discussion
CVD is the leading cause of death in individuals with CKD,
which is defined as a sustained reduction in kidney function in which the glomerular filtration rate remains below
60 mL per minute or the urine albumin-to-creatinine ratio
is >30 mg of albumin/g creatinine for >3 months. End-stage
renal disease (ESRD) is defined as total and permanent
kidney failure typically requiring either dialysis or transplantation. ESRD is associated with very high risk for CVD
events. Diabetes is the leading cause of both CKD and
ESRD. Several studies have evaluated the effect of statin
therapy in patients with CKD and ESRD. The SHARP
study, which examined the effect of LDL-C lowering by a
statin (simvastatin) plus ezetimibe on CVD outcomes in patients with moderate-to-severe CKD, showed a reduction in
MACE associated with LDL lowering, especially in those
with high baseline LDL-C levels (159). However, the prognostic value of on-treatment LDL-C appears to be less in
those with CKD due to diabetic kidney disease than other
causes (160). The event reduction appeared to be decreased
if not absent in those on dialysis. Cholesterol lowering by
statins failed to reduce CVD endpoints in patients with
ESRD on dialysis in either the 4D (161) or AURORA trials
(162). After renal transplantation, statin treatment significantly reduced cardiac death and nonfatal MI but not the
primary CVD endpoint in the ALERT trial (163). However,
the extension trial did find a significant reduction in risk of
cardiac death, nonfatal MI, and cardiac interventional procedures (164). Based on this small number of clinical trials,
we suggest initiating statins to prevent CVD outcomes
in patients with early-to-moderate CKD independent of
other risk factors but not in patients with ESRD on dialysis. Continuation of statin treatment in a patient whose
CKD progresses to requiring dialysis can be left to clinical
judgement.
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the EPA ethyl ester group, 216.5 mg/dL (2.4 mmol/L) (Q1
176.5 [2.0 mmol/L], Q3 272 mg/dL [3.1 mmol/L]) and either established ASCVD or T2D and 2 additional risk factors (76, 77). The RRR for the composite primary endpoint
was 25% (95% CI: 0.68–0.83); P < 0.001. However, the
benefit did not appear to relate to either baseline TG levels
or the change in TG. In addition, the use of an essentially
identical agent, ethyl icosapentate, at a dose resulting in a
comparable on-treatment EPA level, showed a comparable
19% CVD reduction in JELIS, an open-label, randomized,
blinded endpoint trial (153). Other studies have failed to
show a similar benefit of omega-3 fatty acids, including
in subjects with diabetes (74, 154, 155), again, possibly
because not all subjects were hypertriglyceridemic, or possibly due to inadequate doses of omega-3 fatty acids, or
because a combination of both EPA and DHA was used.
The STRENGTH trial of a mixed EPA and DHA formulation in hypertriglyceridemic subjects at a high risk of CVD
has been discontinued by the data monitoring board due
to a low likelihood of success.
The hallmark of diabetic dyslipidemia is hyper
triglyceridemia. Several medications reduce hyper
triglyceridemia in patients with T2D. As exemplified by
the ACCORD study, TG levels fall significantly in response to fenofibrate in patients with diabetes (156). The
VA-HIT trial in men with coronary disease, low HDL-C,
and mild elevations in TG found that gemfibrozil given
without a statin significantly reduced coronary events
(72). Subsequent clinical trials have, to date, failed to
provide definitive evidence for a benefit on CVD outcomes of fibrate therapy, either alone or in combination
with statins, although post hoc analysis of several fibrate
studies indicate that CVD benefit is confined to those
with elevated TG and low HDL-C levels (156–158). The
lack of evidence for CVD benefit is likely due in part to
the fact that these trials have not been limited to subjects
with hypertriglyceridemia (156–158). The PROMINENT
trial, which will test the effect of fibrate treatment on CV
endpoints in hypertriglyceridemic subjects with diabetes, is
due for completion in 2022.
Based on the small number of clinical trials of omega-3
fatty acids with CV endpoints, positive results, which were
confined to EPA ethyl esters, and because the benefits of
fibrates are limited to post hoc analyses, the guideline
writing committee suggests the use of icosapentaenoic acid
ethyl ester at 4 g per day in statin-treated patients with T2D
and residual hypertriglyceridemia. If this is not available or
not accessible, fibrates may be considered, although the evidence for benefit is currently limited to post hoc analyses.
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3.5

In adults with T2D and diabetic retinopathy, we
suggest fibrates in addition to statins to reduce
retinopathy progression. (2⊕OOO)

Technical Remarks:
• This recommendation applies regardless of TG levels.
• The preferred fibrate is fenofibrate.

4. Type 1 diabetes mellitus
4.1

In adults with T1D age 40 years and older and/
or with duration of diabetes > 20 years, and/or
microvascular complications, we suggest statin
therapy, irrespective of the CV risk score, to
reduce CV risk. (2⊕OOO)

Technical Remarks:
• LDL should be the primary target for lipid-lowering
therapy.
• Consider therapy if LDL is over 70 mg/dl (1.8 mmol/L).
• Statins should not be used in women who are pregnant
or trying to become pregnant.
Evidence and discussion
Individuals with T1D have participated in several randomized, controlled CV outcome studies of statins. Statins appear to be equally effective in lipid lowering for patients
with T1D vs T2D and those without diabetes. For example,
in the Heart Protection Study, the reduction in CVD events
was not significantly different in 615 subjects with T1D
compared with 5348 subjects with T2D, albeit the CIs were

wide (115). Hero and colleagues used a Swedish registry
to assess the effects of lipid-lowering therapy in 24 230 individuals with T1D without known CVD included in the
2006–2008 registry (overall mean age 39.4 years). They
were followed until the end of 2012; 5387 were treated with
lipid-lowering medications (97% statins) and 18 843 were
not treated with lipid-lowering medications. After a mean
follow-up of 6 years, the HRs for treated versus untreated
were CVD death, 0.6; all-cause death, 0.56; fatal/nonfatal
stroke, 0.56; fatal/nonfatal MI, 0.78; fatal/nonfatal CHD,
0.85; and fatal/nonfatal CVD, 0.77 (168). A meta-analysis
of statin use in 18 686 subjects with diabetes (1466 of
whom had T1D) in 14 randomized trials of statins reported
a 21% reduction in major CVD events and a 13% reduction in vascular mortality for every 1.0 mmol/L (approximately 40 mg/dL) drop in LDL during a mean follow-up of
4.3 years (118).
There is a paucity of data regarding the age at which
to start statin therapy in subjects with T1D. A 2019 report found that in individuals participating in the T1D
exchange clinic registry, statin use increased from 2%
in subjects aged 10 to 17 years to 4% in subjects age 18
to 25 years and to 21% in subjects age 25 to 39 years.
Most subjects on statin therapy had LDL <100 mg/dL
(2.6 mmol/L); regardless of statin use, subjects with LDL
>100 mg/dL (2.6 mmol/L) were more likely to have at
least 1 additional CVD risk factor compared with those
with LDL <100 mg/dL (2.6 mmol/L) (169). The Pittsburgh
Epidemiology of Diabetes Complications study reported
CVD event rates at 0.98% per year in young adults (age 28
to 38 years) with T1D, with an increase to 3% per year in
adults over 55 years, with CVD accounting for 40% of all
deaths in individuals with T1D >20 years’ duration (170).
A recent study by Rawshani et al demonstrates that age
of T1D onset has a significant impact on CVD risk, with
greatest risk in those with earliest onset of T1D (defined
as <10 years old) (171). Thus, although specific evidence
is lacking to guide which age and/or diabetes duration to
initiate therapy, there is good evidence that duration of diabetes predicts increased CVD risk, and statin therapy reduces CVD risk in subjects with T1D.
4.2

In adults with T1D with CKD in stages 1 to 4, we
suggest statin therapy, irrespective of the CV risk
score, to reduce CV risk. (2⊕OOO)

Technical Remarks:
• LDL should be the primary target for lipid-lowering
therapy.
• Consider therapy if LDL is over 70 mg/dL (1.8 mmol/L).
• When selecting the statin, consider the renal clearance
of the statin: pitavastatin, pravastatin, and rosuvastatin
all have at least partial clearance through the kidney,
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Evidence and discussion
Although the primary CV endpoint was not statistically significant in the placebo-controlled FIELD study of
fenofibrate in patients with T2D, a surprising finding was
the reduction of retinopathy requiring laser treatment in
the fenofibrate group compared with the placebo group
(165). Fenofibrate also delayed progression of retinopathy in the ACCORD trial, in which tight glycemic control but not blood pressure control had a beneficial effect
on retinopathy (166). Also, in a retrospective, matched
cohort study in people with T2D, treatment with fibrates
(largely bezafibrate and fenofibrate, but also ciprofibrate,
gemfibrozil, and, in 1 patient, clofibrate) was independently
associated with a reduced progression to a first diagnosis
of diabetic retinopathy (167). Based on these studies, we
suggest using a fibrate to reduce retinopathy progression in
persons with T2D. Fenofibrate is preferred to gemfibrozil
because fenofibrate was studied in RCTs, and because
gemfibrozil in combination with a statin is associated with
increased risk of myopathy.
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whereas atorvastatin, fluvastatin, lovastatin, and
simvastatin are cleared via the liver.
• All statins require dose adjustments in CKD except for
atorvastatin and fluvastatin.
• Ezetimibe can be added to the statin if required to lower
LDL-C further. No dose adjustments of ezetimibe are
needed in CKD.

4.3

In adults with T1D with obesity, or with high
TG and low HDL-C, we suggest statin therapy,
irrespective of the CV risk score, to reduce CV
risk. (2⊕OOO)

Technical Remarks:
• LDL should be the primary target for lipid-lowering
therapy.
• Consider therapy if LDL-C is over 70 mg/dL
(1.8 mmol/L).
Evidence and discussion
The treatment of hyperglycemia reduces TG levels. The
SEARCH for Diabetes in Youth study found that improved
glycemic control over a 2-year period led to improvements in
lipid profiles, albeit improved glycemic control alone was not

4.4

In adults with T1D and diabetic retinopathy, we
suggest statin therapy, irrespective of the CV risk
score, to reduce CV risk. (2⊕OOO)

Technical Remarks:
• LDL should be the primary target.
• Consider therapy if LDL-C is over 70 mg/dL
(1.8 mmol/L).
Evidence and discussion
A meta-analysis of 20 studies of 19 234 patients with T1D
(n = 4438) or T2D (n = 14 896) found that the presence
of any degree of diabetic retinopathy increased all-cause
mortality and CVD events compared with those without
diabetic retinopathy. The RR was greater for those with
T1D than for those with T2D and remained significant
even after adjusting for traditional CVD risk factors (182).

5. Obesity
5.1

In individuals who have obesity, we advise
assessment of the components of the MetS and
body fat distribution to accurately determine

Downloaded from https://academic.oup.com/jcem/article/105/12/3613/5909161 by guest on 04 August 2022

Evidence and discussion
The presence of renal disease in diabetes increases
CVD risk, but, even in the absence of renal disease,
T1D confers increased CVD risk (172, 173). However,
although renal disease is a CVD risk factor, especially
in T1D, there is no evidence that statins (or any other
lipid-lowering agents) improve renal outcomes; thus,
the use of lipid-lowering therapy is aimed at reducing
CVD risk, not CKD risk. The SHARP study found that
lipid-lowering therapy in patients with diabetes with
CKD stages 1–4 decreased CVD risk; however, this
study did not distinguish between T1D and T2D (159).
Furthermore, although several studies have not shown
any benefit to initiation of lipid-lowering therapy in patients with CKD stage 5 (dialysis), there is no evidence
of any harm (161, 162, 174), albeit none of these studies
were conducted specifically in T1D. The ALERT study
found a benefit of statin therapy in individuals postrenal
transplant (175, 176). Thus, although evidence suggests
that initiation of lipid-lowering therapy in CKD stage 5
is likely of no benefit, there is no evidence to guide the
management of lipid-lowering therapy in patients with
CKD who progress to stage 5. We suggest that lipidlowering therapy should be initiated in patients with
T1D with CKD stages 1–4 or postrenal transplant; if a
patient progresses to stage 5, the lipid-lowering therapy
may be continued, but it should not be initiated in a patient in stage 5 CKD.

sufficient to meet lipid goals (177). Observational studies suggest that intensive glycemic control reduces CVD events (178,
179). Furthermore, as shown in the DCCT/EDIC study in T1D
(179), even a relatively short period of good glycemic control
is associated with decreased CVD events years later, termed a
“legacy effect.” However, those that gained excessive weight
with intensive therapy appear to have less benefit than those
who gained less weight (180). Analyses of the DCCT/EDIC
study over a 30-year follow-up period found that age and sex
were not the dominant predictors of CVD risk factors; rather,
HbA1c and lipid measurements (TG and LDL levels) had the
strongest longitudinal associations. Furthermore, weight was
predictive of blood pressure, heart rate, and lipid profile levels
(181). The timing of the impact of weight gain on CVD risk
appeared delayed: for the first 13 years of EDIC, those who
gained the most weight had increased CVD risk factors but
no increase in CVD events, possibly due to their increased use
of blood pressure and lipid-lowering therapy. However, after
14 years of follow-up, the group with greatest weight gain
had increased CVD events (180).
Thus, individuals with T1D who develop features of
MetS (central obesity, high TG, and low HDL-C) appear
to be at increased CVD risk and should be treated with
lipid-lowering therapy, in addition to diet and increased
physical activity. Early addition of blood pressure and/or
lipid-lowering therapy may help reduce the risk associated
with increased weight gain, but there is no data to support
the timing of additional therapy.
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the level of CVD risk. (Ungraded Good Practice
Statement)

Evidence and discussion
Obesity is frequently associated with MetS, which is a riskenhancing factor for ASCVD, and is treated initially by lifestyle modifications, including a healthy diet and physical
activity. Lipid abnormalities in MetS include elevated TG,
low HDL-C, and increased non-HDL-C. Although LDL-C
may not be above the threshold considered appropriate for
initiating statin treatment, apoB and small dense LDL-C
may be increased (183).
Dyslipidemia in obesity is similar to that of MetS, with
increased TG and FFAs, decreased HDL-C, and, in many
patients, increased apoB and slightly increased LDL-C,
with increased small, dense LDL. The increase in apoB is
partly due to hepatic overproduction of apoB-containing
lipoproteins (184–186). Postprandial hyperlipidemia is
more frequent in obesity, leading to accumulated circulating atherogenic remnants (186–188).
Most epidemiological studies define obesity based on
BMI, which has been shown to be a strong predictor of
CVD mortality. Limitations of BMI have been noted (189).
Anthropometric methods such as waist circumference and
waist/hip ratio have been demonstrated to be better measures of central obesity (190) and better predictors of risk for
ASCVD and diabetes than weight or BMI (186, 191, 192).

Increased waist circumference has been associated with increased mortality within each BMI category (193–195).
Reduction in waist circumference by diet and/or exercise improves cardiometabolic risk factors regardless of
weight loss (196–201). Measurement of waist circumference is relatively simple and can be done either at the iliac
crest or midway between the level of the last rib and the
iliac crest (202). Normal values vary by sex and by ethnicity. A 2020 Consensus Statement of the IAS (International
Atherosclerosis Society) and the ICCR (International Chair
on Cardiovascular Risk) Working Group concluded that
BMI and waist circumference identify high risk better than
either measurement alone (202). The consensus statement
recommended the routine measurement of waist circumference in clinical practice as another vital sign that will help
determine the efficacy of diet and exercise.
5.2

In individuals who have obesity, we suggest
lifestyle measures as the first-line treatment to
reduce plasma TG to lower CV and pancreatitis
risk. (2⊕OOO)

Technical Remarks:
• Reductions in LDL-C and increases in HDL-C are
modest compared with the decrease in TG with lifestyle
measures that produce weight loss.
• Lifestyle therapy–induced changes in the lipid profile in
obesity have not been shown to reduce CVD events.
Evidence and discussion
Weight loss can be achieved and maintained with calorie
restriction, healthy diet, behavioral interventions, and
physical activity. A loss of >5% of body weight is associated with amelioration of some of the comorbidities associated with obesity. Weight loss has a greater effect on TG
than LDL-C (203). The 2013 National Heart, Lung, and
Blood Institute Systematic Review noted a dose–response
relationship between the amount of lifestyle-related weight
loss and improvement in the lipid profile in people with
overweight or obesity (204). Weight loss of 3 kg was associated with TG reductions of approximately 15 mg/dL
(0.17 mmol/L), whereas weight loss of 5 to 8 kg was associated with LDL-C reduction of 5 mg/dL (0.13 mmol/L) and
an increase in HDL-C of 2 to 3 mg/dL (0.5 to 0.8 mmol/L).
A systematic review of clinical trials in patients without
ASCVD observed a similar effect of moderate weight loss
(5 to 10% over 12 to 24 months) on TG levels (-16 mg/
dL or 0.18 mmol/L) and a slightly greater impact on LDL
(-10 mg/dL or 0.26 mmol/L) and total cholesterol (-17 mg/
dL or 0.43 mmol/L), but a nonsignificant effect on HDL
(+0.5 mg/dL or 0.13 mmol/L) (205).

Downloaded from https://academic.oup.com/jcem/article/105/12/3613/5909161 by guest on 04 August 2022

Technical Remarks:
• Diagnosis of MetS requires the presence of 3 of the
following criteria:
◦ Elevated TG ≥ 150 mg/dL (1.7 mmol/L) or on
TG-lowering medication.
Reduced HDL-C <50 mg/dL (1.3 mmol/L) in
◦ 
women and <40 mg/dL (1.0 mmol/L) in men.
S

◦ ystolic blood pressure ≥ 130 mm Hg or diastolic
blood pressure ≥ 85 mm Hg or on blood pressure
medication.
Elevated waist circumference (men ≥ 40 in
◦ 
[102 cm] and women ≥ 35 in [88 cm]), except for
East and South Asian men ≥ 35 in (90 cm) and
women ≥ 31.5 in (80 cm).
◦ Hyperglycemia (but not yet with T2D) is defined
by cutoffs for prediabetes according to fasting
blood glucose, oral glucose tolerance, and/or
HbA1c.
• Body fat distribution can be assessed in clinical practice
by measuring the waist size or the waist/hip ratio.
• Waist size measurement in people with a BMI >35 kg/m2
has potential limitations.
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Technical Remarks:
• Calculation of 10-year risk for ASCVD may be done
using the Pooled Cohort Equations.
• Elevated LDL-C is predictive of CV risk.

In individuals who have obesity, we recommend
the assessment of 10-year risk for ASCVD to guide
the use of lipid-lowering therapy. (1⊕⊕⊕O)

Evidence and discussion
Medications indicated for weight reduction, in combination
with diet and exercise, have variable effects on lipids. The

5.3

Evidence and discussion
RCTs have clearly demonstrated that LDL-C reduction
with statins significantly decreases major ASCVD events.
Subgroup analyses consistently show that the efficacy and
safety of statin therapy are similar in patients with and
without obesity (123). Cholesterol management guidelines
recommend statin therapy as the first pharmacological
choice, and in most guidelines LDL-C is the primary target
(see the “Summary of Cholesterol Treatment Guidelines”
section) (31). As the decision to initiate statin treatment as
adjunct to diet and exercise depends upon the 10-year risk
of ASCVD, we recommend the calculation of 10-year risk in
people with obesity.
In individuals who have obesity and are on
pharmacological therapy for weight reduction, we
suggest reassessment of the lipid profile to evaluate
the risk of CVD and pancreatitis. (2⊕OOO)

5.4

Technical Remark:
• As there are no data on the timing of lipid measurements
after weight loss, we suggest reassessment of lipids after
5% weight loss and periodically thereafter, when the
weight is stable.

Table 4. Change in lipids and lipoproteins (mg/dL per 1-kg weight loss) by intervention
Group

TC

95% CI

I2

Lifestyle (diet, exercise, or combined)
6 mo
-0.60 -1.17, -0.02 84.8%
12 mo
-1.66 -2.83, -0.50 97.4%
Pharmacotherapy
6 mo
-3.29 -3.86, -2.73 41.1%
12 mo
-1.69 -2.77, -0.61 95.1%
Bariatric surgery
6 mo
N/A
N/A
N/A
12 mo
-0.61 -1.04, -0.19 76.2%

TG

95% CI

I2

HDL

95% CI

I2

LDL

95% CI

I2

-3.18
-4.00

-2.19, -4.17
-5.24, -2.77

93.1%
95.3%

0.46
0.46

0.29, 0.63
0.19, 0.71

89.3%
91.7%

-0.35
-1.28

-0.83, 0.13
-2.19, -0.37

93.1%
95.5%

-3.54
-1.25

-4.84, -2.25
-2.94, 0.43

99.5%
83.5%

0.04
0.37

-0.21, 0.28
0.23, 0.52

99.4%
92.9%

-2.57
-1.67

-3.73, -1.41
-2.28, -1.06

99.8%
97.3%

N/A
-2.47

N/A
-3.14, -1.80

N/A
70.9%

N/A
0.42

N/A
0.37, 0.47

N/A
0.0%

-0.66a
-0.33

N/A
-0.77, 0.10

N/A
81.3%

Insufficient data for meta-analysis. I2 is a measure of heterogeneity.
Abbreviations: CI, confidence interval; HDL, high-density lipoprotein, HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C,
low-density lipoprotein cholesterol; TG, triglycerides.
To convert mg/dL to mmol/L for total cholesterol, LDL-C and HDL-C, divide mg/dL by 38.7. To convert mg/dL to mmol/L for TG, divide mg/dL by 88.6.
Reproduced with permission from Hasan B, Nayfeh T, Alzuabi M, et al. “Weight loss and serum lipids in overweight and obese adults: a systematic review and
meta-analysis.” J Clin Endocrinol Metab. 2020;105(12) (2)
a
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In the LOOK AHEAD trial in patients with T2D, the
intensive lifestyle intervention (including a behavioral
weight-loss program, ≥10% group weight loss goal, calorie
restriction, and increased physical activity) was compared
with diabetes support and education (control group) (206).
Analysis of the data over 4 years showed statistically significant differences among the intensive lifestyle and control groups in weight loss (6.2 kg and 0.9 kg, respectively),
TG reduction (25.6 mg/dL and 19.75 mg/dL, respectively),
and HDL-C increase (3.7 mg/dL and 2.0 mg/dL, respectively) (207). LDL-C, adjusted for medications, was reduced by about 9 mg/dL in both groups. Intensive lifestyle
therapy did not reduce CVD events (HR, 0.95; 95% CI:
0.83–1.09), the primary endpoint of LOOK AHEAD, and
the trial was stopped early on the basis of a futility analysis
(206).
The Endocrine Society designed a protocol for a metaanalysis to assess changes in lipids and lipoproteins in adults
with overweight or obesity after 6 to 12 months of weightreducing interventions: lifestyle, pharmacotherapy (US FDA
drugs approved for weight reduction plus metformin), or
bariatric surgery. The meta-analysis was conducted by the
Evidence Practice Center, Mayo Clinic and included 73 RCTs
enrolling 32 496 patients (2). The most favorable effect of
weight loss on lipids was observed in TG (Table 4). With
diet, exercise, or a combination of the 2, TG were reduced by
about 4 mg/dL (0.05 mmol/L) per kg of weight loss, whereas
the reduction in LDL-C was -1.3 mg/dL (0.03 mmol/L) per kg
of weight loss. HDL-C increases at 12 months were 0.5 mg/
dL (0.01 mmol/L) per kg of weight loss.
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do not have diabetes. Dulaglutide and semaglutide, both
GLP1-receptor agonists approved for glycemic control in
T2D, are both known (and indicated) to reduce CVD, as
well as to cause modest weight loss, although neither is officially approved for the latter indication. A randomized CV
outcome trial called SELECT is currently ongoing in patients with obesity but without diabetes, with semaglutide
(2.4 mg/wk), a once-weekly GLP-1 analog (clinicaltrials.
gov Identifier: NCT03574597). SGLT2, primarily indicated for glycemic control in T2D, also cause weight loss,
although none is indicated for this use. Empagliflozin
(111), canagliflozin (112, 214), and dapagliflozin (113) significantly reduced CV morbidity and mortality in RCTs of
patients with diabetes who had or were at risk of ASCVD.
5.5

In individuals with obesity (BMI >40 or >35 kg/m2
with comorbidities), who undergo bariatric surgery,
we suggest measurement of the lipid profile after
bariatric surgery to assess CV risk. (2⊕OOO)

Technical Remarks:
• Malabsorptive bariatric surgery procedures (eg, Rouxen-Y gastric bypass [RYGB]) are more effective than
restrictive procedures (eg, banding, sleeve gastrectomy
[SG]) in decreasing LDL-C levels.
• Both restrictive and malabsorptive procedures
decrease TG.

Table 5. FDA-approved medications for long-term weight management: change in lipids (mg/dL) per 1 kg of weight loss in
randomized controlled trials
Drug

Mechanism of Action

Orlistat

Intestinal lipase inhibitor

Phentermine/
topiramatea

Sympathomimetic amine anorectic/
antiseizure with monoamine
oxidase inhibitor unknown
Opioid antagonist/ norepinephrinedopamine reuptake inhibitor
Glucagon-like-1 receptor agonist,
increases satiety by action in central nervous system

Naltrexone/
bupropion
Liraglutideb

No. No. Active
Trials Treatments

Daily
Dose, mg

19

3313

360

2

2246

4

3088

2

3121

3.75/23
7.5/46
15/92
16/360
32/360
3.0, 1.8

Mean Change mg/dL per kg Weight Loss,
6 and 12 months
Follow-up

TG

LDL-C

HDL-C

6 mo
12 mo
12 mo

-4.85
-1.63
-0.83

-2.89
-1.94
-0.88

-0.04
0.24
0.22

6 mo
12 mo
12 mo

-1.38
-2.91
-1.94

-0.70
-0.94
-0.28

0.19
0.78
0.49

To convert mg/dL to mmol/L for total cholesterol, LDL-C and HDL-C, divide mg/dL by 38.7. To convert mg/dL to mmol/L for TG, divide mg/dL by 88.6.
a
Phentermine/topiramate 15/92 mg was evaluated in 1507 subjects, 7.5/46 mg in 498 subjects, and 3.75/23 mg dose in 241 subjects.
b
Liraglutide 3.0 mg is approved for weight management and was evaluated in 2910 subjects in 2 trials. Liraglutide 1.8 mg is approved for management of type 2
diabetes and was evaluated in 211 subjects in 1 trial.
Abbreviations: FDA, US Food and Drug Administration; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.
Reproduced with permission from Hasan B, Nayfeh T, Alzuabi M, et al. “Weight loss and serum lipids in overweight and obese adults: a systematic review and
meta-analysis.” J Clin Endocrinol Metab. 2020;105(12) (2)
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magnitude of lipid reduction in clinical trials of 12-months
duration is shown in Table 5. These data are from the metaanalysis by Hasan et al. A commonly prescribed medication, phentermine, is only approved for short-term use (up
to 12 weeks) and, therefore, is not included in the table.
Medications indicated for weight management have
varying contraindications and adverse effects, which
must be taken into account in order to be prescribed
safely (208–212). All are contraindicated in pregnancy.
Contraindications, warnings, and common side effects are
summarized in Table 1 in Appendix D.
With the exception of orlistat, these medications act in
the central nervous system, particularly the hypothalamus.
Orlistat decreases intestinal absorption of fat, thus reducing chylomicron production and TG in chylomicronemia.
Case studies have reported that orlistat reduces TG in patients with monogenic LPL deficiency (213).
To date, there is no evidence that medications at the
doses approved for weight reduction reduce CV mortality or morbidity in individuals with obesity. LEADER, a
noninferiority, placebo, controlled trial of liraglutide that
used the lower doses approved for diabetes, found that
liraglutide, median dose 1.78 mg, reduced the rate of major
CV events (HR 0.87, 95% CI: 0.78–0.97), with statistical
significance for superiority as well as noninferiority (108).
However, there is no evidence that higher-dose (3.0 mg/d)
liraglutide has the same effect in patients with obesity who
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• Reassess lipid profile 1 to 3 months after bariatric
surgery and periodically thereafter and when weight is
stable.

6. Thyroid disease
Hypothyroidism is characterized by the relative or absolute
reductions in serum levels of thyroxine (T4). Serum levels
of total or free triiodothyronine (T3), however, are not reliable markers of hypothyroidism. Thyroid-stimulating
hormone (TSH) is elevated in primary hypothyroidism.
However, TSH is typically low or inappropriately normal
in central hypothyroidism, which may be caused by pituitary disease (secondary hypothyroidism) or hypothalamic disorders (tertiary hypothyroidism). Patients with
nonthyroidal chronic illness can have decreased serum
levels of T3, T4, and TSH, and generally lack hypothyroid
symptoms. Patients with generalized thyroid hormone resistance usually have high concentrations of T3 and T4,
with inappropriately normal or elevated TSH and variable degrees of hypothyroid and hyperthyroid symptoms.
Subclinical hypothyroidism is characterized by normal T3

Table 6. Serum lipid changes (mg/dL) per 1-kg weight loss according to bariatric procedure
Group

TC

95% CI

I2

TG

Banding
12 mo
-0.75
-1.97, 0.47
N/A
-6.03
Sleeve gastrectomy
12 mo
0.02
-0.46, 0.51
N/A
-2.43
Malabsorptive bariatric surgery (RYBP + BPD)
6 mo
N/A
N/A
N/A
N/A
12 mo
-0.73 -1.21, -0.26 77.2% -2.13
RYBP
6 mo
N/A
N/A
N/A
N/A
12 mo
-0.62 -1.17, -0.07 75.1% -2.23
BPD
12 mo
-1.12 -1.51, -0.72 N/A
-2.01

I2

HDL

95% CI

I2

LDL

95% CI

-8.31, -3.76

N/A

0.43

0.18, 0.68

N/A

0.89

-0.42, 2.19

N/A

-3.44, -1.42

N/A

0.46

0.35, 0.58

N/A

0.17

-0.30, 0.64

N/A

N/A
-2.72, -1.54

N/A
58.4%

N/A
0.41

N/A
0.36, 0.47

N/A
0.0%

-0.66a
-0.54

N/A
-1.02, -0.07

N/A
82.3%

N/A
-3.04, -1.43

N/A
66.7%

N/A
0.42

N/A
0.36, 0.48

N/A
0.0%

-0.66a
-0.38

N/A
-0.83, 0.07

N/A
74.8%

-2.64, -1.39

N/A

0.38

0.25, 0.50

N/A

-1.12

-1.56,-0.68

N/A

95% CI

I2

Abbreviations: BPD, biliopancreatic diversion; CI, confidence interval; HDL, high-density lipoprotein, HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; RYBP, Roux-en-Y gastric bypass; TG, triglycerides.
a
Data not sufficient for meta-analysis. I2 is a measure of heterogeneity. To convert mg/dL to mmol/L for total cholesterol, LDL-C and HDL-C, divide mg/dL by
38.7. To convert mg/dL to mmol/L for TG, divide mg/dL by 88.6.
Reproduced with permission from Hasan B, Nayfeh T, Alzuabi M, et al. “Weight loss and serum lipids in overweight and obese adults: a systematic review and
meta-analysis.” J Clin Endocrinol Metab. 2020;105(12) (2)
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Evidence and discussion
Guidelines recommend consideration of bariatric surgery in
people with BMI ≥ 40 kg/m2 or BMI ≥35 kg/m2 and 1 or more
weight-related comorbidities, who have not achieved sufficient weight loss following lifestyle and behavioral treatment,
with or without pharmacotherapy (203). In the observational Swedish Obese Subjects (SOS) study, bariatric surgery
was associated with significant reductions in CV death (HR,
0.47; P = 0.002) and CV events (MI or stroke; HR, 0.67; P
<0.001), respectively (215). In a matched, observational cohort of people with obesity and T2D in Sweden, RYGB was
associated with a reduction in the risk of fatal and nonfatal
MI by 49% (HR, 0.51; 95% CI: 0.29–0.91) and CV death by
59% (HR, 0.41; 95% CI: 0.19–0.90) (216). A meta-analysis
has confirmed that bariatric surgery is associated with significantly reduced CV-related mortality (217, 218).
SG and RYGB lead to significant body-weight reduction
and improvement of metabolic comorbidities, including
dyslipidemia. Improvement in the lipid profile is not related
to the amount of weight loss but rather to the type of surgery
(219). Although SG and RYGB decrease TG and increase
HDL-C to a similar extent, reduction in plasma LDL-C is
more pronounced after a malabsorptive procedure (RYGB,
biliopancreatic diversion) than a restrictive (SG, gastric
banding) procedure (220, 221). The effect of malabsorptive
surgery on LDL-C reduction was confirmed in the metaanalysis designed by the Endocrine Society (Table 6). These
clinical observations suggest that the underlying cellular and

molecular mechanisms that modulate LDL-C metabolism
may differ between bariatric procedures (222).
A prospective observational study of 1156 patients with
severe obesity found a large weight loss (mean 35 kg) at
12 years in 418 patients who had undergone RYGB surgery and remission of diabetes in 51% of 84 patients (223).
Mean reductions in LDL-C and TG from baseline in the surgical group were 11.0 mg/dL (0.28 mmol/L) and 62.8 mg/
dL (0.71 mmol/L), respectively, at 12 years. HDL-C increased by 12.9 mg/dL (0.33 mmol/L). These changes in
lipid parameters are consistent with the 1-year data (mg/
dL change per kg of weight loss) in the Endocrine Society
meta-analysis (Table 6).
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6.1

In patients with hyperlipidemia, we recommend
ruling out hypothyroidism as the cause of the
hyperlipidemia before treatment with lipid
lowering medications. (1⊕⊕⊕⊕)

Technical Remark:
• Hypothyroidism can elevate both cholesterol and TG
levels, which improve with treatment.

6.2

In patients with hyperthyroidism, we recommend
re-evaluating the lipid panel after the patient
becomes euthyroid. (1⊕⊕⊕⊕)

Technical Remark:
• Changes in LDL-C have been observed as early as
3 months after the patient is euthyroid.
Evidence and discussion
Hyperthyroidism, unless transient, such as in thyroiditis,
results in decreased levels of total and LDL-C (231) as well
as reduced HDL-C, Lp(a), apoA-1, and apoB (243). The
effects on TG are variable (231). Thyroid hormones affect lipid metabolism by several mechanisms, as addressed
earlier. The Endocrine Society performed a meta-analysis of
the results of 23 randomized and 144 nonrandomized clinical trials that evaluated cholesterol and TG concentrations
in patients with thyroid disorders before and after treatment. In patients with overt hyperthyroidism, treatment
with antithyroid medication, surgery, or radioiodine significantly increased total and LDL-C and HDL-C, but the
increase in TG was not statistically significant (Table 7) (1).
Treatment of subclinical hyperthyroidism did not alter lipid
parameters. Recent studies suggest that control of hyperthyroidism may lead to BMI values that exceed premorbid
levels. Therefore, it is prudent to re-assess not only the lipid
profile, but other factors that increase CV risk at that point
(244, 245).
6.3

In patients with overt hypothyroidism, we suggest
against treating hyperlipidemia until the patient
becomes euthyroid in order to more accurately
assess the lipid profile. (2⊕OOO)

Evidence and discussion
Abundant data dating back over a century demonstrate
that overt hypothyroidism is associated with dyslipidemia.
Descriptive and randomized controlled studies show that
LT4 treatment is effective in lowering elevated serum lipid
levels (246). However, few studies examined the time
course of this association regarding either the development
or the recovery of dyslipidemia with the development or
the correction of hypothyroidism.
Some data suggest that coronary disease is more likely
in patients with hypertension and hypothyroidism than in
patients with hypertension who are euthyroid (230). In elderly patients living in nursing homes, a study found a higher
rate of clinical coronary disease in patients with hypothyroidism compared with euthyroid controls (247). Whether
this observation is due to dyslipidemia, the associated
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and T4, with an elevated TSH (<10 mIU/L) and few, if any,
symptoms attributable to hypothyroidism.
Complicating these diagnoses are data suggesting that
euthyroid elderly patients have higher TSH values that continue to rise with increasing age and are especially notable
as patients reach and continue through their 9th decade
(224). The significance of this is unclear, but there may be
a genetic component, since children of nonagenarians with
elevated TSH have higher TSH levels than age-matched
controls (225).
Thyroid dysfunction has major effects on lipoprotein metabolism. Hypothyroidism is associated with reduced LDL
receptors, reduced cholesterol 7 alpha-hydroxylase, low cholesterol ester transfer protein, and decreased lipoprotein lipase,
which, together, may lead to an elevation in total cholesterol,
TG, LDL-C, and apoB. High-density lipoprotein cholesterol
has been reported to increase, remain unchanged, or decrease.
One study found increased HDL-C in hypothyroid patients,
but reduced cholesterol efflux (226). Increased LDL oxidation has also been demonstrated (227–229). Hypothyroid
patients often have elevated Lp(a) and apoB. These lipid
abnormalities, along with reduced endothelial function and
hypercoagulability, may contribute to an increased risk of
atherosclerosis in patients with hypothyroidism (230).
In overt hyperthyroidism, total cholesterol and LDL-C
are decreased, while TG are normal and HDL-C is unchanged or decreased (see Table 1). The effects of thyroid
hormone on lipid metabolism have been reviewed (231).
Thyroid hormone stimulates hepatic clearance of cholesterol by increasing biliary secretion (232). The increase in
bile acids reduces the cholesterol in the liver, which results
in compensatory increase in hepatic cholesterol synthesis
and the uptake of cholesterol to restore hepatic cholesterol.
Thyroid hormone diminishes the intestinal absorption of
dietary cholesterol (233), increases LDL receptor number
(234), and increases HMGCoA mRNA, protein, and activity (235, 236). Thyroid hormone also stimulates LDL
receptor gene synthesis (237) and increases the activity of
enzymes that metabolize lipoproteins, including hepatic
lipase, LPL, cholesteryl ester transfer protein (CETP), and
lecithin cholesterol acyltransferase (LCAT) (238–242).
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treated with LT4 (Table 8) but were not significantly changed
in patients treated with a combination of LT4 and T3 (1).
In patients with SCH (TSH <10 mIU/L) with
associated hyperlipidemia, we suggest considering
thyroxine treatment as a means of reducing LDL
levels. (2⊕OOO)

6.4

Technical Remark:
• Take into consideration the patient’s age and general
health, the possibility of suppression of TSH, and
whether the patient has CVD.
Evidence and discussion
Prior clinical trials of people with SCH (TSH 4 to 10 mIU/L)
treated with T4 compared with placebo and a meta-analysis
of these trials have failed to show any benefit in terms of
thyroid-related symptoms, fatigue, depressive symptoms, and/
or quality of life (250). However, the meta-analysis performed
for this guideline showed an 11 mg/dL reduction in LDL-C
in patients with SCH treated with T4. The impact of T4 replacement on long-term CV outcomes is unknown. Among

Table 7. Effect of treatment of overt hyperthyroidism on lipid parameters
Lipid Parameter

Baseline Lipid Parameter
Mean, mg/dL (95% CI)

Postintervention Change in
Lipids Mean, mg/dL (95% CI)

Number
of Studies

Total cholesterol
LDL-C
HDL-C
TG

158.7 (153.6, 163.9)
89.2 (76.7, 101.6)
46.5 (43.0, 49.9)
110.1 (99.7, 120.4)

44.4 (37.7, 51.0)
31.1 (24.3, 37.9)
5.5 (1.5, 9.6)
7.3 (–0.5, 15.1)

31
29
32
30

Treatment includes antithyroid medication, surgery, or radioiodine. To convert mg/dL to mmol/L for total cholesterol, LDL-C, and HDL-C, divide mg/dL by 38.7.
To convert mg/dL to mmol/L for TG, divide mg/dL by 88.6.
Abbreviations: CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.
From Kotwal A, Cortes T, Genere N, et al. “Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis.” J Clin Endocrinol Metab.
2020;105(12) (1)

Table 8. Effect of thyroxine replacement on lipid parameters in overt and subclinical hypothyroidism
Population

Lipid Parameter

Baseline Lipid Parameter, mg/dL (95% CI)

Postintervention Change
in Lipids, mg/dL (95% CI)

Number
of Studies

Overt hypothyroidism

Total cholesterol
LDL-C
HDL-C
TG
Total cholesterol
LDL-C
HDL-C
TG

260.3 (252.8, 267.7)
168.8 (161, 176.5)
54.3 (51.5, 57.1)
147.3 (139.4, 155.3)
217.4 (212.1, 222.6)
139.5 (134.3, 144.7)
51.8 (50.1, 53.5)
124.5 (115.8, 133.1)

–58.4 (–64.7, –52.1)
–41.1 (–46.5, –35.7)
–4.1 (–5.7, –2.6)
–27.3 (–36.6, –17.9)
–12.0 (–14.5, –9.6)
–11.1 (–13.1, –9.0)
0.15 (–0.89, 1.9)
–4.5 (–7.9, –1.2)

72
55
57
60
79
74
76
76

Subclinical hypothyroidism

To convert mg/dL to mmol/L for total cholesterol, LDL-C and HDL-C, divide mg/dL by 38.7. To convert mg/dL to mmol/L for TG, divide mg/dL by 88.6.
Abbreviations: CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.
From Kotwal A, Cortes T, Genere N, et al. “The effect of treatment of hyper- and hypothyroidism on serum lipids: a systematic review and meta-analysis.” J Clin
Endocrinol Metab. 2020;105(12) (1)
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autoimmunity, or other effects of hypothyroidism could
not be determined. Conversely, the clinical effects of hypothyroidism in patients with coronary disease are complex.
Hypothyroidism decreases cardiac work and oxygen demand but decreases cardiac contractility, often resulting
in worsened angina. However, classic studies more than a
half-century ago found evidence that general surgery can be
safely performed in patients with hypothyroidism.
In patients with hyperlipidemia, several studies have
shown the prevalence of preexisting overt hypothyroidism
to be between 1.4% and 13%. In a retrospective chart review of over 4000 patients with newly diagnosed hyperlipidemia and who had a serum TSH determined, 3% had
moderate elevations of TSH (>5 mIU/L) and 1.7% had
a TSH over 10 mIU/L (248). The Cardiovascular Health
Study, however, found no association of subacute or overt
hypothyroidism with either increased CV outcomes or with
mortality (249).
In the Endocrine Society-planned meta-analysis of clinical trials that evaluated the effects of treatment of thyroid
disease on lipid parameters, total cholesterol, LDL-C, HDLC, and TG decreased in patients with overt hypothyroidism
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in doses that did not normalize TSH. A cross-over study
of LT4 versus LT3 therapy continued to normalization of
TSH found lower cholesterol levels in the LT3 arm (262).
Nevertheless, The American Thyroid Association guidelines
do not recommend targeting high-normal T3 levels or lownormal TSH levels in people with hypothyroidism who also
have dyslipidemia (263). An RCT of moderate vs weightrelated higher LT4 doses combined with LT3 found that
higher levels of serum-free T4 were associated with lower
total and LDL-C (264).
The American Thyroid Association guidelines do not recommend the routine use of combinations of LT4 and LT3
therapy specifically to improve the lipid profile. Likewise,
genetic testing is not currently recommended for clinical identification of patients with type 2 deiodinase gene
polymorphisms to guide possible combination therapy.
Nor is there a recommendation for monotherapy with LT3
in hypothyroid patients with significant dyslipidemia (263).

7. Excess Glucocorticoids
7.1

In adult patients with Cushing syndrome, we
recommend monitoring the lipid profile in order
to identify cases of dyslipidemia. (1⊕⊕OO)

Technical Remark:
• Monitor lipid profile at the time of diagnosis and
periodically afterwards at the discretion of the treating
physician.
Evidence and discussion
Dyslipidemia is a common metabolic abnormality in
Cushing syndrome, although precise estimates of the prevalence are difficult to obtain because the definitions and
cutoffs for dyslipidemia vary across studies, and the criteria also vary across lipid guidelines over time. Patient cohorts reported in Cushing studies are relatively small, and
the reference populations used for comparison may or may
not be matched for BMI (265). Estimates for the prevalence
of dyslipidemia in active Cushing disease range from 38%
to 71% (266). The dyslipidemia in Cushing syndrome is
characterized by elevated plasma total cholesterol and TG
due to increased circulating VLDL and LDL particles (267),
and variable levels of HDL-C (268, 269). Dyslipidemia severity can be influenced by the severity and duration of
hypercortisolemia, presence of diabetes, and degree of visceral obesity.
The pathophysiology of dyslipidemia in glucocorticoid
excess is complex and incompletely understood, involving
both direct and indirect effects of glucocorticoids on liver
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the studies included in the meta-analysis, 82% defined SCH
as normal T4 and TSH 5–10 mIU/L. In 18% of the studies,
T4 was normal and TSH levels were in the range of 10 to
20 mIU/L.
Descriptive studies of populations with SCH generally
support the concept that such patients have lipid abnormalities, although the data are not uniform. Several groups
have reported higher levels of total cholesterol and LDL-C
in individuals with SCH compared with euthyroid subjects
and even in patients with TSH values <10 mIU/L (251–
253). However, other studies find elevations only in those
with TSH >10 mIU/L (254). Generally, lipid levels decrease
after treatment with LT4, although the time course of improvement is not stated.
In the Endocrine Society meta-analysis of patients with
SCH, total cholesterol, LDL-C, and TG were reduced after
LT4 treatment, but the magnitude of these changes was
less in comparison to patients with overt hypothyroidism
(Table 8). In patients with SCH who were not treated with
LT4, lipids did not change over time.
The relationship of SCH and other indices of CVD risk
and clinical events have been studied with varying results
based on age and degree of TSH elevation. A retrospective
study found fewer ischemic events in patients younger than
70 years of age with SCH and who had their TSH levels
normalized, but not in older patients (255).
The risk of MI was found to be increased in
postmenopausal women with SCH (256). A 2017 metaanalysis found increased CV events in patients with TSH
values >10 mIU/L and a nonstatistically significant increase
in patients with TSH >7 mIU/L (257). A meta-analysis of
almost 3500 adults with SCH (TSH 4.5 to 19.9 mIU/L)
found no increased risk of stroke vs age- and sex-adjusted
pooled HRs across all groups, but did find a significant increased risk in people younger than 65 years of age (258).
In a comparison of subgroups with TSH 4.5 to 6.9 mIU/L,
7 to 9.9 mIU/L, and 10–19.9 mIU/L, fatal stroke increased
with higher TSH levels but the trend was not significant.
A meta-analysis of individual participant data from 11
prospective studies in 55 287 adults (over a half-million
person-years) including 3450 adults with SCH found an increased risk of CVD in patients with TSH 10 to 19.9 mIU/L
but not in those with lower levels of TSH (259). CHD mortality was increased in patients with TSH 10 to 19.9 mIU/L
and 7 to 9.9 mIU/L, although only statistically significant
in the higher TSH group (259). Several, generally small,
studies of SCH have also found higher levels of c-reactive
protein (CRP), Lp(a), and cIMT when compared with ageand gender-matched controls (260, 261).
The precise clinical value of L-triiodothyronine (LT3)
treatment in reducing elevated lipids remains unclear.
Daily therapy with LT3 alone reduced total cholesterol
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Lipid-lowering therapy in Cushing syndrome
7.2

In adults with persistent endogenous Cushing
syndrome, we suggest statin therapy, as adjunct
to lifestyle modification, to reduce CV risk
irrespective of the CV risk score. (2⊕OOO)

Technical Remarks:
• LDL-C should be the primary target, and therapy should
be considered if LDL-C is over 70 mg/dL (1.8 mmol/L).
• Patients receiving mitotane therapy for Cushing
syndrome commonly develop secondary dyslipidemia
from therapy.
• Lipid-lowering therapy may not be appropriate for
patients with limited life expectancy, such as those with
an underlying malignancy.
7.3

In adults with cured Cushing syndrome, we advise
the approach to CV risk assessment and treatment
be the same as in the general population.
(Ungraded Good Practice Statement)

Evidence and discussion
Chronic hypercortisolism due to Cushing syndrome is associated with the development of MetS with hypertension,
insulin resistance, dyslipidemia, a prothrombotic state, and
visceral obesity, which may increase the risk of ASCVD.
Patients with active Cushing disease have a high prevalence
of hypertension (55% to 85%), obesity (32% to 41%), and
diabetes mellitus (20% to 47%) (266). A long-term follow-up
study and meta-analysis of patients with Cushing disease

demonstrated that overall mortality is 2.2-fold greater than
in the general population (275). CVD (MI, stroke) is the
most common cause of death in Cushing syndrome (276). In
a cohort study of 343 patients with Cushing syndrome evaluated over the pre- and postdiagnosis and treatment periods,
the risk of MI (HR, 3.7; 95% CI, 2.4–5.5) and stroke (HR,
2.0; 95% CI, 1.3–3.2) were increased (277). Patients with
Cushing syndrome who achieve remission generally have
much better outcomes compared with those with persistent
disease, with a standardized mortality ratio of 1.2 (95% CI:
0.45, 3.18) compared with 5.50 (95% CI: 2.69, 11.26) in
those with persistent disease (275). A small study of patients
younger than 45 years of age who achieved long-term remission of Cushing syndrome had evidence of subclinical
coronary atherosclerosis on cardiac CT imaging (30%, 3/10,
P = 0.01) compared with age- and gender-matched controls
(0%, 0/20) (278).
Several medications used for the treatment of Cushing
syndrome have important effects on lipids. Ketoconazole
is an imidazole derivative that inhibits several key enzymes in cortisol biosynthesis. Ketoconazole is also an inhibitor of cholesterol biosynthesis, and treatment can lead
to an approximately 25% reduction in apoB and LDL-C
levels (267). Importantly, ketoconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4) and can markedly increase plasma levels of certain statins, specifically
simvastatin, lovastatin, and, to a lesser extent, atorvastatin.
This can significantly increase the risk of myotoxicity from
statin therapy. Therefore, statins not metabolized by the
CYP3A4 system (including fluvastatin, pravastatin, and
rosuvastatin) should be used when cholesterol-lowering
therapy is required in the setting of ketoconazole therapy.
Mifepristone, a glucocorticoid-receptor antagonist,
has been shown to improve glycemic control, diastolic
blood pressure, and weight in patients with endogenous
Cushing syndrome. After 24 weeks of mifepristone treatment, mean HDL-C was significantly reduced by 14.2 ±
11.9 mg/dL (0.37 ± 0.31 mmol/L) from a mean baseline of
62.3 ± 27.8 mg/dL (1.6 ± 0.72 mmol/L); there were no statistically significant changes in LDL-C or TG (279). Weight
loss achieved with mifepristone treatment persisted for 2
additional years in patients who remained on therapy (280).
Pasireotide, a somatostatin analogue, has been shown
to significantly decrease cortisol levels in Cushing disease.
A phase 3 double-blind trial of pasireotide administered subcutaneously twice daily in patients with Cushing disease reported significant reductions in systolic and diastolic blood
pressure, weight, and LDL-C (-15 mg/dL [-0.4 mmol/L];
95% CI, -23 to -8 mg/dL [-0.6 to -0.2 mmol/L]) (281).
Another phase 3 trial of a longer acting formulation of
pasireotide, administered once a month, also found a reduction in blood pressure and weight, but LDL-C levels were
not reported (282). In both studies, the use of pasireotide
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and adipose tissue (267). Patients with Cushing syndrome
have increased hepatic synthesis and secretion of VLDL and
also demonstrate increased visceral fat distribution compared with controls (270, 271). Although short-term increases in glucocorticoids stimulate lipolysis, proadipogenic
effects are more prominent in chronic hypercortisolism.
Glucocorticoids stimulate preadipocyte differentiation
and inhibit adenosine monophosphate (AMP)-activated
protein kinase (AMPK) in visceral adipose tissue, leading
to increased lipogenesis and fat storage. Glucocorticoids
stimulate AMPK in the liver, promoting fatty acid and cholesterol synthesis, and contributing to development of hepatic steatosis (272).
Patients who achieve successful remission of Cushing
syndrome after treatment do experience improvement in
dyslipidemia and other CV risk factors such as obesity,
hypertension, and diabetes (273). However, these risk factors persist after cure in a significant proportion of patients
(274). Therefore, patients may require monitoring and
treatment for dyslipidemia after successful biochemical remission of Cushing disease.
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Values and preferences
The advice to offer statin therapy to reduce CV risk in adult
patients with persistent Cushing syndrome places higher
value on the consistent evidence of excess CV morbidity
and mortality in Cushing syndrome, and the long-term
safety and efficacy of LDL-lowering therapy with statins
in the general population of patients with dyslipidemia,
hypertension, diabetes, and obesity. There are no RCTs of
statins or other lipid-lowering therapies evaluating CV outcomes specifically in patients with persistent Cushing syndrome or cured Cushing syndrome. As with treatment of
CV risk factors in general, performing an individualized
risk assessment with shared decision-making is prudent for
determining the most appropriate treatment for individual
patients.
Lipid management in chronic glucocorticoid therapy
7.4

In adults receiving chronic glucocorticoid
therapy above replacement levels, we suggest the
assessment and treatment of lipids and other CV
risk factors because of the increased risk of CVD.
(2⊕OOO)

Technical Remark:
• Effects of glucocorticoid therapy on lipids and CV risk
will vary based on the dose of glucocorticoid, duration
of treatment, and underlying disease/indications.
Evidence and discussion
The literature on the prevalence of glucocorticoid therapy–
induced dyslipidemia (elevated total and LDL-C and TG)
is conflicting, with 1 large study demonstrating no clear

association (285) and another in patients with hypopituitarism on glucocorticoid replacement demonstrating
a dose-dependent effect on total cholesterol, LDL, and
TG levels (286). The effects of exogenous glucocorticoid
therapy on lipid metabolism are influenced by many factors, including dose and route of administration, duration
of therapy, underlying medical conditions, and concurrent
medications.
Several observational studies have found a significant association between chronic glucocorticoid therapy
and the risk of ASCVD. A cohort study of patients in the
United Kingdom compared people who were prescribed
systemic glucocorticoids and who also had a diagnosis of
iatrogenic Cushing syndrome (n = 547) with those prescribed glucocorticoids without a diagnosis of iatrogenic
Cushing syndrome (n = 3231) and those not prescribed
systemic glucocorticoids (n = 3282) (287). A multivariate
analysis adjusted for age, sex, intensity of glucocorticoid
use, underlying disease, smoking status, anticoagulant use,
and therapies for diabetes, hypertension, and dyslipidemia
showed a strong relationship between iatrogenic Cushing
syndrome and CV events: adjusted HR, 2.27 (95% CI,
1.48–3.47) for CHD and 3.77 (95% CI, 2.41–5.90) for
heart failure. A nested case-control study of over 50 000
patients with at least 1 prescription for oral or nonsystemic
glucocorticoid therapy found an increased risk of ischemic heart disease (OR, 1.20; 95% CI, 1.11–1.29) (288).
However, it is unclear if the estimated increased risk was
clinically important, given the nested case-control design.
A second cohort study with over 68 000 glucocorticoid
users compared with over 82 000 nonusers showed a riskadjusted RR of CV events of 2.56 (CI, 2.18–2.99) in patients receiving high-dose glucocorticoids (289). Another
nested case-control analysis of a large cohort found that
users of higher dose glucocorticoids (equivalent to >10 mg
of prednisolone per day) had a greater risk of acute MI compared to nonusers (OR, 2.15; 95% CI, 1.45–3.14) (290).
Robust tools for estimating ASCVD event risk related to
chronic glucocorticoid therapy are lacking. However, the
QRISK3 10-year CV risk prediction algorithm developed
in the United Kingdom has recently incorporated corticosteroid use as a clinical variable in its risk prediction algorithm (291).
The effects of glucocorticoid-replacement therapy regimens on CV risk factors have also been explored in patients
with adrenal insufficiency (292). A study of 2424 patients
with hypopituitarism found a dose-dependent increase in
mean serum total cholesterol, TG, LDL-C, and BMI in patients receiving glucocorticoid doses equivalent to ≥20 mg
per day of hydrocortisone, compared with patients without
central adrenal insufficiency and those receiving doses
equivalent to <20 mg per day of hydrocortisone (286). The

Downloaded from https://academic.oup.com/jcem/article/105/12/3613/5909161 by guest on 04 August 2022

was associated with a significant increase in hyperglycemia,
HbA1c, and in some cases new diabetes.
Mitotane, a diphenylmethane derivative that acts as a
mitochondrial toxin in adrenal tissue, has been used for
the treatment of adrenal cortical carcinoma and refractory
Cushing syndrome. The drug also inhibits cortisol synthesis
through the inhibition of multiple enzymes (283). Mitotane
use commonly causes an increase in cholesterol and TG
levels, with maximal changes in cholesterol occurring 1
to 5 months after drug initiation (284). Mitotane can increase cholesterol levels by over 60%, but this can be successfully managed with statin therapy (265). Mitotane is
a lipophilic agent that binds to lipoproteins in serum, and
such binding inhibits the activity of mitotane in vivo, suggesting that the lipoprotein-free fraction is the more active
form. It has been suggested that statins, by decreasing the
lipoprotein-bound fraction, might increase mitotane efficacy in patients with adrenocortical carcinoma (284).
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risks of overreplacement of glucocorticoids are becoming
better appreciated. However, there are currently no studies
that clearly delineate the optimal glucocorticoid regimen in
terms of metabolic profile and ASCVD risk.

8. Disorders of growth hormone secretion
Adult growth hormone deficiency
Adult GHD is a distinct syndrome and may be the result
of prior childhood GHD, structural lesions, trauma, or
idiopathic in etiology. GHD is the most common endocrine abnormality in patients with hypopituitarism.
Hypopituitarism with complete or partial failure of secretion of 1 or more pituitary hormones may arise from
specific gene mutations or may be related to sellar tumors, such as pituitary neoplasms or craniopharyngioma,
or infiltrative/inflammatory disorders, radiation, or traumatic brain injury. Adult-onset hypopituitarism is generally permanent and heterogeneous, requiring replacement.
8.1

In adults with GHD, we recommend obtaining a
lipid profile at diagnosis to assess for dyslipidemia.
(1⊕⊕⊕O)

Evidence and discussion
GHD adversely affects the lipid profile (293–296). Adults
with GHD commonly develop dyslipidemia characterized
by elevated plasma total cholesterol and LDL-C; effects
on TG and HDL-C are variable (293, 297–301). Increased
small dense LDL-C particles have been observed (299, 302)
and, in 1 study, increased postprandial remnant lipoproteins, which decreased after GH replacement (303). There
are no consistent alterations in apoB, apoA-1, or Lp(a)
levels (293, 297, 299).

8.2

In adults with GHD associated with
hypopituitarism, we suggest assessment and
treatment of lipids and other CV risk factors.
(2⊕OOO)

Technical Remarks:
• LDL-C should be the primary target.
• Consider therapy if LDL-C is over 70 mg/dL
(1.8 mmol/L).
Evidence and discussion
Hypopituitarism is associated with an increased risk of premature mortality when compared to age- and sex-matched
controls (311–315). Mortality is increased in both men and
women with adult GHD, but rates are higher in women
(312, 316, 317). Age is also a risk factor, with standardized mortality ratios higher in younger individuals compared with older adults. Evidence suggests that patients
with adult GHD have an increased risk of CV morbidity
and mortality. Hypopituitarism with deficiency of GH and
other pituitary hormones is associated with a reduced life
expectancy, and a 2-fold higher risk of CV death compared with healthy individuals (315, 318). Observational
studies have found increased MI and CV mortality in patients with hypopituitarism on conventional replacement
therapy (314, 319). Increased coronary artery calcifications and cIMT have been observed in patients with GHD
(320, 321). GHD may have direct adverse effects on the
myocardium and endothelium, and indirect effects mediated through increased CV risk factors, hypercoagulability,
decreased exercise performance, and/or reduced pulmonary
capacity (322). Although GHD has been hypothesized as a
contributor to the excess CV mortality in hypopituitarism,
the exact mechanisms remain unclear.
The technical remark to consider lipid-lowering therapy
if LDL-C is above 70 mg/dL is a suggestion. There are no
RCTs showing a reduction in ASCVD events in patients
with GHD and associated hypopituitarism. However, as
discussed previously, evidence from numerous RCTs of
statins shows that ASCVD benefit is based upon the absolute amount of LDL-C reduction and the baseline risk
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Values and preferences
There are a lack of high-quality clinical outcome studies
evaluating the effect of lipid therapy on ASCVD outcomes specifically in Cushing syndrome as well as in
patients taking glucocorticoids chronically. Evaluating
CV risk associated with chronic glucocorticoid therapy
is complicated by the wide variability in the CV risks
of the underlying conditions that are being treated with
glucocorticoid therapy, dose and duration of glucocorticoid therapy, and the presence of other ASCVD
risk factors in the population. The advice to assess and
treat dyslipidemia and other risk factors places higher
value on the observational evidence that chronic glucocorticoid therapy is a relevant marker of increased CV
risk and should be a consideration when engaging patients in shared decision-making regarding the benefits
and risks of lipid-lowering therapy.

GH increases the expression of hepatic LDL receptors and reduces PCSK9 expression (304–306); GH treatment of GHD adults has been shown to decrease plasma
LDL-C levels by increasing clearance of LDL and apoB-100
(307–309) and VLDL. GHD results in body composition
changes with decreased lean body mass and increased visceral adiposity, a phenotype associated with increased insulin resistance and dyslipidemia (296). Insulin resistance is
considered a low-grade inflammatory state, and increased
CRP levels and interleukin-6 levels have been observed in
GHD (310).

The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 12

of the patient. Trials of statins in combination with either
ezetimibe or PCSK9 antibodies show that reduction in
LDL-C to 55 mg/dL and to 40 mg/dL is beneficial in patients at high risk of ASCVD.
8.3

In adult patients with GHD, we recommend
against using GH replacement solely to lower
LDL-C to reduce CV risk. (1⊕⊕⊕O)

Growth hormone excess (acromegaly)
8.4

In adults with acromegaly, we suggest
measurement of the usual lipid profile before and
after treatment of GH excess. (2⊕OOO)

Evidence and discussion
Acromegaly is characterized by chronic GH hypersecretion,
commonly due to a somatotroph pituitary adenoma.
Exposure to excess GH is associated with 2- to 3-fold increase in mortality and morbidity (341) manifested as

hypertrophic cardiomyopathy, diastolic and systolic dysfunction, hypertension, arrhythmias, valvular diseases, and/
or accelerated atherosclerosis. Metabolic complications
such as T2D and associated dyslipidemia can also occur.
Whether the risk of ASCVD in acromegaly is increased
needs further investigation.
GH exerts an overall lipolytic effect, inducing the hydrolysis of TG to FFAs and glycerol. GH inhibits hepatic
lipase and LPL activity, and lipid abnormalities in GH
excess may be related to decreased activity of these lipases (342, 343). GH also modulates tissue response to insulin, and insulin resistance and glucose intolerance may
be seen in acromegaly. These alterations can contribute
to hypertriglyceridemia in patients with acromegaly.
Increased CETP activity has been observed in active acromegaly (343), whereas decreased CETP and LCAT activity were demonstrated in another small cohort (344).
The most common lipid abnormality in acromegaly is
mild-to-moderate hypertriglyceridemia (342, 344). Effects
of GH excess on plasma cholesterol levels are variable
(345). Increased small, dense LDL particles can occur despite lower LDL-C levels (343, 346). HDL-C levels may
be unchanged or reduced. One study showed increased
apolipoprotein E (apoE) or apoA-1 levels compared with
controls (347), whereas another found no differences in
apoA-1 or apoB levels (348).
Several studies have examined changes in lipids after surgical and medical treatment of acromegaly. After surgery,
TG returned to normal, and total and LDL-C remained
unchanged (349–351). Treatment of acromegaly with
octreotide reduced TG and LDL-C and increased HDL-C
(346, 352), but had no effect on plasma lipids when administered after surgery (353). Even incomplete biochemical
improvement (characterized by inadequate GH suppression
after oral glucose tolerance test or absence of normalization
of insulin-like growth factor 1 levels) appeared to be sufficient to improve total cholesterol, LDL-C, TG, and Lp(a)
levels compared with pretreatment levels (354). GH-receptor
antagonist therapy with pegvisomant increased TG levels in
healthy men (355) and increased total and LDL-C levels in
patients with acromegaly (356, 357).
Elevated levels of Lp(a) are associated with an increased
risk of ASCVD. Lp(a) levels may be higher in individuals
with acromegaly compared with controls without acromegaly, and may decrease after surgical treatment or somatostatin analog therapy (346–349, 358, 359). A study
of patients with acromegaly found that mean Lp(a) was
significantly reduced from 39.5 mg/dL before surgery to
28 mg/dL after surgery in patients who achieved remission
(350). However, in the group of patients with persistent acromegaly after surgery, mean Lp(a) (52 mg/dL before surgery) did not significantly change after surgery.
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Evidence and discussion
Long-term GH replacement improves the lipid profile in
patients with GHD, with a decrease in total cholesterol
and LDL-C, no change or increase in HDL-C, and no
change in TG levels (300, 323–330). The reduction in
LDL-C is much smaller than that achieved with statin
therapy, and LDL particle size may remain unchanged
(302). Treatment with GH increases apoA and Lp(a)
levels (331–334).
In observational studies GH replacement is associated with improvement in cIMT (335, 336). There is no
evidence to suggest that GH-replacement therapy decreases mortality in men and women (337). One study
in GHD patients on long-term GH-replacement therapy
observed a decreased risk of nonfatal stroke in both
men and women (338). Small non-randomized studies
have observed decreased CV events in individuals on
GH-replacement therapy (319, 339), strong data are
lacking.
A single observational study has shown that the addition of GH to statin therapy in hypopituitary patients is associated with an additive LDL-C reduction (340). Whether
the increase in Lp(a) levels that occurs with GH therapy
enhances CVD risk is unknown.
In summary, GH replacement results in a small reduction in LDL-C, which is of a much lower magnitude compared with the reduction observed with statins. There is
insufficient evidence to show that GH replacement has a
beneficial effect on ASCVD outcomes. Therefore, we do not
recommend GH replacement solely for reducing LDL-C or
ASCVD risk in patients with GHD. Assessment of ASCVD
risk and therapy should be based on ASCVD risk factors.
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9. Polycystic ovary syndrome
PCOS is a complex phenotypically heterogenous disorder in women of reproductive age characterized by
hyperandrogenism, ovulatory dysfunction, and/or polycystic
ovarian morphology. Metabolic abnormalities, primarily
insulin resistance and compensatory hyperinsulinemia, are
evident in many affected women (360–362).
Lipid abnormalities
9.1

Technical Remarks:
• PCOS is associated with CV risk factors.
• Conduct a lipid screening both before and intermittently
during hormonal therapy.
• In PCOS, hypertriglyceridemia is the most common
lipid abnormality.
Evidence and discussion
Dyslipidemia is very common in women with PCOS and occurs in up to 70% of US women with this diagnosis (363).
Lipid metabolism in PCOS is altered by a multitude of factors and is not fully explained by visceral obesity alone
(364, 365). Several patterns of dyslipidemia have been described, but women with PCOS often exhibit an atherogenic lipid profile, similar to that in diabetes and MetS,
characterized by increased TG, low HDL-C, and normal or
increased LDL-C; qualitative alterations include increased
small, dense LDL particles (365–375). These characteristic
lipid changes occur throughout the reproductive span from
early adulthood, persist after menopause, and appear to be
driven by visceral adiposity, insulin resistance (374, 376,
377), hyperandrogenism (378–380), and/or genetic and environmental factors (373, 381, 382). Studies have found no
alterations in apoB levels in women with PCOS, reduced
apo A-1 levels (368), higher concentrations of Lp(a), especially in nonobese women with PCOS (369, 383, 384), and
decreased cholesterol efflux capacity (385).
Women with ovulatory PCOS show a milder atherogenic
lipid profile or normal lipids compared with those with anovulatory PCOS (384, 386). Lean women with PCOS may
have only low HDL-C levels, whereas those with obesity
also have elevations in TG (387). The prevalence of elevated LDL-C levels above 100 mg/dL (2.6 mmol/L) ranges
between 24% and 40% (365, 388, 389) and occurs irrespective of body weight (373).

Effect of treatment of PCOS on lipids
Lifestyle changes in women with PCOS, recommended
as the first line of therapy, result in improvements in
body composition, hyperandrogenism, insulin resistance, and ovulation but, overall, appears to have minimal to no impact on lipids (399–402). The effect of
metformin on lipid levels in women with PCOS appears
to be variable. Oral contraceptives (OCPs) containing
estrogen increase TG levels. This increase may be substantial in genetically susceptible individuals who may
have high TG before taking OCPs and may lead to pancreatitis. Estrogen is also associated with an increase in
HDL-C and a decrease in LDL-C ranging from 5% to
20% (403).
In women who do not desire conception, statin therapy
may be considered based on risk factors, with lower LDL-C
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In women with PCOS, we recommend obtaining a
fasting screening lipid panel at diagnosis to assess
CV risk. (1⊕⊕⊕O)

Cardiovascular risk
ASCVD risk in women with PCOS has been hard to characterize and is potentially conferred by the existence of
metabolic dysfunction driven primarily by underlying insulin resistance. Women with PCOS often have ASCVD
risk factors, such as abdominal obesity, and components of
MetS with underlying insulin resistance. Insulin resistance
may occur independently of obesity and is usually severe in
women with hyperandrogenism and chronic anovulation.
In the United States, up to 80% of women with PCOS
are obese (390); however, outside of the United States, the
prevalence of obesity is estimated to be 50% (391). MetS
is also more common in women with PCOS compared
with BMI-comparable women without PCOS, and has
been shown to be 2- to 5-fold higher in women with PCOS
than without (374). Based on the National Cholesterol
Education Program Adult Treatment Panel III criteria,
34% to 46% of US Caucasian women with PCOS have
MetS (392). Several studies have evaluated CVD risk factors. Early reports suggested that women with PCOS might
have an increased CVD risk (393), but subsequent small
studies have not confirmed this (394–396). There are no
long-term prospective studies assessing CVD risk in PCOS,
and evidence for increased CVD morbidity and mortality in
women with PCOS remains inconclusive (397).
Based on existing data, our recommendation is to screen
all women with PCOS with a lipid profile at the time of
diagnosis. Additional screening for CV risk factors, such
as family history of premature or early CVD, cigarette
smoking, impaired glucose tolerance/T2D, hypertension, or
obstructive sleep apnea is important to stratify risk in these
women (389, 398).
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goals in those with MetS, T2D, or overt vascular or renal
disease (389).

10. Menopause and hormonal replacement
10.1

9.2

In women with PCOS, we suggest against using
lipid-lowering therapies to treat hyperandrogenism
or infertility. (2⊕OOO)

Technical Remarks:
• Hormone therapy increases the risk of cardiovascular
disease, specifically venous thromboembolism and
stroke. However, the absolute risk of cardiovascular
disease is lower in younger compared to older
postmenopausal women.
• Hormone therapy is described as estrogen ±
progesterone/a progestin.
Evidence and discussion
Estrogen has a role in the metabolism of TG, cholesterol,
and fatty acids in the liver through a variety of mechanisms. Estrogen has been shown to increase VLDL synthesis,
upregulate the LDL receptor, and improve insulin sensitivity
in the liver (420). The changes in lipid and lipoprotein levels
across menopause are relatively small, and variable results
are reported in different studies. In general, there is a shift
towards a more atherogenic profile with a predominance of
smaller, denser LDL particles, decreases in HDL-C, and increases in total cholesterol levels postmenopause compared
to premenopause. Surgically-induced menopause triggers
an abrupt drop in estrogen levels (421–423). The increase
in LDL-C levels postmenopause may be due to increases in
PCSK9 (424), although any possible clinical or pathophysiological significance of this is unknown, and postmenopausal
women have not been described to have any uniquely strong
response to PCSK9-inhibitory monoclonal antibodies.
The treatment of postmenopausal symptoms may involve the use of estrogen with or without progesterone or
a progestin. Oral estrogen therapy increases HDL-C by up
to 15% and decreases LDL-C by up to 20%. Transdermal
estrogen has similar effects on lipid levels but generally less
of a change in lipid levels compared with oral estrogen.
Progestins tend to decrease HDL-C levels, thus the use of
combined estrogen and progesterone (required for the prevention of adverse endometrial effects) tends to blunt lipid
changes compared with estrogen alone (425, 426).
Estrogen may dramatically increase TG levels in patients
with an underlying predisposition to hypertriglyceridemia,
which could trigger acute pancreatitis. This risk of
postmenopausal hormone therapy–induced pancreatitis
appears to be limited. A population-based case-control
study examining postmenopausal hormone therapy use
and pancreatitis found no significant increase in the risk
of pancreatitis among current or former users of estrogen
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Evidence and discussion
Large-scale clinical studies of statins in women with PCOS,
either as monotherapy or in combination with other therapies, are very limited. Statins are effective in decreasing
total cholesterol and LDL-C in women with PCOS, with no
evidence of effect on HDL-C when compared with placebo
or OCPs (404–408). Significant TG reduction has been observed in all these studies. There are currently no long-term
studies evaluating the effect of statins on CV outcomes in
women with PCOS.
There is a small but increasing body of evidence that
statins may improve testosterone levels in women with
PCOS. Treatment with atorvastatin has been shown to
decrease biochemical hyperandrogenism in these women
(404, 405, 409), but the evidence is not sufficient to recommend the use of statins for reducing androgens. In
addition, statins are contraindicated in pregnancy, and
adequate contraception is essential for women of reproductive age taking statins. Small studies have evaluated
the use of metformin in combination with simvastatin
or placebo and found similar reductions in testosterone and luteinizing hormone (LH) levels (410, 411).
Treatment with simvastatin alone has been shown to
be more effective in decreasing testosterone levels, hirsutism, menstrual irregularity, and ovarian volume compared with the use of metformin alone or in combination
therapy with simvastatin (412, 413). Antiandrogenic effects have not been demonstrated with ezetimibe (414).
Inhibition of ovarian theca-interstitial cell proliferation
and steroidogenesis in vitro due to reduced availability
of testosterone precursors thought to be related to statin
therapy have been proposed as possible mechanisms
(415–417).
Data on the effects of statins on insulin sensitivity and
glucose tolerance in women with PCOS are conflicting.
Several, although not all, studies demonstrated a worsening
of insulin resistance in women treated in the statin arm
(405, 408, 418). Therefore, because PCOS is already a risk
factor for diabetes, we suggest not using statin therapy to
decrease androgen levels in women with PCOS until clear
evidence is available.
There is limited to no evidence for use of statins as adjunct therapy during in vitro fertilization procedures; therefore, it is not recommended (419).

In postmenopausal women, we recommend
treating dyslipidemia with statin therapy rather
than hormone therapy. (1⊕⊕OO)
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10.2

In postmenopausal women on hormone therapy
and with other risk factors for CVD, we
recommend statin therapy to reduce CV risk.
(1⊕⊕⊕⊕)

Technical Remarks:
• Hormone therapy increases the risk of cardiovascular
disease, specifically venous thromboembolism and
stroke. However, the absolute risk of cardiovascular
disease is lower in younger compared to older
postmenopausal women.

• Hormone therapy is described as estrogen ±
progesterone/a progestin.
• Menopause may be associated with an increase in
LDL-C and a decrease in HDL-C.
• Risk factors may be traditional risk factors or riskenhancing factors.

Evidence and discussion
Although postmenopausal hormone therapy appears to increase CVD risk when started >10 years after menopause, it
decreases that risk when started <10 years postmenopause.
The use of statins in postmenopausal women has beneficial effects on CVD risk, including women both using and
not using hormone therapy (436). A post hoc analysis of
the HERS trial found that statin use was associated with
lower rates of CVD events (437). Furthermore, a nested
case-control study suggested that statin use may attenuate
the increased thromboembolic risk seen with hormone
replacement therapy in menopause (438). It is important
to note that a large share of even newly postmenopausal
women have sufficient CVD risk to warrant serious consideration of statin therapy. Further, prior or concurrent initiation of statin treatment appears to blunt or even eliminate
the trend towards increased CVD soon after the initiation
of estrogen therapy, and it appears to potentiate any beneficial CVD effect associated with hormone therapy (439).
Thus, in women using hormone therapy, we recommend
the use of lipid-lowering therapy to reduce CVD risk.
10.3

In women who enter menopause early (<40 to
45 years old), we recommend assessment and
treatment of lipids and other CV risk factors.
(1⊕⊕⊕O)

Technical Remarks:
• Early menopause enhances CVD risk.
• ASCVD risk should be calculated and followed after
menopause.
Evidence and discussion
Several studies have reported that a younger age at menopause predicts CVD independently of traditional risk factors (440–443). Kryczka and colleagues report that adding
early menopause (≤3 years from onset) to the 10-year atherosclerotic disease risk estimator and to the systematic
coronary risk evaluation (SCORE) model significantly improves their predictive value (444). In an analysis of pooled
individual data from 15 observational studies in 5 countries, the risk of ASCVD, including MI, angina, and stroke,
was 1.5-fold higher in women with premature menopause
(<40 years) and 1.3-fold higher in women with early
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or combined estrogen/progestins compared to nonusers
(427); however, there are many reports of estrogen-induced
hypertriglyceridemia and pancreatitis (428, 429).
For years, observational and case-control studies suggested that hormone therapy for menopause reduced CVD;
however, 2 large RCTs (HERS [430] and WHI [431] concluded that hormone therapy, specifically oral conjugated
equine estrogens 0.625 mg plus medroxyprogesterone
acetate 2.5 mg, or oral conjugated equine estrogens 0.625
mg alone, increased CVD (CHD events and nonfatal MI
as well as venous thromboembolism and stroke), especially when given to older women (>10 years after age of
menopause) (432, 433). In the WHI trials of conjugated
equine estrogen (CEE), either alone or in combination
with medroxyprogesterone acetate (MPA), increased CHD
(nonfatal MI or coronary death) risk was found with CEE
+ MPA at one year (HR 1.80; 95% CI, 1.08–2.99), but was
lower or neutral with time. In post-intervention follow up,
CHD events were elevated with CEE + MPA, and reduced
with CEE compared to placebo, but not statistically significant (433). In both trials, in the intervention phase, stroke
(usually ischemic), deep vein thrombosis, and total cardiovascular events were significantly increased, although the
risk was lower in younger women (433). Thus, hormone
therapy increases the risk of CVD, especially if started late
(>age 60 years or >10 years postmenopause).
A meta-analysis found that hormone therapy significantly reduces CVD in younger, but not older women
(434). A Cochrane Database systematic review concluded
that hormone therapy in postmenopausal women has no
benefit on CVD risk and potential harm (largely due to
the risk of thromboembolic events and stroke) (435). We
do not recommend the use of hormone therapy to treat
dyslipidemia. Although this guideline focuses on treatment of lipid disorders to reduce CVD risk, and does not
make recommendations regarding HT for postmenopausal
women, the literature suggests that HT may be appropriate
for treatment of menopausal symptoms such as hot flashes,
night sweating, and disrupted sleep, especially in relatively
healthy younger postmenopausal women.
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menopause (40 to 44 years) compared with women who
experienced menopause at age 50 to 51 years (443). These
data are consistent with another study of pooled individual
participant data, which found an inverse relationship between age at menopause and coronary heart disease events
(445). Thus, we recommend the assessment of lipids and
other CVD risk factors and use of lipid-lowering therapy
to reduce CVD risk in women who enter menopause early,
defined as younger than age 40–45 years.

The lipid profile in men with hypogonadism may show increased LDL-C and TG, and low HDL-C (150, 446, 447).
Replacement doses of testosterone have minor effects
on circulating lipids in men with low testosterone (448).
Men with hypogonadism, however, have increased CVD
risk, but the reasons for this may be multiple. Low levels
of testosterone are associated with low levels of HDL-C
and elevated TG, as well as insulin resistance, increased
waist circumference, increased FFAs, and other features
of the MetS. Testosterone replacement has been shown to
improve insulin sensitivity (449–451). In contrast to the
doses of testosterone used for replacement, higher-dose androgens, often used to increase muscle mass, lead to profound effects on circulating lipids. Although testosterone
therapies to improve well-being or athletic performance are
often done illicitly, some patients will have such treatments
prescribed by their doctors.

Technical Remark:
• Supraphysiological doses of androgens will reduce
HDL-C levels.
Evidence and discussion
Effects of androgens on lipids are most evident with
supraphysiologic hormone usage. Exuberant use of androgens, often taken for athletic enhancement, lowered HDL
by >50% to a mean level of 23 mg/dL (0.6 mmol/L) and
raised LDL >50% to 188 mg/dL (4.9 mmol/L) (454). These
effects were shown to reverse several months after the discontinuation of anabolic steroids (454–456). Other effects
of androgenic anabolic steroids include increased apoB,
and decreased Lp(a) (457).
Androgens, especially testosterone, are activators of
hepatic lipase, an enzyme that hydrolyzes phospholipids in
HDL, assists with the clearance of small VLDL and converts LDL into small, dense LDL. For this reason, anabolic
steroids markedly suppress HDL-C levels and sometimes
also raise TG (150, 458).

12. Gender-affirming hormone therapy
12.1

11.1

In patients with low testosterone levels, we
suggest testosterone therapy as symptomatically
indicated, and not as an approach to improve
dyslipidemia or CVD risk. (2⊕⊕OO)

Evidence and discussion
The effects of androgens on circulating lipoproteins levels
have been studied in the setting of replacement therapies
and with the use of illicit body building and athleticenhancing drugs. Replacement doses of testosterone have
been found to have either minimal effects on lipids (reduction in LDL-C and TG, or decrease in HDL-C) or no effect
(448). One study comparing different forms of replacement found no change in circulating lipids (452).
Pending the results of additional long-term studies, the
potential adverse effects of testosterone replacement on CVD
are concerning. The use of these agents, which have limited
but beneficial effects on sexual function and mood (453),
should alert the clinician to more aggressively control other
risk factors and consider a lower goal for LDL reduction.

In patients with low HDL (<30 mg/dL
[0.8 mmol/L]), especially in the absence of
hypertriglyceridemia, we advise clinical or
biochemical investigation of anabolic steroid
abuse. (Ungraded Good Practice Statement)

In transwomen and transmen who have taken
or are taking gender-affirming hormone therapy,
we advise assessing CV risk by guidelines for
nontransgender adults. (Ungraded Good Practice
Statement)

Technical Remark:
• There are no data to guide the selection of a gender
marker in risk calculators for individuals on genderaffirming hormone therapy.
Evidence and discussion
Studies of lipid changes in transgender individuals are
limited. Several studies of testosterone therapy for transgender males reported a reduction in HDL and an increase
in TG levels (150, 457, 459). Similarly, a meta-analysis
found significant increases in TG and LDL-C, significant
reductions in HDL-C, and no change in total cholesterol
in transmen taking hormonal therapy (460). The estimated
increase in TG was 9 and 21 mg/dL (0.1 and 0.2 mmol/L)
at 3 to 6 months and ≥24 months of therapy, respectively,
and the increase in LDL-C was 11 and 17.8 mg/dL (0.3 and
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11. Hypogonadism and testosterone replacement
and abuse

11.2
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13. Considerations for implementation of the
guidelines
This section provides a brief overview of lifestyle measures
and the efficacy and safety of medications for hypercholesterolemia and hypertriglyceridemia.
Lifestyle therapy
A healthy diet and physical activity are essential components of a treatment plan for dyslipidemia to prevent or
reduce ASCVD (35, 462, 463). Information on lifestyle
modifications for the reduction of LDL-C and TG can
be found in the 2013 AHA/ACC Guideline on Lifestyle
Management to Reduce Cardiovascular Risk (464). Food
groups for a healthy diet include vegetables, fruits, legumes
(lentils, beans, peas, chickpeas), whole grain cereals, bread,
low fat dairy products (skimmed milk, low-fat yogurt),
low-fat poultry without skin, lean and oily fish without
the skin, nontropical vegetable oils, and nuts. The dietary
components may be modified for individuals with diabetes
or other disorders that benefit from nutrition therapy, and
the calories may be adjusted for maintenance of weight
loss or for weight reduction. Calories from saturated fat
should constitute no more than 5% to 6% of the total calorie count and should avoid trans-fat. Sodium restriction

Table 9. Statins: LDL-C reduction by dose and major drug interactions
Statin

Estimated Percent of LDL-C Reduction by Dose
High intensity, Moderate intensity,
≥50%
30–50%

Atorvastatin
40 mg, 80 mg 10 mg, 20 mg
Rosuvastatinb 20 mg, 40 mg 5 mg, 10 mg
Simvastatin
–
20 mg, 40 mg

Pravastatin
Pitavastatin
Lovastatin

–
–
–

40 mg, 80 mg
1 mg, 2 mg, 4 mg
40 mg, 80 mg

Fluvastatin

–

40 mg BID

Low intensity, <30%

Major Drug Interactionsa
Gemfibrozil should be avoided in all statins

–
–
10 mg

Clarithromycin, itraconazole, colchicine, cyclosporine, niacin
Cyclosporine, darolutamide, niacin
Verapamil, diltiazem, amlodipine, macrolide antibiotics, amiodarone,
dronedarone, antifungal azoles, nefazadone, danazol, ranolazine,
colchicine, cyclosporine, daptomycin, niacin
10 mg, 20 mg Macrolide antibiotics, colchicine, cyclosporine
–
Erythromycin, rifampin, colchicine, niacin
20 mg
Verapamil, diltiazem, amiodarone, dronedarone, macrolide
antibiotics, antifungal azoles, nefazadone, danazol, ranolazine,
colchicine, cyclosporine, niacin
20 mg, 40 mg Fluconazole, colchicine, cyclosporine, niacin, glyburide, phenytoin

Bold font represent drugs and doses specifically studied in CVD outcome trials that demonstrated significant reduction in vascular events (123, 467)
Abbreviations: CVD, cardiovascular disease, HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol.
a
Some of the drugs listed require a reduction in statin dose of some statins and should be avoided in others. Macrolide antibiotics include clarithromycin, erythromycin and telithromycin. Azole antifungals include itraconazole, ketoconazole, posaconazole, and voriconazole. All statins have varying interactions with HIV
protease inhibitors and other antiretroviral medications, and hepatitis C protease inhibitors (142). For more information on interactions and dose limitations,
see product labeling and Newman et al. 2019 “Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association” (142).
b
Due to increased rosuvastatin plasma concentrations in Asian patients, initiation with the 5 mg dose is suggested.
From the prescribing information of Parke-Davis Div of Pfizer, Inc. 2020, SciGen Pharmaceuticals 2020, NuCare Pharmaceuticals, Inc. 2020, PD-Rx Pharmaceuticals,
Inc. 2020, Kowa Pharmaceuticals America, Inc. 2009, Teva Pharmaceuticals USA, Inc. 2020, Mylan Pharmaceuticals, Inc. 2020 (468–474).
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0.5 mmol/L) at 12 and ≥24 months, respectively. HDL-C
was reduced at all time points (-6.5 mg/dL [-0.2 mmol/L],
-8.1 mg/dL [-.2 mmol./L], and -8.5 mg/dL [-0.2 mmol/L]).
These estimates were associated with wide 95% CIs and
only a small number of studies had data at the earliest and
latest time points. In transwomen, the only lipid parameter
with a significant change was TG, which increased by an
estimated 31.9 mg/dL (0.4 mmol/L) (95% CI, 3.9–59.9) at
≥24 months. Triglycerides were increased in transwomen
taking oral estrogens, but not in transwomen treated with
transdermal estrogen.
There is a paucity of data evaluating CVD and CVD
risk in transmen and transwomen. In the meta-analysis
described above, there were too few CV events to make
an assessment (460). Although it appears that mortality is
increased in individuals taking gender-affirming hormone
therapy compared with the general population, the increased mortality is due in part to suicides, acquired immunodeficiency syndrome (AIDS), and drug abuse. CVD
death was increased only in current but not past users of
ethinyl estradiol (461). In the absence of any further data,
we suggest assessing ASCVD risk per usual guidelines. The
choice of which gender flag to use in the risk assessment is
unknown.
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Pharmacological treatment for LDL-C reduction: statins
Statins are the first line of pharmacological treatment as adjunct to diet and exercise to reduce LDL-C (Table 9). Statins
reduce LDL-C by inhibiting HMG-Co A reductase, which
controls the rate-limiting step in the cholesterol synthesis
pathway, thereby reducing LDL-C synthesis, which leads to
upregulation of LDL receptors. Numerous long-term RCTs
of a median duration of 5.1 years, and meta-analyses of
these trials have proven that statins reduce atherosclerotic
vascular events in patients with and without ASCVD by
22% per mmol/L (38.6 mg/dL) reduction in LDL-C (123).
The decision to start a statin depends upon the LDL-C level
and the ASCVD risk of the patient, taking into account riskenhancing factors, potential risks and benefits, and patient
preference. Assessment of 10-year ASCVD risk in adults
with an LDL-C of 70 to 190 mg/dL (1.8 to 4.9 mmol/L)
and without a history of ASCVD should be done by the
AHA/ACC Pooled Cohort Equations calculator. The choice
of a moderate or high-intensity statin is dependent upon
the ASCVD risk of the patient and the baseline LDL-C. In
many guidelines, LDL-C is the target of therapy. Specific
goals for LDL-C (<130 mg/dL [3.4 mmol/L], <100 mg/
dL [2.6 mmol/L], <70 mg/dL [1.8 mmol/L], <55 mg/
dL [1.4 mmol/L]), which are risk dependent, are recommended in some guidelines (462, 463, 475, 476). However,
the 2018 ACC/AHA guideline for cholesterol management
recommends monitoring the percentage of the reduction
in LDL-C and specifies a threshold for LDL-C in high-risk
patients (LDL-C 70 mg/dL [1.8 mmol/L]), which, when
exceeded, warrants intensification of statin treatment and
possibly the addition of a nonstatin drug (35).

The use of statins in patients over the age of 75 years has
been debated. Data published in 2019 from a participantlevel meta-analysis of 28 RCTs (median duration 4.9 years)
in 186 854 participants (including 14 483 older than
75 years at randomization) found a significant 21% RR
reduction in major vascular events per every 1.0 mmol/L
(38.7 mg/dL) reduction in LDL-C in adults older than
75 years at randomization (477). This RR reduction did
not differ among the 6 subgroups by age (≤ 55, 56 to 60,
61 to 65, 66 to 70, 71 to 75, and >75 years). These data
suggest a benefit in continuing statin therapy in adults over
the age of 75 who have an intermediate or high risk of
ASCVD, and the consideration of using a moderate intensity statin at a lower dose, or a low intensity statin. Factors
to consider in older patients are polypharmacy, potential
drug interactions, mental health, the prognosis of other diseases, and the wishes of the patient.

Non-statin LDL-C–lowering medications
Nonstatin medications (Table 10) are useful when, despite
lifestyle changes and maximally tolerated statin therapy,
more LDL-C reduction is needed.
The first medication to consider as adjunct to statin treatment is ezetimibe 10 mg, which is an inhibitor of the critical mediator of cholesterol absorption in the intestine, the
Niemann-Pick-C1-like 1 receptor. This receptor is also expressed in the liver. Ezetimibe is generally used with a statin.
For additional LDL-C reduction in patients taking a
statin, subcutaneous injection (every 2 weeks or once a
month) of monoclonal antibodies to PCSK-9 (alirocumab
and evolocumab) may be used either with the statin or
with the statin plus ezetimibe. These medications block the
effects of PCSK9 (a proprotein convertase) on degradation
of LDL receptors in the liver. They are indicated as adjunct
to diet, and either alone or in combination with other lipid
lowering medications, for reducing CV events in people
with ASCVD, and for reducing LDL-C in patients with FH
(eg, heterozygous FH). Evolocumab also has an indication
as adjunct to diet and lipid-lowering medications for treatment of homozygous FH. The cost of PCSK9 inhibitors
may be prohibitive for some patients.
If more LDL-C reduction is desired in patients taking
maximally tolerated statin therapy and ezetimibe, and cost
or intolerance of injections prevent the use of monoclonal
antibodies to PCSK9, a bile acid sequestrant may be added
provided that TG are below 500 mg/dL (5.6 mmol/L). Bile
acid–binding resins include colestipol, cholestyramine, and
colesevelam, which are generally used in combination with
a statin or a statin and ezetimibe. Bile acid sequestrants
lower cholesterol by binding to bile acids in the gastrointestinal (GI) tract, preventing their absorption, thereby
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to 2 g daily is recommended for those with high blood
pressure. The DASH diet and the AHA diet use this general
approach. Reductions in TG are usually greater than reductions in LDL-C. Reduced risk of ASCVD has been demonstrated with the Mediterranean diet supplemented with
extra virgin olive oil or nuts in the PREDIMED randomized
trial in high-risk subjects with no history of ASCVD (465).
US government guidelines recommend a total of 150 to
300 minutes a week of moderate intensity aerobic physical activity, or 75 to 150 minutes a week of vigorous exercise, as well as resistance training at least twice a week for
adults (466). These recommendations also apply to older
adults, who should add balance training. Studies of the effects of physical activity on lipids are inconsistent (466).
The 2018 Physical Activity Guidelines Advisory Committee
concluded, from a review of meta-analyses and individual
studies, that physical activity decreased LDL-C by 2.5 to
6.0 mg/dL (0.1 to 0.2 mmol/L) but had no consistent effect
on TG (466).
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Table 10. Medications for additional LDL-C reduction in patients taking statins (maximal tolerated doses)
Mechanism of Action

Ezetimibe

Binds to Nieman Pick N1L1 10 mg daily
receptor and prevents
absorption of cholesterol
from GI tract
Prevents degradation of LDL 75 mg every 2 wks
or 300 mg every
receptor by inhibiting
4 wks
PCSK9
Prevents degradation of LDL 140 mg @ 2 wks
subcutaneously
receptor by inhibiting
or 420 mg subPCSK9
cutaneously once
monthly
Bile acid sequestrant
8–16 g daily in divided doses, once
or twice a day
starting with 4 g

Alirocumaba

Evolocumaba

Cholestyramine

Dose for LDL-C
Reduction

LDL-C Reduction

Major Drug Interactions

15–20%

Cyclosporine, fenofibrate, fibrates,
cholestyramine

56–61% on background of
statin

None known

63–71% on a background of None known
a statin;
41–45% on background of
statin + ezetimibe
12–25%

Colesevelam

Bile acid sequestrant

15–18%
1250–1875 mg by
mouth two times
daily

Bempedoic acid

ATP citrate lyase inhibitor,
inhibitor of cholesterol
synthesis

180 mg by mouth
daily

18% on a background of a
statin

When given concomitantly with
warfarin, thiazide diuretics, thyroxine, estrogens and progestins,
tetracycline, phenobarbital, penicillin G, acetaminophen, phosphate supplements
When given concomitantly with oral
contraceptives, levothyroxine,
warfarin, glimepiride, glipizide,
phenytoin
Limit simvastatin to 20 mg,
pravastatin limit to 40 mg, cyclosporine

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; ATP, adenosine triphosphate; CVD, cardiovascular disease; FH, familial hypercholesterolemia; GI,
gastrointestinal; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; N1L1, N1-linker 1; PCSK9, proprotein convertase subtilisin/kexin
type 9.
a
Alirocumab and evolocumab are indicated to reduce the risk of ASCVD events in patients with established CVD. They are also indicated as adjunct to diet alone,
or in combination with other lipid-lowering therapies to reduce LDL-C in patients with primary hyperlipidemia (eg, heterozygous FH). Evolocumab is also
approved alone in combination with other lipid-lowering therapies in patients with homozygous FH who require additional lowering of LDL-C. The other
medications in this table are not indicated to reduce ASCVD events.
From the prescribing information for NuCare Pharmaceuticals, Inc. 2020, Esperion Therapeautics 2020, Ohm Laboratories Inc. 2020, Sanofi-Aventis, U.S. LLC
2018, Amgen Inc. 2017, Eon Labs 2020, Daiichi Sankyo 2020 (470, 478–483). All medications are to be used as adjunct to diet and exercise.

increasing hepatic synthesis of bile acids, which reduces the
amount of cholesterol in the liver. Reduced hepatic cholesterol leads to the upregulation of LDL receptors.
Bempedoic acid is an adenosine-triphosphate citrate
lyase inhibitor approved by the US FDA in 2020 for use as
an adjunct to diet and maximally tolerated statin therapy in
adults with heterozygous FH or established ASCVD, who
require additional reduction in LDL-C (478). The effect of
bempedoic acid on CV morbidity and mortality has not
been determined but is under investigation.
Treatment for hypertriglyceridemia
In patients with elevated TG, initial management includes the identification and treatment of secondary factors that raise TG, and the initiation or adjustment of
lifestyle therapy. Secondary factors include endocrine

diseases discussed in this guideline, chronic liver and
kidney disease, and medications (estrogens, glucocorticoids, mitotane, tamoxifen, raloxifene, bile acid resins,
protease inhibitors, retinoids, hydrochlorothiazide, propranolol, metoprolol, cyclosporine, tacrolimus, phenothiazine, aripiprazole, olanzapine, quetiapine, and
risperidone). For patients with persistent elevation in TG
up to 500 mg/dL (5.6 mmol/L) per day, statins are the first
choice of pharmacological therapy as adjunct to lifestyle
changes. A fibrate may also be used with the caution that
the combination of a fibrate and a statin increases the risk
of myopathy. This risk is more common with gemfibrozil
compared with fenofibrate (see “Hypertriglyceridemia:
Fibrates” section). In addition, as noted in this guideline, EPA ethyl ester is recommended to reduce ASCVD
risk in statin-treated patients with TG of 150–499 mg/dL
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Safety of lipid-lowering medications
Hypercholesterolemia
Statins
When using any medication, the possibility of adverse
events must be considered. The safety of the statin class of
medications has been reviewed (125, 142, 484). Therefore,
the most serious safety considerations will be described
here.
Myopathy/rhabdomyolysis
The hallmark serious adverse effect of statins is myopathy (incidence <0.1%), defined here and in the prescribing information for most statins as unexplained
muscle pain or weakness (or other muscle symptoms
such as stiffness or cramping), with creatine kinase (CK)
elevation >10 times the upper limits of normal (ULN)
(142, 485). As women generally have lower CK levels
than men (486, 487), if a sex-adjusted normal range is
not used, myopathy may present in women at lower-fold
elevations in CK. African American women have similar
CK levels compared with non-Hispanic white men, and
African American men have higher CK levels compared
with non-Hispanic white men.
The time from initiation of statin treatment to myopathy varies and may occur years after statin initiation.
When CK levels are extremely high, such as above 10 000
IU/L or greater than 40 times ULN, rhabdomyolysis,
which is a severe form of myopathy, should be considered.

Rhabdomyolysis may be associated with renal impairment,
including acute renal failure and myoglobinuria, but not
in all cases. This is a medical emergency. Information on
the presentation and treatment of statin-induced rhabdomyolysis can be found in Endocrine and Metabolic Medical
Emergencies: A Clinician’s Guide, Second Edition (488).
Myopathy is rare, with incidence <0.1% for most statins
and 1% for simvastatin 80 mg, a dose no longer used (489).
The incidence of rhabdomyolysis is even lower at <0.01%.
Possible risk factors for myopathy/rhabdomyolysis include older age (490, 491), female sex, diabetes, Chinese
ancestry (490), renal insufficiency, pre-existing muscle disease, hypothyroidism, and drug interactions. The mechanism of myopathy is not known.
In a patient with unexplained muscle symptoms, CK
levels will distinguish nonserious muscle symptoms from
myopathy. In patients with myopathy, discontinuation of
the statin usually results in resolution of muscle symptoms
within days, and reduction in CK, which returns to normal
within 2 to 3 weeks. If rhabdomyolysis is suspected, intensive hydration is usually effective in preventing renal failure
(492). Other causes or precipitating factors of myopathy
should be considered and interacting medications discontinued, if possible (488).
About 10% of patients stop statin use because of adverse symptoms, not necessarily caused by the statin, and
are often labeled statin intolerant (493, 494). The most
common symptoms are muscle weakness or pain, and these
are usually not accompanied by increases in CK. Statinassociated muscle symptoms are caused by the statin in
<1% of patients, as demonstrated by large, long-term,
placebo, controlled CVD outcome trials (495, 496) and
meta-analyses of these trials (125, 497). In the 2016 metaanalysis of 12 statin CVD outcome studies in 97 000
subjects, myalgia or muscle ache occurred in 5162 (11.7%)
participants allocated statins versus 5015 (11.4%) participants allocated placebo (P = 0.10) (125). In 4 double-blind,
placebo-controlled, randomized trials of statins that specifically queried muscle symptoms, none found a statistically
significant difference in muscle symptoms between statin
and placebo groups, using the intention-to-treat analyses
(496, 498–500). In an electronic database review, 90% of
statin-intolerant patients tolerated the same or a different
statin when re-challenged (494), and, in 2 RCTs, in patients
labeled statin intolerant (493, 501), the vast majority could
tolerate a statin under double-blind conditions. These data
taken together suggest that the intolerance is not pharmacologic in most patients.
Members of the Writing Committee sought to incorporate the patient’s voice into this guideline by developing
and administering a brief survey about CVD and statin
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(1.7–5.6 mmol/L), and either ASCVD or T2D and 2 additional risk factors (76).
The risk of pancreatitis increases with TG > 500 mg/dL
(5.6 mmol/L) and is even greater as TG rise to 1000 mg/dL
(11.3 mmol/L) or higher. Diet and exercise, and the treatment of secondary factors, may lower TG. However, if TG
reduction is not sufficient, pharmacological therapy (statin,
fibrates, or omega-3 fatty acids) should be considered.
Patients with TG levels of about 1000 mg/dL
(11.3 mmol/L) or greater may have 1 or multiple genetic
mutations, and a greater sensitivity to medications and
other secondary factors that increase TG. Monogenetic
hypertriglyceridemia, such as LPL deficiency, is rare and
is often diagnosed in childhood or adolescence. For such
extreme elevations in TG, a diet with very low-fat content, as little simple sugar as possible, and no alcohol
may reduce TG. The addition of fibrates or omega-3
fatty acids may be useful. Niacin also reduces TG but
has safety concerns (see “Hypertriglyceridemia: Niacin”
section).
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New-onset diabetes
Randomized-controlled trials and meta-analyses of RCTs
show that statins increase the risk of newly diagnosed diabetes mellitus (143, 144, 502, 503), most commonly in patients with multiple risk factors for diabetes (146, 503),
with an absolute risk of about 0.2% per year depending
upon the baseline risk of the population (143, 144). The
mechanisms are not fully known. Despite the increased
risk of newly diagnosed diabetes, statins still have a favorable benefit/risk ratio, even in patients predisposed to develop diabetes, and are usually continued in those patients
who develop new diabetes (see Section 3, “Type 2 Diabetes
Mellitus”).
Hepatic adverse events
Statins, which act in the liver, cause confirmed, doserelated, asymptomatic elevations in hepatic transaminases greater than 3 times ULN, with elevation in
alanine aminotransferase (ALT) greater than aspartate
aminotransferase (AST), in up to 1% of patients in clinical
trials (127, 504), but these patients usually do not develop
severe liver disease (505). Studies including an RCT in patients with chronic liver disease, show that statins are safe
in patients with nonalcoholic fatty liver disease, including
those with modest elevations in transaminases (<3 times
ULN) (506, 507). Therefore, statins may be safely initiated
when needed for LDL-C and/or CV risk reduction in individuals with transaminase elevations up to 3 times ULN
and/or other evidence of hepatic steatosis.
Severe liver injury (hepatoxicity) is extremely rare (508–
510), estimated to occur in about 1 in 100 000 patients

(509) and not detectable in clinical trials. Monitoring of
ALT and AST does not prevent severe liver disease (505).
Steroidogenesis
Although statins inhibit HMG-CoA reductase, the ratelimiting enzyme in the cholesterol synthesis pathway, studies
of lovastatin, simvastatin, and pravastatin show that these
statins do not have a clinically significant effect on steroid
hormone synthesis, although some evidence suggests that
statins reduce androgen levels in patients with PCOS, as
discussed previously. Hormones evaluated include cortisol,
adrenocorticotropic hormone (511–513), basal or human
chorionic gonadotropin (HCG)-stimulated testosterone,
free testosterone index, sex hormone–binding globulin
(SHBG), LH, or follicle-stimulating hormone (FSH) (514).
In 1 small trial, simvastatin 80 mg, a dose no longer recommended, reduced bioavailable testosterone in 81 men
by 10% compared with placebo, but not total or free testosterone, FSH, LH, SHBG, or the response to HCG (513).
Because statins are contraindicated in pregnancy and recommended for use in women of reproductive age only if
they use contraception and are very unlikely to conceive,
few studies have examined the effect of statins on gonadal
function in women. Simvastatin 40 mg compared with placebo in a double-blind RCT in normal cycling premenopausal women had no effect on the menstrual cycle or
progesterone synthesis (515).

Nonstatin therapies
Monoclonal antibodies to proprotein convertase
subtilisin/kexin type 9
The most common adverse effect of evolocumab and
alirocumab is injection site reaction, which occurs in about
2% to 4% of patients (129). Severe hypersensitivity reactions are rare, as are other allergic reactions, including urticaria, nummular eczema, and hypersensitivity vasculitis.
Available data show no effect on steroidogenesis and lipidsoluble vitamins (516).
Ezetimibe
Elevated transaminases have been observed but are rare
in patients taking ezetimibe, and likely not caused by
ezetimibe. However, the drug should not be used in patients
with moderate or severe liver disease.
Randomized-controlled trial data during 6 years of
follow-up found no evidence that ezetimibe caused myopathy/rhabdomyolysis, more than a 3-fold elevation in
hepatic transaminases, gallbladder problems (including
cholecystectomy), or cancer (517). Ezetimibe increases
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use in collaboration with a patient advocacy organization
who helped us identify members with diabetes. Although
the response rate to the survey was low, some of the information was of interest. Of 348 patients who answered the
survey, 67% were female, the majority were age 50 years
and older, 62% were affected with T1D and 38% with
T2D, and approximately 6% recorded that they had a history of heart attack. Nearly two-thirds were taking a statin
as prescribed, but an additional one-quarter of these patients were not taking a statin, although it had been recommended by their doctor. The reasons for not taking a
statin were largely related to concerns about side effects,
including muscle aches and muscle disease, memory loss,
and liver disease. Of patients taking a statin as prescribed,
about one-third reported side effects, largely muscle aches.
These data are consistent with the medical literature but
should be interpreted with caution because they are observational and from a survey with a low response rate.
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plasma levels of cyclosporine; therefore, levels of cyclosporine should be monitored.

Bempedoic acid
Bempedoic acid was approved by the FDA in 2020, and
therefore safety data were limited at the time of writing
this guideline. Drug interactions of bempedoic acid with
simvastatin and pravastatin increase concentrations of
these statins, which could increase the risk of myopathy
(478). Therefore, concomitant simvastatin should be
limited to a dose of 20 mg, and pravastatin to a dose of
40 mg. Bempedoic acid increases uric acid levels, and gout
was observed in 1.5% of patients taking bempedoic acid in
clinical trials compared with 0.4% of patients on placebo.
The placebo-corrected incidence of other adverse effects in
clinical trials were benign prostatic hyperplasia in about
1% of patients and tendon rupture in 0.5% of patients. An
increase in hemoglobin of ≥2 g/dL in 3% of patients, an increase in platelet counts of 5% and transient elevations of
AST and/or ALT to above 3 times the upper limit of normal
in about 1% of patients usually resolved or improved with
continued treatment or after discontinuation of treatment.

Hypertriglyceridemia
Fibrates
Fenofibrate is much less likely than gemfibrozil to induce
myopathy when administered with a statin (156). For this
reason, the recommendation in statin labels is to avoid
gemfibrozil. In an evaluation of the US Adverse Event
Reporting System, of 3 519 000 prescriptions for fenofibrate
and a statin, 4.5 cases of rhabdomyolysis were reported per
million prescriptions (519). In contrast, for 6 750 000 prescriptions of gemfibrozil and a statin, 87 cases of rhabdomyolysis were reported per million prescriptions (519). In

a large randomized double-blind CVD outcome trial (over
5000 patients) evaluating fenofibrate and placebo on a
background of simvastatin, with duration of follow-up of
about 5 years, the incidence of CK elevations more than 10
times ULN was 0.4% in the fenofibrate group and 0.3% in
the placebo group (156).
Omega-3 fatty acids (prescription)
Omega-3 fatty acids, which can be a combination of
eicosapentanoic acid (EPA) and docosapentaenoic acid or
EPA alone, reduce the production of very low density lipoproteins in the liver, which are TG-rich and may also increase the clearance of TG-rich lipoproteins by increasing
LPL activity. The REDUCE-IT trial compared CV outcomes in participants with high ASCVD risk, randomized
to eicosaptaenoic acid ethyl ester or placebo (76). A significant reduction in ASCVD events was found and the risk/
benefit was favorable. However, there were more hospitalizations for atrial fibrillation/flutter (3.1% vs 2.1%) and
more events of serious bleeding (2.7% vs 2.1%) in the EPA
ethyl ester group.
Omega-3-acid-ethyl-esters (combination of EPA and
DHA), which are indicated to lower the risk of pancreatitis
in patients with TG >500 mg/dL (5.6 mmol/L), but do not
have evidence for reduction in ASCVD risk, have been associated with an increase in atrial fibrillation and bleeding.
Niacin
Niacin reduces TG, total cholesterol and LDL-C, and increases HDL-C. Prescription niacin is no longer available
in Europe because of its adverse safety profile. The most
common adverse events are flushing and pruritis. Niacin
also increases plasma glucose and worsens glycemic control
(520), and it is associated with an increased risk of newly
diagnosed diabetes (521). Other serious adverse effects of
niacin identified in the AIM High (522) and HPS2-THRIVE
clinical trials (523) include hepatotoxicity (which is rare),
infection, GI bleeding, and myopathy. The latter trial, with
a follow-up period of about 4 years, did not show a benefit
on ASCVD of adding niacin-laropiprant to a statin. This result and the safety hazards associated with niacin treatment
suggest that niacin should have limited use today (524) and
should probably not be used in people with diabetes or impaired glucose tolerance.

Method of development of evidence-based
clinical practice guidelines: participants
Participants
The Writing Committee consisted of 10 content experts
representing expertise in lipid disorders, endocrinology,
diabetes, preventive cardiology, and clinical epidemiology.
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Bile acid–binding resins
Adverse effects of bile acid–binding resins include constipation, abdominal pain, bloating, flatulence, and increased
hepatic transaminases. Of the medications in this class,
colesevelam seems to be the best tolerated. Bile acid binding
decreases the absorption of folic acid and fat-soluble vitamins and a variety of medicines. To prevent this, medications should be taken 2 to 4 hours before or 4 to 6 hours
after the bile acid–binding resin. Colesevelam appears
to cause fewer GI side-effects, and so is likely the besttolerated agent in this class. Further, it has greater selectivity for bile acids and so seems less likely to interfere with
absorption of other medications and nutrients. Bile acid
resins may cause a 10% to 20% increase in TG (81, 518) in
individuals with TG levels above 500 mg/dL (5.6 mmol/L),
and so are contraindicated in this setting.
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Table 11. GRADE classification of guideline recommendations
Quality of Evidence

High Quality

Moderate Quality

Description of Evidence

Well-performed RCTs

RCTs with some lim- RCTs with seitations
rious flaws

Very strong evidence
from unbiased observational studies

Strong evidence from Some evidence
from observaunbiased observational studies
tional studies

One of the committee members brought an international
perspective to this guideline topic. The Writing Committee
also included a clinical practice guideline methodologist
who led the team of comparative effectiveness researchers
that conducted the systematic reviews and meta-analyses.
Guideline development process
The Endocrine Society’s guideline development process
combines elements of the GRADE framework (525) with
an approach that was felt to be more appropriate for the
rare endocrine disease space where scientific evidence is
limited or nonexistent. The Society applies the steps in the
GRADE framework to research questions for which there
is an ample body of knowledge of low-to-moderate quality
or higher (see Table 11 for descriptions of low and moderate quality evidence). In these situations, GRADE provides methodological and statistical rigor, which results in
robust recommendations, which are classified using quality
of evidence and strength of recommendation, as described
in by Guyatt et al (526) and are represented graphically in
Table 11.
Where evidence is extremely limited and/or not systematically analyzed, we provide recommendations based on
an expert review of the limited data. This process is less
systematic than the GRADE methodological framework;
however, these recommendations are also clearly classified
using the GRADE classification system.
Some of the Society’s clinical practice guidelines also
include Ungraded Good Practice Statements (527). This
unclassified clinical guidance can include expert opinion
statements on good practice, references to recommendations made in other guidelines, and observations on preventive care and shared decision-making.
Guideline recommendations include the relevant population, intervention, comparator, and outcome. When further clarification on implementation is needed, we include

Very Low Quality

1|⊕⊕⊕O

1|⊕⊕OO

Unsystematic
clinical
observations
Very indirect
evidence observational
studies
1|⊕OOO

2|⊕⊕⊕O

2|⊕⊕OO

2|⊕OOO

a Technical Remarks section. These provide supplementary
information such as timing, setting, dosing regimens, and
necessary expertise. All recommendations are followed by
a synopsis of the evidence that underpins it. Authors may
also include short statements on patients’ values and preferences, the balance of benefits and harms, and minority
opinions, where relevant.
It should be noted that the Society’s guideline development process is currently instituting new approaches and
processes.
Internal and External Review
Approximately 18 months into the development process,
Endocrine Society clinical practice guidelines undergo a
Comment Review Period of 1 month, where there is an
opportunity for internal and external stakeholders to review the guidelines draft and provide comments. These
stakeholders include Endocrine Society members, the
Society’s Clinical Guidelines Committee (CGC), representatives of any co-sponsoring organizations, a representative of Council, and an Expert Reviewer. Following
revisions to the guideline manuscript in response to
Comment Review Period comments, it is returned to
CGC, the Council Reviewer, and the Expert Reviewer for
a second review and ballot. Finally, the guidelines manuscript is subject to the Journal of Clinical Endocrinology
& Metabolism’s publisher’s review prior to publication.
This review is undertaken by an individual with expertise
in the topic, without relevant conflicts of interest, and
external to the guideline writing committee, CGC, and
Council.
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1|⊕⊕⊕⊕
Strong (1): “We recommend…”
Strength of
Benefits clearly outweigh harms
Recomand burdens and vice versa
mendation
2|⊕⊕⊕⊕
Conditional (2): “We suggest…”
Benefits closely balanced with
harms and burdens

Low Quality
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Two major classes of circulating lipids, TG and cholesterol,
are transported as the core components of lipoproteins.
The apolipo-proteins on the surface of lipoproteins allow
these particles to be soluble in a water environment and
interact with enzymes and cell surface receptors, thus controlling their ability to supply lipids to tissues.
Triglycerides are the major storage forms of energy
and are derived from dietary fat and from synthesis in the
liver. In the small intestine, TG are assembled into chylomicrons, which enter the circulation via the thoracic duct.
Chylomicrons are normally not found in fasting plasma.
The liver synthesizes and secretes TG in the form of VLDL,
which contains TG synthesized from fatty acids that are recycled from the adipose tissue, obtained from lipoproteins,
or synthesized from glucose and/or amino acids. Lipolysis
of TG from TG-rich lipoproteins is performed primarily by
interaction with LPL, which is associated with the luminal
surface of capillaries, and results in the release of fatty acids
from their glycerol backbone, thereby supplying lipids for
energy or storage by muscles and adipose tissue. The lipoproteins resulting from this reaction are either chylomicron
or VLDL remnants, because TG, but not cholesterol or
cholesteryl ester, are removed from the particles. With further loss of TG, VLDL remnants generate low-density LDL,
which are removed from the circulation primarily by liver
LDL receptors. All the chylomicron remnants and some of
the VLDL remnants are cleared in the liver by both the LDL
receptor and at least 1 other pathway mediated by LRP.
High-density lipoprotein has a distinct metabolic pathway
that includes its production from the liver and gut, the addition and removal of lipids in the circulation, and clearance
mainly in the liver. A more complete review of lipoprotein
physiology can be found in standard texts, and an illustrative figure of endogenous and exogenous pathways of lipid
metabolism in a 2019 review on lipid management (528).
The clinical approach to abnormal levels of plasma
lipids focuses on abnormal circulating levels of lipoproteins. Primary disorders of lipoprotein metabolism must
be separated from the effects of endocrine disorders and
disorders of other organ systems on lipids. Monogenic primary disorders are rare. Other primary disorders are mostly
polygenic and common, and easily influenced by multiple
factors including environmental factors such as diet, exercise, and medications. Routinely normal levels of TG and
other biomarkers are based on population distributions;
however, clinicians may be better served by the concepts
of “optimal” and “elevated,” which can be used to indicate
thresholds for clinical action. Various guidelines and scientific statements have denoted TG levels above 150 mg/
dL (1.7 mmol/L), 170 mg/dL (1.9 mmol/L), or 200 mg/dL
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may be expressed as dysbetalipoproteinemia because of
secondary disorders that alter lipid metabolism, including
obesity, diabetes, and hypothyroidism. When an individual
has the E2/E2 genotype on the background of other genes
predisposing to hyperlipidemia, dysbetalipoproteinemia
occurs largely because apoE2 binding to the LDL receptor
is defective, decreasing the hepatic catabolism of apoE2containing VLDL.

Appendix C
Cholesterol Treatment Guidelines
In 2013, the AHA and the ACC published new guidelines
for the “treatment of blood cholesterol to reduce atherosclerotic CV risk in adults” (532). Those guidelines were
dramatically different than prior National Institutes of
Health–sponsored guidelines, written under the umbrella
of the Adult Treatment Panel (533–535). The 2013 AHA/
ACC guidelines (532), which were the 4th version of the
Adult Treatment Panel guidelines, removed goals or targets
for LDL-C, which had been a central component of the
prior Adult Treatment Panel guidelines published in 1988,
1993, and 2001, as well as updates published in 2004 and
2006 (536). The 2006 update, titled “AHA/ACC Guidelines
for Secondary Prevention for Patients with Coronary and
Other Atherosclerotic Vascular Disease,” was based on
13 RCTs and recommended the strongest LDL goals to
that time.
By 2013, health professionals were well educated in the
use of LDL-C for both the initiation of treatment for hypercholesterolemia and for setting goals. The 2013 AHA/ACC
guidelines altered the paradigm to be used by health care
providers to identify, treat, and follow patients who needed
cholesterol lowering by eliminating LDL-C goals (533–
536). Patients were followed by assessing the percentage of
reduction in LDL-C.
The guidelines defined high-risk patient management
groups (history of ASCVD, diabetes mellitus, severe elevation in LDL-C) that required lipid-lowering medication as adjunct to diet and lifestyle therapies, without
assessment of the 10-year ASCVD risk score. They also
defined, based upon the 10-year risk of ASCVD, primary
prevention groups that would be likely to benefit from
statin therapy. The 10-year risk of ASCVD was calculated
from the ACC/AHA Pooled Cohort Equations. Statins
were grouped by intensity of LDL-C reduction, and highintensity statins, which reduced LDL-C by 50% or more,
were recommended for the highest risk patients. Patients
were followed by assessing the percentage of reduction
in LDL-C.
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(2.3 mmol/L) as elevated (35, 529, 530). While extremely
high levels of TG can cause acute (and recurrent/chronic)
pancreatitis (with the risk increasing above a fasting TG
of 500 mg/dL [5.6 mmol/L]) (531), the pathophysiologic
imperative to treat less dramatic elevations (such as 150–
500 mg/dL [1.7–5.6 mmol/L]) until recently were not supported by clear-cut clinical trial data. This changed with
the REDUCE-IT trial (76), which is discussed in these
guidelines. For hypercholesterolemia, the realization that
average cholesterol increased CV risk prompted a different
metric: what had been average cholesterol levels became
abnormal, as they were associated with increased ASCVD.
Further support came from studies that showed that reducing LDL-C decreased ASCVD (123, 124, 129, 130, 159).
Increased plasma levels of TG occur only in the setting of increased circulating levels of VLDL and/or chylomicrons. Because TG lipolysis of these 2 lipoproteins has a
common pathway via LPL, very-elevated levels of VLDL
can saturate this pathway, reducing and delaying lipolysis
of chylomicrons, leading to their accumulation even in
fasting plasma. This tends to occur as TG levels begin to
exceed 500 mg/dL (5.6 mmol/L). Higher TG levels, above
1000 mg/dL (11.3 mmol/L), are always associated with
fasting chylomicronemia. In addition to being larger than
VLDL, and therefore more buoyant, chylomicrons contain
a shortened form of the major structural protein, apoB48,
so named because it is 48% of apoB100, which is the form
of apoB in VLDL and LDL and the main ligand for the
LDL receptor.
The major cholesterol-carrying lipoproteins are LDL
and HDL, and hypercholesterolemia is usually due to increased LDL concentration. In most clinical situations and
in most large research studies, LDL-C levels are estimated
by the Friedewald method, subtracting HDL-C and TG/5
(an estimate of VLDL cholesterol) from the total cholesterol. With TG levels >150 mg/dL (1.7 mmol/L), this estimate is inaccurate; it is also inaccurate at very low levels of
LDL-C (<70 mg/dL [1.8 mmol/L]).
Two conditions can cause both increased TG and increased cholesterol. One is “combined hyperlipidemia,”
characterized by increased VLDL and LDL levels. The
other is the rare disorder dysbetalipoproteinemia (formerly
known as Type III hyperlipidemia in the Frederickson
classification), with increased levels of circulating remnant particles that contain both comparable amounts
of TG and cholesterol, such that VLDL has a TG-tocholesterol ratio of 3 or less instead of the typical ratio of
5. Dysbetalipoproteinemia usually results from homozygosity of apoE2, 1 of the 3 isoforms of apoE, plus 1 or
more other poorly understood factors. The E2/E2 genotype
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1.
2.

3.

4.

5.

6.

7.

8.

9.

In all individuals, emphasize a heart-healthy lifestyle
across the life course.
In patients with clinical ASCVD, reduce LDL-C with
high-intensity statin therapy or maximally tolerated
statin therapy.
In very high-risk ASCVD, use an LDL-C threshold of
70 mg/dL (1.8 mmol/L) to consider the addition of
nonstatins to statin therapy.
In patients with severe primary hypercholesterolemia
(LDL-C level ≥190 mg/dL [4.9 mmol/L]), without
calculating 10-year ASCVD risk, begin high-intensity
statin therapy.
In patients 40 to 75 years of age with diabetes
mellitus and LDL-C ≥70 mg/dL (1.8 mmol/L), start
moderate-intensity statin therapy without calculating
the 10-year ASCVD risk.
In adults 40 to 75 years of age evaluated for primary
ASCVD prevention, have a clinician–patient risk
discussion before starting statin therapy.
In adults 40 to 75 years of age without diabetes
mellitus and with LDL-C levels ≥70 mg/dL
(1.8 mmol/L), at a 10-year ASCVD risk of ≥7.5%,
start a moderate intensity statin if a discussion of
treatment options favors statin therapy.
In adults 40 to 75 years of age without diabetes
mellitus and a 10-year risk of 7.5% to 19.9%
(intermediate risk), risk-enhancing factors favor the
initiation of statin therapy.
In adults 40 to 75 years of age without diabetes
mellitus and with LDL-C levels ≥70 mg/dL to
189 mg/dL (1.8 to 4.9 mmol/L), at a 10-year ASCVD
risk of ≥7.5% to 19.9%, if a decision about statin
therapy is uncertain, consider measuring CAC.

10.

Assess adherence and the percentage response to
LDL-C–lowering medication and lifestyle changes
with repeat lipid measurement 4 to 12 weeks after
statin initiation or dose adjustment, repeated every 3
to 12 months, as needed.

The guideline also states that in patients with a 10-year
risk of ASCVD at 5% to 7.5% (borderline risk), riskenhancing factors may favor statin therapy.
The 2018 ACC/AHA guidelines on cholesterol management are compared (and provided in chronological order
below) to existing guidelines from other organizations in
the United States, Canada, and Europe.
National Lipid Association Recommendations for PatientCentered Management of Dyslipidemia: Part 1 – Full
Report (2015)
These guidelines, the first published post-2013, stressed
treatment goals, noting that the authors did not agree with
the AHA/ACC 2013 guidelines (23). The National Lipid
Association (NLA) report utilized 4 risk categories, and in
sharp contrast with the AHA/ACC 2013 guidelines, recommended treatment goals for each category.
The NLA guidance also differed from the 2013 AHA/
ACC guidelines by using levels of non-HDL-C as the primary treatment goal and both LDL-C and apoB levels
as secondary goals. For low-, moderate-, and high-risk
groups, the primary goal was non-HDL-C <130 mg/
dL (3.4 mmol/L), with secondary goals of <100 mg/dL
(2.6 mmol/L) for LDL-C and <90 mg/dL (0.002 mmol/L)
for apoB. For the very high-risk group, NLA recommended
a non-HDL-C goal of <100 mg/dL (2.6 mmol/L), with
LDL-C and apoB goals of <70 mg/dL (0.001 mmol/L) and
<80 mg/dL (0.002 mmol/L), respectively. The NLA guideline combined populations with T1D and T2D together regardless of age, duration of disease, or presence or absence
of microangiopathy. The NLA participated in the development and publication of the 2018 AHA/ACC guidelines
and supported them fully, although some features of the
2015 NLA guidelines were not addressed in the new 2018
AHA/ACC guidelines (35).
2016 Canadian Cardiovascular Society Guidelines for
the Management of Dyslipidemia for the Prevention of
Cardiovascular Disease in the Adult
This is an update of their 2012 guidelines, and the major
recommendations include CVD risk assessment every
5 years for adults ages 40–75 years using a Framingham
Risk Score modified by family history or a Cardiovascular
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2018 AHA/ACC cholesterol clinical practice guidelines
In 2018, new guidelines were published by the AHA/ACC
(35). These guidelines defined high-risk patient groups for
treatment with high-intensity statin therapy, as well as
groups who would benefit from moderate-intensity statins.
They acknowledged new CV endpoint data for ezetimibe
and PCSK9-inhibiting monoclonal antibodies by formally
endorsing these statin adjuncts. They also recommended
calculation of the 10-year risk in patients with diabetes
and no history of ASCVD. In addition, these guidelines
recommended the consideration of risk-enhancing factors
and CAC scoring to further define risk and/or aid decisions about the initiation of statin treatment or intensification of therapy. The guideline’s “Top 10 Take-Home
Messages” are:
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2017 American Association of Clinical Endocrinologists
and American College of Endocrinology Guidelines
for Management of Dyslipidemia and Prevention of
Cardiovascular Disease
This is an update of the American Association of Clinical
Endocrinologists (AACE) 2012 guidelines and defines 5 risk
categories accompanied by LDL-C, non-HDL-C, and apoB
goals (475). Extreme risk is defined as progressive ASCVD,
including unstable angina after achieving an LDL-C goal
of <70 mg/dL (1.8 mmol/L), established ASCVD in individuals with diabetes mellitus, CKD, heterozygous FH, or
premature ASCVD occurring at ages <55 years for males
and <65 years for females. For the extreme risk group, the
treatment goals are the most aggressive of any previous
guideline: LDL-C <55 mg/dL (1.4 mmol/L), non-HDL-C
<80 mg/dL (2.1 mmol/L), or apoB <70 mg/dL (0.7 g/L).
For adults with very high risk (defined as acute coronary
syndrome, coronary or carotid artery disease, or peripheral
vascular disease, or 10-year risk >20%, diabetes or chronic
renal disease stages 3 or 4 with >1 additional risk factor, or
heterozygous FH), treatment goals are LDL-C <70 mg/dL
(1.8 mmol/L), non-HDL-C <100 mg/dL (2.6 mmol/L), and

apoB <80 mg/dL (0.8 g/L). Lower treatment goals, with
LDL-C <100 mg/dL (2.6 mmol/L), non-HDL-C <130 mg/
dL (3.2 mmol/L), and apoB <90 mg/dL (0.9 g/L) are recommended for individuals with high risk or moderate
risk. For individuals with low CVD risk (defined as zero
risk factors), the LDL-C goal is <130 mg/dL (3.4 mmol/L).
Although LDL-C is the primary goal parameter, the AACE
recommends using non-HDL-C first when TG levels are between 200 and 500 mg/dL (2.3 and 5.6 mmol/L).
2019 European Society of Cardiology and European
Atherosclerosis Society Guidelines for the Management of
Dyslipidemia
This is an update of the 2016 guidelines from these 2 major
European societies. They identify 4 patient groups as having
very high or high total CV risk: (1) documented CVD, (2)
T1D or T2D, (3) very high levels of risk factors generating
a 10-year cumulative risk score of >10% for a first fatal
CV event using a calculated SCORE assessment tool, and
(4) CKD (462). Individuals with lower levels of risk are
categorized using their SCORE: 5% to 10% for high risk,
1% to 5% for moderate risk, and <1% for low risk. The
use of SCORE for predicting fatal events is unique to the
ESC/EAS and is based on their belief that such an approach
eliminates bias and misdiagnosis. Low-density lipoprotein
cholesterol has been designated as the treatment goal lipid
biomarker, with non-HDL-C used as a secondary goal after
the LDL-C goal has been reached. Apolipoprotein B is recommended as a potential secondary target, similar to nonHDL-C, if an assay for apoB is readily available. The ESC/
EAS recommends treatment goals based on CV risk: very
high CV risk, whether secondary or primary prevention,
LDL-C goal of <1.4 mmol/L (55 mg/dL), and LDL-C reduction of >50% from baseline; high CV risk, LDL-C goal
of <1.8 mmol/L (70 mg/dL) and a reduction of at least 50%
if the baseline LDL-C is between 1.8 and 3.5 mmol/L (70
and 135 mg/dL); for moderate risk, LDL-C of <2.6 mmol/L
(100 mg/dL); for low risk, an LDL-C <3.0 mmol/L (116 mg/
dL). For individuals with ASCVD who have a second vascular event within 2 years while taking maximal tolerated
doses of a statin, ESC/EAS guidelines suggest consideration
of an LDL-C goal of <1.0 mmol/L (40 mg/dL). Secondary
goals are non-HDL-C 0.8 mmol/L (30 mg/dL) higher
than for LDL-C, and apoB <65 mg/dL, <80 mg/dL, and
<100 mg/dL for very high-risk, high-risk, and moderaterisk groups, respectively.
Overall, the ESC/EAS guidelines differ from others by
having more levels of LDL-C goals depending on risk,
and also a suggestion for reducing LDL-C to <40 mg/dL
(1.0 mmol/L) for people with ASCVD and recent vascular
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Life Expectancy Model, which estimates CV age (476).
These differ from the Pooled Cohort Equations risk score
used in the AHA/ACC guidelines. They proposed LDL-C
as the primary target for therapy and non-HDL or apoB
as alternative targets, which is different from the AHA/
ACC 2018 and from the NLA 2015 guidelines. For all secondary prevention and high-risk primary prevention, the
Canadian Cardiovascular Society recommends a target of
LDL-C <2.0 mmol/L (about <80 mg/dL), or a >50% reduction in LDL-C, an apoB <80 mg/dL, or a non-HDL-C
<2.6 mmol/L (about <100 mg/dL). They also recommend
even more aggressive therapy for individuals with recent
acute coronary syndromes and established CAD with
an LDL-C target of <1.8 mmol/L (about <70 mg/dL) or
>50% reduction. Such therapy might require the combination of nonstatin agents like ezetimibe with a maximally
tolerated statin. Overall, the Canadian recommendations
have some differences from the 2018 AHA/ACC guidelines,
such as the use of target levels of LDL-C, apoB, and nonHDL-C, although the 2018 guidelines are much closer to
the Canadian guidelines than were the 2013 AHA/ACC
guidelines. They differ from those of the NLA by choosing
LDL-C rather than non-HDL-C goals and by suggesting
a >50% LDL-C reduction as an alternative to an LDL-C
of 70 mg/dL in the highest-risk group. However, as noted,
the NLA has now aligned itself with the 2018 AHA/ACC
guidelines.
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events. Another difference is the use of fatal ASCVD events
as the target of prevention, but this is not critical to the
function of the guidelines.

American Diabetes Association Standards of Medical Care
in Diabetes – 2020: Lipid Management
The ADA updates their guidelines for diabetes management annually, and the 2020 update (537) aligned their recommendations for statin treatment with the 2018 AHA/
ACC guidelines for the management of blood cholesterol.

In contrast to prior American Diabetes Association (ADA)
Standards of Medical Care, recommendations for lipid
management in adults with diabetes were individualized
based upon the presence of ASCVD, or risk for ASCVD, diabetic kidney disease, or heart failure. Lifestyle modification
is recommended for all patients with diabetes. For patients
of all ages with diabetes and ASCVD, high-intensity statin
therapy as adjunct to lifestyle is recommended. For patients
with ASCVD and LDL-C ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin therapy, the ADA suggests consideration of additional LDL-C lowering therapy, with either
ezetimibe (possibly preferred because of lower cost) or a
PCSK9 inhibitor. In individuals with diabetes and without
ASCVD but older than 40 years of age, moderate-intensity
statins are recommended (as adjunct to lifestyle), with consideration of high-intensity statin treatment for those with
multiple ASCVD risk factors or in the age range of 50 to
70 years, and consideration of the addition of ezetimibe to
maximally tolerated statin therapy in adults with a 10-year
ASCVD risk of 20% or greater.
In people older than 75 years and with diabetes, and
who are not taking a statin, the ADA suggests considering
statin treatment after a discussion about the potential risks/
benefits. For younger adults with diabetes, in the age range
of 20–39 years, the ADA suggests consideration of statin
therapy in those with other ASCVD risk factors.
The authors of the 2020 Standards of Care had the opportunity to consider the results of the REDUCE-IT trial
(76), which showed a CVD benefit of the omega-3 fatty acid,
EPA ethyl ester, 4 g daily, when added to statin therapy in
adults with elevated TG up to 500 mg/dL (5.6 mmol/L) and
either ASCVD or T2D with additional risk factors. Based
on these data, the ADA recommended consideration of EPA
ethyl ester to reduce ASCVD risk in statin-treated adults
with diabetes and TG levels between 135 and 499 mg/dL
(1.5 and 5.6 mmol/L).
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2019 Endocrine Society Clinical Practice Guideline:
Primary Prevention of ASCVD and T2DM in Patients at
Metabolic Risk
This guideline provides recommendations for the management of lipids, blood pressure, blood glucose, and excess
weight or increased waist circumference in patients with
increased metabolic risk (defined in the guideline), who
have not developed ASCVD or T2D (463). Lifestyle and
behavioral therapies, and medical and pharmacologic management are discussed. High-intensity statin treatment is
recommended for people ages 40 to 75 with increased metabolic risk and LDL-C of 190 mg/dL (4.9 mmol/L) or greater
to achieve a ≥50% reduction in LDL-C, and also for individuals ages 40 to 75 with increased metabolic risk who have
a 10-year ASCVD risk ≥7.5% to either achieve an LDL-C
goal of <100 mg/dL (2.6 mmol/L), or a ≥50% reduction in
LDL-C. In individuals with increased metabolic risk and a
10-year ASCVD risk of 5.0% to 7.5%, moderate-intensity
statin therapy is recommended to achieve an LDL-C goal
of <130 mg/dL (3.4 mmol/L) or a 30% to 50% reduction
in LDL-C. In individuals with increased metabolic risk who
are older than 75 years and have a 10-year risk ≥7.5%, the
guideline recommends discussion with the patient of the
risks/benefits for statin therapy on an individualized basis in
order to reach a decision about statin treatment.
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Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, decreased appetite, fatigue,
dizziness, increased lipase

Nausea, constipation, vomiting, diarrhea, headache, dizziness, insomnia, dry mouth

Paresthesia, dizziness, insomnia, dysgeusia, constipation, dry mouth

Steatorrhea, oily spotting, flatulence with discharge, fecal urgency, incontinence

Common Adverse Reactions
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From prescribing information Roche Laboratories Inc. 1999, Novo Nordisk 2020, VIVUS 2012, Nalpropion Pharmaceuticals 2020 (209–211, 538).

Liraglutide, 3 mg

Naltrexone/
bupropion

Phentermine/
topiramate

Chronic malabsorption, cholestasis, pregnancy Reduced levels of fat-soluble vitamins, interaction with cyclosporine
(reduced cyclosporine levels), severe liver injury, worsening of renal
function in patients with chronic kidney disease, increased gastrointestinal side effects if high-fat diet
Use with monoamine oxidase inhibitors, hyIncreased heart rate, suicidal behavior, acute myopia and secondary
perthyroidism, glaucoma, pregnancy
angle closure glaucoma, mood and sleep disorders, cognitive impairment, metabolic acidosis, increased creatinine
Suicidal ideation and behavior, neuropsychiatric adverse events during
Uncontrolled hypertension, seizure disorders,
smoking cessation, risk of seizure, increased blood pressure and
anorexia, bulimia, abrupt discontinuheart rate, angle closure glaucoma in patients with untreated narrow
ation of alcohol, benzodiazepines, or
angel, hepatitis, liver dysfunction
barbiturates, pregnancy
Thyroid C cell tumors, acute pancreatitis, acute gallbladder disease,
Personal or family history of medullary thysevere hypoglycemia when used with sulfonylurea or other glucose
roid carcinoma or multiple endocrine neosecretagogue, increased heart rate, impaired renal function, suicidal
plasia type 2, pregnancy
behavior or ideation

Orlistat

Warnings

Contraindications

Safety of Medications for Weight Reduction in Obesity Table

Medication

Appendix D.
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